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ABSTRACT 
 Clusianone isolated from Garcinia parvifolia has been studied for its 
anticancer properties and cytotoxicity to human respiratory cells. The clusianone 
was first isolated using solvent extraction, column chromatography, thin layer 
chromatography and finally recrystallization method through solvent evaporation 
including seed crystal to induce crystal growth of clusianone. The clusianone was 
characterized using X-ray crystallography, ESI-MS, NMR and melting point. 
During the course of this research, clusianone was chemically modified and eight 
different derivatives abbreviated as CMet, CHyd, CMxA, CMeA, CEtA, CPryl, 
CGeryl and CDMet were obtained. Some of the chemical methods employed were 
hydrogenation, methylation, demethylation, ketone reduction via addition of amine 
derivatives and O-alkylation to install additional prenyl and geranyl chain into 
clusianone. Further studies of the role of the clusianone derivatives were presented 
in its in vitro anticancer activity. The anticancer test and cytotoxicity effect were 
tested using MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
assay. Specific normal human and cancer cell lines were used in the assay being 
MRC5 (lung fibroblast), A549 (lung adenocarcinoma, NP69 (nasopharyngeal 
epithelial cell and HK1 (squamous carcinoma of the nasopharynx). Preliminary 
study of clusianone and derivatives showed cytotoxicity effect in dose dependent 
manner. Based on the results, clusianone and compound CMeA demonstrated good 
anticancer activity showing IC50 values below 5 µM against A549 and HK1 cancer 
cells and at the same time affecting less of the MRC5 and NP69 normal cells. 
Western blot method was employed to further elucidate the downregulation of the 
protein expression of β-tubulin including cell cycle regulators Cdk1 and cyclin B1 
for clusianone and CMeA derivative treated carcinoma cells. Clusianone and 
compound CMeA demonstrated potential antimicrotubule agent characteristic since 
expression of β-tubulin and cell cycle regulators Cdk1/cyclin B1 were 
downregulated in A549 cells. As for HK1 cells, clusianone downregulated β-tubulin 
protein without affecting Cdk1 and cyclin B1 expression. In contrast, compound 
CMeA showed prominent downregulation of   β-tubulin, CDK1 and cyclin B1 
proteins especially after 48 hours treatment in HK1 cells.  
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hr Hour 
mg  Miligram 
mmol  Milimoles 
ppm                        Parts per million 
mAb  Monoclonal antibody 
kDa                             Kilo Dalton 
rel. int. Relative intensity 
v/v Volume to volume ratio 
ACN  Acetonitrile 
APS                       Ammonium Persulphate 
ATP                       Adenosine 5’ TriPhosphate 
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BSA                       Bovine Serum Albumin 
CDK/Cdk  Cyclin Dependent Kinase 
DNA                       Deoxyribose Nucleic Acid 
DMSO                    Dimethyl sulfoxide 
EC50 Half maximal effective concentration  
EDTA                    Ethylenediaminetetraaceticacid 
ELISA                    Enzyme-Linked Immunosorbent assay 
Et2O Diethyl ether 
EtOAc                    Ethyl acetate 
ESIMS                   Electron spray ionisation mass spectrum 
FBS                        Fetal Bovine Serum 
FTIR Fourier Transform Infrared Spectroscopy 
H2                                       Hydrogen gas 
H2O                        Water 
HCl                       Hydrochloride Acid 
IC50  Half maximal inhibitory concentration  
MgSO4 Magnesium Sulphate 
Me2SO4                         Dimethyl sulfide 
MIC  Minimum Inhibitory concentration  
K2CO3                            Potassium Carbonate 
NSCLC                  Non-small cell lung cancer 
OD                      Optical density 
Pd/C                     Paladium on carbon 
RPMI                  Rosewell Park Memorial Institute medium 
SDS                    Sodium Dodecyl Sulphate 
Si gel                           Silica gel 
TEMED              N’, N , N’ , N’ – Tetramethyethylenediamine 
UNMC                University of Nottingham Malaysia Campus 
1H NMR              Proton-Nuclear Magnetic Resonance 
13C NMR                Carbon-13 Nuclear Magnetic Resonance 
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CHAPTER 1: ANTICANCER COMPOUNDS FROM NATURAL 
PRODUCTS 
1.0 Cancer 
Cancer is a disease whereby the normal cells divides uncontrollably 
resulting in the formation of masses of tissue known as tumours. Consequently, 
the out of control cells proliferation not only forms into a  lump form but may 
also spread to another organ via blood circulatory system leading to metastasis. 
In this case, the tumour is known as malignant tumour which results in cancer. 
Tumours which do not metastasize or lacks the ability to invade neighbouring 
tissues are called benign tumour. Benign tumours are non-cancerous since it is 
self-limiting, non-invasive and have slower growth rate compared to malignant 
tumours (Kufe et al., 2003).  
The occurrence of cells dividing uncontrollably is linked to the 
mutations to DNA which subsequently causing damage to the genes which is 
an essential key component in cell division. There are four types of genes which 
governs cell division progress and process which are oncogenes initiating cell 
division, tumour suppressor genes preventing cells from dividing , suicide genes 
controls cell death via apoptosis  and finally DNA-repair genes instructing a cell 
to repair damaged DNA (Visvader, 2011).  
The severity of cancer is classified in stages: 0, I, II, III and IV with the 
higher scale indicating cancer has progressively moved to a severe stage. Stage 
0 indicates patients detected at an early stage of cancer whereby few cells 
growth is diagnosed. Subsequent stages I, II, III and IV are classified based on 
the tumour size, aggressiveness related to the growth of cancer and finally to 
which extend the cancer has spread to the neighbouring tissues or even to 
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different organs of the patient. Patients diagnosed with a stage IV cancer will 
go through severe pain due to obstruction of airway or blood vessels, alteration 
or malfunction of organ, fever, fatigue, weight loss and eventually die 
(Provencio et al., 2011).  
Cancers are now second to cardiovascular diseases with  an estimation 
of 13% of total deaths each year with the most common being: lung cancer (1.4 
million deaths), stomach cancer (740,000 deaths), liver cancer (700,000 deaths), 
colorectal cancer (610,000 deaths) and breast cancer (460,000 deaths) (Lalla et 
al., 2008). As such, invasive cancer has been the leading cause of death in both 
developed country and developing country.  Based on the demographic changes 
studies in low-income and middle-income countries, the occurrence of cancer 
is expected to elevate from 13.3 to 21.4 million cases between 2010 and 2030 
(McCormack & Boffetta, 2011).  
 
1.1 Types of respiratory related carcinoma and its causes 
Respiratory related cancers and diseases are becoming one of the most 
alarming health conditions in mankind. Lung cancer is currently the highest 
incident compared to other types of cancers and also the major cause of death 
related to cancer cases both in men and women worldwide (Cancer Research 
UK, 2011). Majority cases of  lung cancers are carcinomas that derive 
from epithelial cells and are known as primary lung cancers. However, failure 
to provide early treatments will consequently spread the deadly cells via 
metastasis invading nearby tissue or other parts of the body which are known as 
secondary lung cancer. Some of the causative factors contributing to respiratory 
related cancers are tobacco smoking, air pollution and haze phenomena by rapid 
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industrialization, open burning, automobile exhaust, exposure to radon gas and 
asbestos. Cancer of the lung and bronchus (all cell types), larynx, nasal cavity, 
paranasal sinuses and nasopharynx are associated with both tobacco smokers 
and exposure to second-hand tobacco smoke. The carcinogenic agents in the 
tobacco smokes are polycyclic aromatic hydrocarbons, N-nitrosamines, 1,3-
butadiene, benzene, aromatic amines and various aldehydes (Cogliano et al., 
2011). In this research project, the lung adenocarcinoma cells (A549) and the 
novel squamous nasopharynx cells (HK1) have been specifically selected since 
clusianone (29) has never been tested against respiratory carcinoma cell lines. 
Both A549 and HK1 cells overexpress human growth factor receptor (EGFR) 
(Stabile et al., 2005; Ma et al., 2010).    
 
1.1.1 Lung cancer 
Lung cancer can be identified by observing their morphology and 
appearance under the microscope. Generally, there are two main types of lung 
cancers commonly known as non-small cell lung cancer and small cell lung 
cancer. Non-small cell lung cancer (NSCLC) accounts for 80-85% of lung 
cancers while small cell lung cancer accounts for the remaining 15-20% 
(Goulart et al., 2001).  
Lung adenocarcinoma (Figure 1.1) accounts for 40% of the lung cancer 
cases with 15% and 10% of five years survival rates of these cases respectively, 
in the United States and Europe (Parkin et al., 2002). Several options are 
available to treat lung cancer such as surgery, radiation, chemotherapy and 
targeted therapy. Patients treated with chemotherapy will be treated with two 
combinations of drugs which are a combination of one platinum based drug and 
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other commonly used drugs such as paclitaxel, docetaxel, etoposide, 
vinorelbine, gemcitabine and pemetrexed. This type of chemotherapy is also 
known as chemotherapeutic drug cocktails. The platinum-based chemotherapy 
drug used is either cisplatin or carboplatin drug which is widely used in the 
treatment of advanced non-small cell lung carcinoma (Bareschino et al., 2011).  
 
 
Figure1.1 The location of both adenocarcinoma of the lung (A) and 
nasopharynx carcinoma (B) from (Chen, 2012) 
 
 
1.1.2 Nasopharyngeal cancer 
 Nasopharyngeal carcinoma (NPC) is a type of malignant neoplasm 
arising from the mucosal epithelium of the nasopharynx, which is located at the 
entrance of the Eustachian tube (Figure 1.1). It is also generally classified as 
head and neck cancer type. Nasopharyngeal cancer is very predominant in 
Southern China (including Hong Kong) and also prevalent in South East Asian 
countries. The World Health Organization classifies nasopharyngeal carcinoma 
into three types namely squamous cell carcinoma, non-keratinizing carcinoma 
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and undifferentiated carcinoma. Elderly generation affected by NPC are most 
likely to be affected by squamous cell carcinoma. Similarly to lung cancer cells, 
these nasopharyngeal carcinoma cells have the tendency to metastasize and 
normally spreads to  cervical lymph nodes (Brennan, 2006). 
One of the main contributors of NPC is the consumption of salted 
preserved fish which is consumed in several regions around the world especially 
in the different areas of Southern China. The over expression of epidermal 
growth factor receptor (EGFR) are observed in some NPC cells and can be 
linked to being the contributing factor of the cancer  (Ma et al., 2010). Some 
studies confirmed that there is a link between NPC and human leukocyte antigen 
profile. A study reported the affected siblings in Singapore having a 20-fold risk 
for NPC because they  were identified with a gene locus close to human 
leukocyte antigen (Parkin et al., 2002). A type of virus known as EBV (Epstein-
Barr virus) is also associated with particular forms of NPC including other types 
of cancers such as Hodgkin's lymphoma and Burkitt's lymphoma (Maeda et al., 
2009).  
An association between EBV infection and this cancer is complex and 
not many researches have been conducted to completely understand the link 
between the EBV and NPC. However, one possible mechanism to link between 
the salted fish consumption includes the formation of N-nitrosamines and other 
N-nitroso compounds during the processing of the fish and/or endogenously 
after ingestion in the human body. There was also experimental data indicating 
salted fish extracts which can reactivate EBV in latently infected cells in vitro 
(Secretan et al., 2009).  
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NPC is treated by using surgery, radiation and chemotherapy and 
targeted therapy. A number of drugs have been tested and approved for the 
treatment of NPC such as gemcitabine, capecitabine, oxaliplatin as well as 
platinum based drug cisplatin. Cisplatin is used together with another drug such 
as 5-fluorouracil (5-FU) even after radiation therapy for better eradication of the 
remaining cancer cells in a patient’s body. Similarly to the treatment of NSCLC, 
patients diagnosed with NPC can be treated with targeted therapy utilizing 
cetuximab monoclonal antibodies (Chan, 2010). 
 
1.2 Natural products for cancer treatment 
Terrestrial plants have been used as disease treatment by humans 
thousands of years ago, ever since our ancestors have been chewing on herbs to 
relieve from pain or sufferings from diseases. It is estimated that only 10%  of  
the 250,000-300,000 plants all over the world have been investigated for the 
presence of bioactive compounds (McChesney et al., 2007). By 1992, it was 
reported that the National Cancer Institute (NCI) managed to screen 33,000 
plant extracts and found 3 plant extracts that were active against antitumour 
activity.  In addition to the screening activity, many efforts were also made to 
improve the methods used to screen the cytotoxicity effect of these plant 
extracts against various tumour cell lines (Rates, 2001).  
By 1995, NCI successfully prepared 40,000 plants extracts and 18,000 
extracts were tested for antitumour activity. In addition, the biodiversity of our 
country tropical rainforest gives us more opportunity to discover the various 
secondary metabolites which could have potential cancer fighting mechanism.  
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Over the last few decades, scientists have utilized different methods of 
synthesis including total synthesis, semi-synthesis and combinatorial chemistry 
to produce lead compounds that are natural product inspired. This makes 
structural derivatives selection for the new drug easier since natural product-
lead compounds  most often possess ‘drug-like features’. Some drugs were 
chemically modified from its originally isolated plant lead compound and 
showed a stronger effect compared to its original compound when tested against 
antitumour activity (Rates, 2001).  
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1.3 Problem statement  
The current state of research on clusianone (29) emphasizes the total 
synthesis of clusianone (29) involving 30-40 reaction steps with low yield 
production. Furthermore, natural product research in the optimization of 
clusianone (29) from plant extracts using expensive high speed counter-current 
chromatography afforded high yield of clusianone (29) with only 90% purity. 
Unfortunately, the limited supply of high purity (˃ 98%) clusianone (29) 
prevented further potential anticancer activity and clusianone (29) derivatives 
development. The isolation of clusianone (29) from the leaves of G. parvifolia 
has made the optimization method a lot more efficient and sustainable since it 
was present more abundantly as compared to other parts of Clusiaceae plant. 
This potentially allowed the discovery of clusianone (29) derivatives as 
cytotoxic compounds. 
To date, potential anticancer pathway studies of clusianone (29) were 
performed on HepG2 cells which were estrogen receptor (ER) positive cells. It 
was also postulated that clusianone (29) interaction with estrogen receptor (ER) 
may have contributed to apoptosis via intrinsic pathway in HepG2 cells. 
However in this research, male derived lung cells A549 and nasopharyngeal 
cells HK1 were specifically selected since these cells expressed almost 
insignificant estrogen receptors (ER) compared to cells derived from female 
cells. These A549 and HK1 cells overexpress human growth factor receptor 
(EGFR). Since type B PPAP compounds have been demonstrating inhibitory 
activity of tubulin assembly of carcinoma cells, mode of action of clusianone 
(29) and derivatives were further studied as antimicrotubule agents.  
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1.4 Aims and objectives of the research 
 
Based on the problem statements, the research has been performed 
with the following specific objectives:  
 
1) Optimization of high purity (˃ 98%) clusianone (29)  from leaves of 
G.parvifolia through recrystallization method. 
 
2) To synthesize clusianone (29) derivatives with less than 2 step reaction with  
more than 50% yield and to characterize the derivatives using ESI-MS, X-ray 
crystallography, 1H NMR and 13C NMR spectroscopic methods. 
  
3) To evaluate cytotoxicity and study the structure-activity relationship of 
clusianone (29) and derivatives on MRC5 (lung fibroblast), A549 (lung 
adenocarcinoma), NP69 (immortalized nasopharyngeal epithelial cell and HK1 
(squamous carcinoma of the nasopharynx) using MTT (3-(4, 5-dimethylthiazol-
2-yl)-2, 5-diphenyltetrazolium bromide) assay. 
 
4) To determine the downregulation of protein expression of β-tubulin, Cdk1 
and cyclin B1 by clusianone (29) and potent derivatives treated cancer cells 
using Western blot method.   
 
5) To propose affinity and type of interaction of the inhibitors of clusianone (29) 
and potent derivative towards microtubule system of cancer cell lines and 
determine the cell cycle arrest triggered by the inhibitor of clusianone (29) and 
potent derivative by studying the cell cycle regulators expression. 
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1.5 Research scopes  
There are three main research approaches performed in order to study 
the potential anticancer pathway of clusianone (29) and derivatives.  
The first approach was the extraction, isolation and optimization of the 
amount of clusianone (29) that can be obtained from the leaves of G. parvifolia. 
The isolation was carried out by successive Si gel gravity column 
chromatography which involves chlorophyll removal step with the aid of 
vacuum liquid chromatography. Subsequent fraction purification through 
recrystallization was to afford high purity (˃98%) clusianone (29).  
The second approach was to conduct structure modification to 
clusianone (29) by using straightforward synthetic steps by means of small scale 
reaction conditions. Characterization of clusianone (29) and derivatives was 
performed using spectroscopy methods including electron spray ionisation mass 
spectrometry and nuclear magnetic resonance. Structure elucidation using X-
ray diffraction method was employed for compounds obtained in crystal forms. 
The clusianone (29) derivatives ideally produced in good yield (˃50%) were 
studied for cytotoxic activities. 
 The third approach was to screen the cytotoxic potential activities of 
clusianone (29) and potent derivatives against MRC5 (lung fibroblast), A549 
(lung adenocarcinoma), NP69 (immortalized nasopharyngeal epithelial cell and 
HK1 (squamous carcinoma of the nasopharynx) using MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Pathway studies 
were conducted using Western blot method to investigate the biological 
property of clusianone (29) and potent derivative as antimicrotubule agents. 
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Western blot method was employed to further elucidate the downregulation of 
the protein expression of β-tubulin including cell cycle regulators Cdk1 and 
cyclin B1 in clusianone (29) and potent derivative treated carcinoma cells. 
 
1.6 Significant of the research  
             The significant of the research was the development of imine derivative 
of clusianone (29) which have led to the discovery of potent CMeA (56) as 
antimicrotubule agent. Most of the published papers on structure-activity 
relationship of PPAP compounds were addressing hydroxyl group as the main 
functional group contributing to its potential cytotoxic activity. Focus of this 
study was to introduce amine functional group into clusianone (29) structure 
and enhance current clusianone (29) potential anticancer activities. The results 
obtained from biological tests revealed clusianone (29) as a potential 
antimicrotubule agent. Furthermore, the research provides information 
regarding the respiratory carcinoma cell death occurrence by clusianone (29) 
and CMeA (56).  Overall, this research has provided the insights of clusianone 
(29) and CMeA (56) being a potential antimicrotubule agent since expression 
of β-tubulin and cell cycle regulators Cdk1 and cyclin B1 were downregulated 
and consequently signifying cell death via apoptosis occurring upon cell cycle 
arrest at G2/M phase. 
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CHAPTER 2: LITERATURE REVIEW 
 
2.0 Clusiaceae family plants 
Plants in the Clusiaceae family are abundance source of phytochemicals 
particularly secondary metabolites with various biological activities (Acuña et 
al., 2009). The major classes of secondary metabolites have been isolated from 
these plants are xanthones, coumarins and benzophenones. The Clusiaceae 
comprises of 36 genera and around 1610 species which are mainly distributed 
throughout the tropics, although plants in a few genera are found in temperate 
regions. The previously segregated genera Rheedia, Ochrocarpus, 
Pentaphalangium and Tripetalum are now accepted as part of genus Garcinia 
(Table 2.1) (Gustafsson et al., 2014). The presence of latex is a common 
character of this family. The Clusiaceae is comprised of three subfamilies: the 
Kielmeyeroideae, the Hypericoideae, and the Clusioideae.  
The genus Garcinia includes more than 250 species of dioecious trees 
and shrubs with pantropical distribution, with its center of diversity in Southeast 
Asia and Madagascar. The floral characters exhibit a high variability in this 
genus, thus taxonomical issues arise when studying these plants. A broad 
concept of the genus was supported by a recent molecular phylogenetic study, 
including a geographically, morphologically, and taxonomically 
comprehensive sampling (Sweeney, 2008). To date, research has shown that 
extracts of the Garcinia genus particularly G. mangostana (Moongkarndi et al., 
2004), G. cowa (Deharo & Ginsburg, 2011), G. atroviridis (Mackeen et al., 
2000) and G. parvifolia (Syamsudin et al., 2007) exhibit diverse biological 
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activities such as antibacterial, antioxidant, antiinflammatory, antitumor-
promoting, cytotoxic, antimalarial, and antiplasmodial.  
 
Table 2.1 Classification of genera in the Clusiaceae modified from 
(Gustafsson et al., 2014) 
A. Subfamily 
Kielmeyeroideae 
Engler 
 
 
 
 
 
 
 
Tribe Calophylleae Choisy       Tribe Endodesmieae Engler 
Neotatae Maguire                       Endodesmia Bentham 
Marila Swarzt                             Lebrunia Staner 
Mahurea Aublet 
Kielmeyera Martius  
Caraipa Aublet 
Haploclathra Bentham 
Poeciloneuron Beddome 
Mesua L. 
Kayea Wall 
Mammea L. 
Calophyllum L.  
 
B. Subfamily 
     Hypericoideae     
     Engler 
 
 
 
 
 
 
Tribe Vismieae Choisy                 Tribe Hyperiaceae Choisy  
Vismia Vand                                   Hypericum L. 
Harungana Lamarck                      Lianthus N.Robson 
                                                       Triadenum Raf. 
Tribe Cratoxyleae  
Bentham                                         Thornea (Breedlove& 
Cratoxylum Blume                         Mc.Clintock)  
Eliea Cambess                               Santomasia N.Robson 
C. Subfamily 
     Clusioideae  
     Engler             
 
 
 
 
 
 
 
Tribe Clusielleae (P.F.Stevens)    Tribe Symhonieae Choisy      
Clusiella Planch. & Triana               Pentadesma Sabine            
                                                          Moronobea Aublet 
Tribe Clusieae Choisy                     Platonia Martius 
Clusia L.                                           Montrouziera Planch &  
Dystovomita D’Arcy                         Triana                          
Tovomita Aublet                                Lorostemon Ducke 
Chrysochlamys Poepp.                      Thysanostemon Maguire       
Tovomitidium Ducke                         Symphonia L.f. 
Tribe Garcinieae Choisy 
Garcinia L. 
Penthalangium Warb. 
Rheedia L. 
Tripetalum K.Schum. 
Allanblackia Oliver 
Ochrocarpus Thouars 
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2.1 Garcinia parvifolia (Miq.) Miq 
G. parvifolia’s is also known as ‘asam kandis’ in Malaysia. The species 
of Garcinia is found mainly in Kalimantan, Indonesia including other world 
tropics such as Thailand, Peninsular Malaysia, Sumatera, Java, Borneo 
(Sarawak, Brunei, Sabah and Kalimantan), Celebes, Moluccas and New Guinea. 
It is a sub-canopy tree reaching 25 meters tall with green leaves and 
yellow/orange fruit (Figure 2.1). Young G. parvifolia leaves are used in 
Indonesian cooking and the fruit is edible. The leaves grow to a length of 3.5 
cm-17 cm long with the width in the range of 2.0-7.0 cm and petiole length from 
0.5-1.5 cm (Lim, 2012). 
 
 
Figure 2.1 (A) G. parvifolia tree in Sg.Congkak, Selangor. (B) Pink flower of 
G. parvifolia plant and (C) yellow pale orange fruit of G. parvifolia  from (Lim, 
2012). 
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Some species have been used as traditional medicines and have been 
shown to contain isoprenylated xanthones and bioflavonoids. Crude extracts of 
some parts of G. parvifolia such as roots, stem bark, fruit and leaf, can be 
dissolved in various organic solvents such as ethanol, hexane, methanol and 
ethyl acetate. The crude extracts of these plants were screened for anticancer, 
antibacterial, antioxidant and antiplasmodial activities (Lim, 2012). To date, the 
leaf extract of G. parvifolia has afforded significant amount of  novel prenylated 
depsidones compounds which demonstrated good cytotoxic activity (Xu et al., 
2000).   
Some studies using the stem bark and root extracts of this plant have 
shown to have strong bioactivity such as antiplasmodial and antibacterial 
activities particularly against Staphylococcus aureus (Syamsudin et al., 2007). 
Phytochemical studies on leaves of G. parvifolia has led to the further discovery 
of new benzoquinone derivative namely parvifoliquinone (1) and other six 
known compounds which include two phloroglucinols, depsidones, flavonoid, 
xanthone and benzopyran derivative. These compounds were further tested on 
methicillin- resistant Staphylococcus aureus (MRSA) and parvifoliol B (2) 
showed potential antibacterial activity  with a MIC of 32 µg/mL 
(Rukachaisirikul et al., 2008). 
Two known xanthones, parvixanthones A (3) and rubraxanthone (4) 
isolated from G. parvifolia exhibited cytotoxic to L1210 murine leukemic cells 
with the  IC50 values in the range of 3-8 µg/mL (Kardono, 2006). Apart from 
this other compounds isolated from this species includes xanthones: 
rubraxanthone (4), triterpenoids: α-amyrin (5) (Ee & Cheow, 2007), daphnifolin 
(6), benzophenone:  isoxanthochymol (7) (Ee et al., 2009). Rubraxanthone (4) 
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was found to exhibit strong lethal dose activity against the larvae of Aedes 
aegypti and human promyelocytic leukemia cells (HL60).  
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2.2 Chemistry of PPAP (Polycyclic polyprenylated acylphloroglucinols) 
PPAPs consists of a bicyclo[3.3.1]nonane-2,4,9-trione skeleton 
surrounded by substituents made up of several prenyl and geranyl groups 
including an acyl group. There are further classified as PPAP type A (8), B (9) 
and C (10) by the relative position and configuration of  the substituents that 
possesses one common central bicyclo[3.3.1]nonane-2,4,9-trione core as shown 
in (Figure 2.2) (Biber et al., 2011). Since these benzophenones have a few 
prenyl groups attached to central bicyclo [3.3.1] nonane-2,4,9-trione, they exert 
hydrophobicity characteristic and are known to be non-polar phenolic 
compounds (Ciochina & Grossman, 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  2.2 Type A, B and C PPAPs extracted from (Ciochina & Grossman, 
2006). 
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The first PPAP isolated was hyperforin (11), and it is now classified as 
type A (8) PPAP (Cuesta-Rubio et al., 2001). In 1975, Bystrov and coworkers 
were able to determine hyperforin‘s structure and its absolute stereochemistry 
(Bystrov et al., 1975). The first two type B (9) PPAPs named xanthochymol 
(12) and isoxanthochymol (7) were isolated in 1973 by Rama Rao and 
coworkers from fruits of G. xanthochymus. The structure given at the time for 
xanthochymol (12) was monocyclic.  
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Type B (9) PPAP clusianone (29) was discovered in crystal forms for 
the first time in the bark extracts of Clusia congestiflora, and the structure was 
determined using X-ray crystallography in 1976 (McCandlish et al., 1976). 
Nemorosone (13) and hydroxynemorosone (14) were first isolated by Oliveira 
who assigned them to be type C (11) PPAP (Oliveira et al., 1996). However in  
2001, nemoresone (13) isolation from floral resins of Clusia rosea and 
nemorosone characterization revealed that it had the type A (8) structure where 
the positions of the bridgehead substituents were different from the previously 
assigned substituents position (Cuesta-Rubio et al., 2001). 
The first type C (11) PPAP was reported by the Lin group in 2004, and 
they have isolated garcinielliptones M (15)  and L (16)  from the seeds of G. 
subelliptica (Weng et al., 2004). 
 
2.3 Biosynthesis hypothesis of PPAP 
Phytochemistry via labelling experiment and various enzymology 
studies in plants showed that one acyl-CoA and three malonyl-CoA units are 
involved in polyketide-type biosynthesis (Adam et al., 2002). Thereafter, 
acylphloroclucinol is produced by cyclized tetraketide through Diekmann 
condensation reaction (Scheme 2.1). Subsequent prenylation or geranylation  
reactions are catalysed by enzyme occurs in order to introduce prenyl and 
geranyl pyrophosphate to the phloroglucinol compound (Boubakir et al., 2005; 
Liu et al., 2003; Ciochina & Grossman, 2006). 
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Scheme 2.1 Biosynthesis of MPAPs modified  from (Ciochina & Grossman, 
2006) 
 
 According to Cuesta-Rubio et al. (2001), a tertiary carbocation 
formation is involved in the creation of type A (8) and type B (9) PPAP (Scheme 
2.2). This tertiary carbocation is formed when the geminal prenyl groups of an 
MPAP reacts with prenyl pyrophosphate (PPO). Finally, type A (8) PPAP is 
formed when C(1) attacks the tertiary carbocation  and type B is formed when 
C(5) attacks the tertiary carbocation (Cuesta-Rubio et al., 2001). 
 
Scheme 2.2  Proposed cyclization of MPAPs  in formation of  type A (8) and 
type B (9) PPAPs modified from (Ciochina & Grossman, 2006) 
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The synthetic communities of PPAP compounds are now turning into 
biosynthetic inspired approach to create new derivatives of PPAP compounds. 
According to the biosynthetic hypothesis, PPAP compounds are assumed to be 
derived from three main components with the starting component being a 
desoxyhumulone substrate as shown in Scheme 2.3 and additional two prenyl 
cations. The function of the two prenyl groups is to build the bicyclo [3.3.1] 
nonane core through two major events which is through dearomative 
prenylation and alkene-intercepted prenylation. The biosynthetic hypothesis 
employed in the method development afforded type A (8) PPAP such as 
nemoresone (13). The research has also successfully synthesize different types 
of type A (8) and type B (9) PPAP  derivatives through both double 
decarboxylative allylation (DcA) and dearomative conjunctive allylic alkylation 
(DCAA) (Grenning et al., 2014).  
 
Scheme 2.3 Biosynthetic hypothesis of PPAP’s (Grenning et al., 2014) 
 
 
 
 
22 
 
2.4 Anticancer effects of Polycyclic polyprenylated acylphloroglucinols 
from Clusiaceae 
Hyperforin (11) is a type A PPAP commonly found in the plant of genus 
Hypericum. Hyperforin (11) was isolated from St.John’s wort (Hypericum 
perforatum) and the discovery has led scientist to reveal its ability to inhibit 
tumour cell growth by induction of cell death via apoptosis. Interestingly, some 
research using hyperforin (11) has permitted in vivo test to be investigated in 
rats and in vitro test on various human tumour cell lines. Remarkably, IC50 
values of the tumor growth of hyperforin (11) on human carcinoma cell lines 
were between the range of 1-7 µM while subsequent test on rat tumour cell lines 
demonstrated IC50 value between the range of 1-9 µM. The effects of hyperforin 
(11) were dose dependent generation of apoptotic oligonucleosomes, typical 
DNA-laddering and apoptosis-specific morphological changes (Schempp et al., 
2002).  
In vitro hyperforin (11) test against MT-450 mammary carcinoma cell 
increased the activity of caspase-9 and caspase-3 which were  related to proteins 
expressed during the process programmed cell death. Further in vitro test using 
MT-450 mammary carcinoma cell also compared the activity of both hyperforin 
(11) and paclitaxel (17) which prevailed that hyperforin (11) solely was 
responsible for the rapid loss of mitochondrial transmembrane potential and 
displayed vacuolization of mitochondria when visualized under electron 
microscope. In addition, isolated mitochondria from MT-450 mammary 
carcinoma cell revealed that hyperforin (11) was capable of releasing 
cytochrome c and postulated that hyperforin (11) initiates cell death via 
mitochondria-mediated apoptosis pathway. Most importantly, the results of in 
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vivo test utilising autologous MT-450 breast carcinoma in Wistar rats were 
profound with hyperforin (11) demonstrating almost comparable cytotoxicity 
activity to paclitaxel (17) with no effects of acute toxicity (Schempp et al., 
2002). In subsequent approach, scientists have also managed to create potent 
derivative of hyperforin (11) namely Aristoforin (19) and it has shown 
significant antitumor activity in both in vitro MT-450 rat mammary tumour cells 
and in vivo experiments (Gartner et al., 2005; Richard, 2014).  
 
Nemorosone (13), a natural-occurring type A PPAP from Clusia Rosea, 
has gained attention from the natural product community due to its strong 
anticancer activity on various cancer cell lines such as colon, liver, lung, ovary 
and breast carcinoma with an interesting molecular mechanism of action. 
Nemorosone (13) exhibited cytotoxicity activity against neuroblastoma cell line 
with IC50 in the range below 6.5 µM. Consequently, nemorosone (13) induced 
DNA damage and caspase-3 activation leading to apoptosis which was observed 
in a dose dependent manner. Cell cycle analysis using flow cytometry showed 
that nemorosone treated cells were majority in the G0/G1 fraction and declined 
in S-phase population (Pardo-Andreu et al., 2011).  
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To further investigate the cell cycle arrest at G1 to S phase, 
immunostaining technique utilizing Western blot was employed to study the 
expression of p21Cip1(cyclin dependent kinase inhibitor). The p21Cip1 are 
essential as regulators of cyclin D/cyclin dependent kinases (Cdk) 4 and cyclin 
E/cyclin dependent kinases (Cdk) 2 which are important cell cycle regulators in 
G1 progression to S phase of cell cycle. Based on the Western blot analysis, 
nemorosone (13) induced the overexpression of p21Cip1 in a dose dependent 
manner indicating cell death via cell cycle arrest at G1 to S phase (Díaz-Carballo 
et al., 2008). Apart from this, studies using cytotoxicity assay revealed that 
nemorosone (13) exhibit the toxic effect in the range (1–25 μM) on liver 
carcinoma (HepG2) cells. In order to study mechanism of action of nemorosone 
(13), mitochondrial were isolated from rat liver cells. The results indicated that 
nemorosone caused early mitochondrial impairment along with ATP depletion 
(Pardo-Andreu et al., 2011). 
Garcinol (20) and xanthochymol (12) are two most prominent type B 
PPAP with various bioactivity have been studied and cited for its anticancer 
bioactivity  over the past few years (Pan et al., 2001; Matsumoto et al., 2003; 
Hong et al., 2007; Protiva et al., 2008; Padhye et al., 2009; Zhang et al., 2011). 
Most of these including animal model experiments indicate garcinol (20) 
induced cell cycle arrest at G1 phase. Type B PPAP compound such as 
xanthochymol (12), guttiferone E (21), garcinol (20) and oblongifolin A (22) 
have been tested for tubulin assembly assay and remarkably xanthochymol 
demonstrated significant activity almost comparable to taxol (17) in tubulin 
assembly inhibition test in nasopharyngeal carcinoma (KB) cells (Roux et al., 
2000). It is noticed that oblongifolin (22) showed weak inhibition activity 
25 
 
against tubulin assembly assay compared to garcinol (20) (Hamed et al., 2006). 
Garcinol’s (20) effect on some cancer lines have been linked with the increase 
in the activity of caspase-3, possibly inducing apoptosis (Matsumoto et al., 
2003; Hong et al., 2007). Apart from caspase activation, type B PPAP 
compounds have been associated with the same mechanism as that of paclitaxel 
(17), but at a lower potency (Roux et al., 2000).  
 
 
As for type C PPAP, garcinielliptones FB (23) was isolated from 
Garcinia subelliptica and has shown moderate activity against liver (IC50= 6.8 
μg/mL), breast (IC50 = 6.3 μg/mL) and colon (IC50= 11.2 μg/mL) cancer cell 
lines (Wu et al., 2008). In addition, the extraction and column chromatography 
fractionation of fruit extracts of Garcinia subelliptica afforded six new 
polyisoprenylated benzophenoids (±)-garcinialiptinone A (24), B (25), C (26) 
and D (27) and several known compound xanthochymol (12), isoxanthochymol 
(7) and cycloxanthochymol (28). All compounds were tested against non-small 
lung carcinoma (A549), prostate carcinoma (DU145), and nasopharyngeal 
OHO
O
O
OH
OH
OHO
O
O
OH
OH
OHO
O
O
OH
OH
(20) (21) (22)
26 
 
carcinoma (KB) cell lines together with paclitaxel as a drug control. The 
cytotoxicity data showed that all the polyisoprenylated benzophenoids 
compounds had significant IC50 value in between the range 4-5 µg/mL although 
it is  2000-fold less effective than paclitaxel (Zhang et al., 2011). 
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2.5 Clusianone (29) type B PPAP (Polycyclic polyprenylated 
acylphloroglucinols) 
Clusianone (29) is a polycyclic polyprenylated acylpholroglucinols 
(PPAP) isolated from the plants of the Clusiaceae (Guttiferae) family which has 
gained significant interest to study its potential bioactivity. Naturally occurring 
clusianone (29), exhibited anti-HIV (Piccinelli et al., 2005) and anti-cancer 
properties (Ito et al., 2003; Reis et al., 2014).  
First reported in 1976, clusianone (29) was isolated from the roots of 
Clusia congestiflora and X-ray diffraction analysis has firmly established the 
equatorial orientation of the 3-methyl-2-butenyl group at C-7 position 
(McCandlish et al., 1976). Subsequent isolation of clusianone (29) from Clusia 
sandiensis (Monache et al., 1991) and Clusia spiritu-santensis (Oliveira et al., 
1996) reported the NMR spectroscopy of clusianone (29) and its methyl 
derivative respectively which leads to the contradictory NMR data for 
clusianone (29). Unfortunately, due to the complexity of the data and the 
unavailability of authentic sample of clusianone (29), no report was made of the 
C (7) stereochemistry.  
Santos and coworkers isolated 7-epiclusianone (30) from Rheedia 
gardneriana and reported its NMR (Santos et al., 2001) including  X-ray crystal 
structure (Santos et al., 1998), showing the C(7) exo isomerism. The absolute 
structure of (+)-7- epi-clusianone (30) possessing the C-7 prenyl group at axial 
orientation while comparing to clusianone (29) that was isolated in 1976 had C-
7 prenyl group established at equatorial position.  
Finally, in 2005, both tautomeric pairs of clusianone (29) and epi-
clusianone (30) were isolated from the fruits of Clusia torresii (Piccinelli et al., 
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2005). The structures were solved by NMR spectroscopy and the report 
confirmed that the compound isolated from Clusia sandiensis in 1991 was 
actually epiclusianone (30). In this study, the clusianone (29) were isolated from 
the leaves of G. parvifolia collected from tree in a reserved forest Sungai 
Congkak Selangor (Nagalingam et al., 2013). 
 
 
 
                  
 
                   (29)  (30) 
Over the last decade, attempts to study the bioactivity of clusianone (29) 
which includes cancer chemopreventive activity and HIV activity has gained 
much interest from the international chemical community to make research 
breakthrough in the total synthesis of clusianone (29) (Njardarson, 2012). These 
growing evidence has consequently led the chemist community to explore 
various methods in the total synthesis of clusianone (29) (Tsukano et al., 2007; 
Ahmad et al., 2007; Nuhant et al., 2007; Qi & Porco, 2007; Garnsey et al., 2011; 
Boyce & Porco, 2014; Horeischi et al., 2015). However, further structure- 
activity relationship of naturally occurring clusianone (29) derivatives has never 
been reported. Therefore, the novelty of this research was emphasized on the 
structure-activity relationship of clusianone (29) which was approached via 
novel synthesis method which was to modify the naturally occurring clusianone 
(29) through chemical synthetic routes.  
O
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2.5.1 Isolation and optimization of clusianone (29) from Clusiaceae family 
Plants 
 In this research, the leaves of G. parvifolia were used to isolate 
clusianone (29) (Nagalingam et al., 2013). The isolation of clusianone (29) from 
the leaves of G. parvifolia has made the optimization of the compound a lot 
more efficient and sustainable since it was present more abundantly as 
compared to those clusianone (29) isolated from dried stem barks of G. assigu 
(Ito et al., 2003) and roots of Hypericum hypericoides (Christian et al., 2008). 
Exploitation of some plants  may result in the extinction of the plant species 
which also leads to the loss of the genes governing the biosynthesis pathway 
required for the production of interesting phytochemicals present in secondary 
metabolite forms (Rates, 2001). 
To date optimization of clusianone (29) from the male flowers of Clusia 
fluminensis was carried out using high speed counter current chromatography 
(HSCCC) (Silva et al., 2012). It was reported that the presence of clusianone 
(29) was 37% of the resin composition of the flowers (Bittrich et al., 2000). 
However, the fact that the clusianone (29) were isolated from flowers clearly 
indicates that this plant collection could only be obtained during the flowering 
season. One point to be taken note was the fact that the isolation of clusianone 
(29) throughout the history has proven that this compound could exist in the 
various parts of the targeted Clusiaceae plant which covers the fruits (Piccinelli 
et al., 2005), flowers (Bittrich et al., 2000; Silva et al., 2012), leaves 
(Nagalingam et al., 2013), roots (McCandlish et al., 1976; Christian et al., 
2008), stems and barks (Ito et al., 2003). 
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2.5.2 Bioactivity of clusianone (29) and its epimer  
2.5.2.1 Chemopreventive and anticancer activity 
Clusianone (29) exhibited chemopreventive activity as reported by Ito 
and coworkers (Ito et al., 2003). Clusianone (29) isolated from Garcinia assigu 
was treated to Raji cells. Treatment of the clusianone (29) on Epstein-Barr virus 
early antigen (EBV-EA) activation induced by 12-O-tetrade-canoylphorbol-13-
acetate (TPA) in Raji cells showed potential chemopreventive activity when 
compared to glycyrrhetic acid, a known anti-tumor promoter (Ito et al., 2003).  
Clusianone (29) and other polyprenylated acylphloroglucinols (PPAPs) 
such as nemorosone (13) are known cytotoxic compounds. Simpkins screened 
synthetic clusianone (29) for cytotoxicity in cervix carcinoma (HeLa), breast 
carcinoma (MCF7) and pancreatic carcinoma (MIA-PaCa-2) cell lines. The IC50 
was evaluated using the resazurin assay. Both enantiomers of clusianone (29) 
were evaluated separately with (-)-clusianone giving the lower IC50 values 
(more potent) than (+)-clusianone (29). Clusianone (29) was most potent in 
cervix carcinoma cells: IC50 3.0 (+/- 1.1) μM for (-)-clusianone. The IC50 values 
ranged from 3.0 to 8.3 μM for the three cancer cell lines (Simpkins et al., 2012). 
It has been by protonophoric mitochondrial uncoupling; efflux of 
mitochondrial proposed by Reis et al. (2014) that clusianone (29) causes its 
cytotoxicity effects in HepG2 (hepatocarcinoma) cells protons from the internal 
membrane space into the mitochondrial matrix resulting in dissipation of 
membrane potential. At low concentrations necrosis predominated as the main 
route of cell death possibly due to depleted ATP levels; at higher concentrations 
mitochondria-mediated apoptosis dominated. This method of cytotoxicity was 
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similar to that identified for nemorosone (13) which is a regioisomer of 
clusianone (29) (Pardo-Andreu et al., 2011).  
However, the extent of protonophoric and cytotoxic activity is less for 
clusianone (29) than nemorosone (13). HepG2 cell death was preceded by a 
concentration-dependent mitochondrial membrane potential dissipation and 
decreased mitochondrial ATP levels, suggesting that the cytotoxic function of 
clusianone (29) includes early mitochondrial impairment, which could then lead 
to apoptosis via the intrinsic pathway. It has been suggested that nemorosone 
(13) is most active as an anticancer agent against estrogen receptor (ER) positive 
cells, most likely due to its antiestrogenic activity (Camargo et al., 2013).  
Since HepG2 cells express ER, the nemorosone (13) and clusianone (29) 
interaction with this receptor could also contribute to HepG2 cell death. It has 
been demonstrated that the removal of the 3-hydroxyl substituent from estradiol 
significantly decreases receptor binding (Chernayaev et al., 1975). Similarly, 
nemorosone (13) and clusianone (29) contain a hydroxyl group capable of 
mimicking the hydroxyl group in the ring of estradiol, which interacts with the 
receptor, these compounds could conceivably bind to and compete for the 
estrogen receptor. Thus, a lower binding capacity of clusianone (29) to this 
receptor could be expected due to the presence of an intramolecular hydrogen 
bond involving the hydroxyl group with the juxta-posed carbonyl group at C15 
(Reis et al., 2014).  
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2.5.2.2 Anti HIV properties 
Clusianone (29) has not only become of interest as a potential anti-
cancer agent. There has been a lot of work investigating its anti-HIV properties. 
When tested in HIV infected C8166 human T lymphoblastoid cells both 
clusianone (29) and 7-epiclusianone (30) were active against gp120 at very low 
concentrations (EC50 0.02-2.0 μM); however, this was also associated with 
increased toxicity to uninfected C8166 cells. Clusianone (29) acts at the 
attachment and fusion part of the HIV infection cycle as it prevents the gp120- 
CD4 interaction between the virus and the host cell (Piccinelli et al., 2005). A 
further study of the anti-HIV activity of individually synthesized enantiomers 
of clusianone (29) showed very similar IC50 values for (+)-clusianone and (-)-
clusianone (29) of 1.53 and 1.13 μM, respectively (Garnsey et al., 2011). 
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2.6 Antimicrotubule agents derived from natural product via chemical 
modification 
Natural product compounds have been an inspiration to medicinal 
chemist because these molecules possess drug likeliness and biological 
friendliness compared to totally synthetic molecules. Scientist has utilized 
different methods of synthesis including total synthesis, semi-synthesis and 
combinatorial chemistry to produce lead compounds that are natural product 
inspired (Figure 2.3). Particularly synthesis and molecular modelling 
researchers prefer using natural product drug as a template, making them a 
reliable candidate to further drugs development studies. Some of the natural 
plant-lead compound such as taxol (17), xanthochymol (12), and guttiferone 
(21) were further chemically modified and remarkably the efforts lead to the 
discovery of a more potent lead compound in tubulin assembly inhibition 
activity.  
 
Figure 2.3 The sources of anticancer drugs over the period 01/1981-12/2010 
extracted from (Cragg & Newman, 2013). 
 
ND, 28%N,13%
S*/NM,2%
S*,10%
V,2%
B,13%
S/NM, 9%
S, 21%
S - Totally synthetic
N - Natural Products
ND - Natural Products derived
S*-Totally synthesized inspired
by Natural Product
NM- Natural Product mimic
B -Biological metabolite
V -Vaccines
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To date, structure-activity relationship studies through chemical 
modification on type B PPAP compound as mixture form of xanthochymol (12) 
and guttiferone (21) have been studied. These compounds were claimed to be 
inseparable but exist as major compounds estimated about 40% of the crude 
extract of G. pyrifera. The research successfully synthesized 14 types of various 
derivatives of both naturally occurring xanthochymol (12) and guttiferone (21) 
in mixture forms through hydrogenation, esterification of enol by methylation 
and cyclization, partial dimethylation and hydroxyl modification of the benzoyl 
group. Further to this, the compounds (31-45) were tested against nasopharynx 
(KB) cells and also on microtubule disassembly assay. The studies revealed that 
methylation of the catechol groups and hydroxyl group results in the loss of the 
activity of microtubule assembly inhibition assay unless only one of the enol 
group was methylated. In addition, hydrogenation of all the double bonds has 
led to the loss of microtubule assembly inhibition activity meanwhile 
glycosylated compound (44) through OH modification of one of the catechol 
groups showed interesting microtubule assembly inhibition activity. However, 
one point to be noted is the microtubule assembly inhibition activity has no 
relation to its cytotoxic activity on KB cells (Roux et al., 2000).  
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(39) R1= R2=Me, R3=O, R4=OMe
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One of the phenomenal drug discoveries in natural product is paclitaxel 
(Taxol) (17), a naturally occurring diterpene alkaloid isolated from the bark of 
Pacific Yew, Taxus brevifolia. The drug taxol (17) has been approved by Food 
and Drugs Administration (FDA) and currently commercialized by Bristol-
Myers Squibb (BMS) for the treatment of ovarian cancer, breast cancer, 
advanced kaposi sarcoma, non-small lung cancer, head and neck cancer. 
However, the initial efforts to obtain taxol (17) were hindered by the low yields 
and the most critical factor was that the yew trees have to be harvested in order 
to move forward with large scale extraction of the limited supply of stem barks. 
Consequently, the relative shortage, slow growth and development of the Taxus 
trees made the efforts non-sustainable (Fu et al., 2009).  
Successively, scientist manage to semi-synthesize taxol (17) by the 
conversion of the relatively abundant baccatins to paclitaxel (17) (Baloglu & 
Kingston, 1999). In addition, the non-sustainable efforts were solved by 
isolating paclitaxel (17) and its precursors from fresh branches and leaves 
instead of barks (Witherup et al., 1990; Eric et al., 2000; Zu et al., 2008). 
Significantly, the abundance of renewable resources such as leaves and 
branches instead of using the tree bark provides a good alternative for the 
commercial production of paclitaxel (17). 
Subsequent attempts led to the search for other taxane derivatives 
produced from abundant sources and major accomplishment achieved via semi- 
synthesis method with the discovery of docetaxel (Taxotere) (18) by Bissery 
and co-worker at the French Centre national de la recherché scientifique 
(CNRS). Docetaxel (18) is a semi-synthesis product derived from an inactive 
taxane precursor which can be isolated from the abundantly present yew species 
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such as the European Yew, Taxus baccata. Docetaxel (18) has better solubility 
in water compared to taxol (17) which makes it easier to be administered to 
patients (Bissery et al., 1991). Moreover, docetaxel (18) is almost 100 fold more 
potent anticancer agent than taxol (17) in phosphorylating Bcl-2 (B-cell 
Lymphoma 2) which was related to the differential pro-apoptotic activity in 
cancer cells (Gligorov & Lotz, 2004). Bcl-2 is important protein regulators 
involved in the programmed cell death. Research also revealed that docetaxel 
(18) has a longer retention time in a cell as compared to taxol (17) since it has 
greater cellular uptake into tumour cells and slower efflux from tumour cells 
(Herbst & Khuri, 2003).  
Interestingly, combretastatin (46) has exhibited good inhibitory activity 
against the microtubule dynamics of cancer cells. Combretastatin (46) a class of 
natural phenol isolated from Combretum caffrum possess varying ability to 
cause vascular disruption in tumors. Some of the most potent combretastatin 
which is currently being investigated in phase-I/II clinical trials known is 
phosphate prodrug (CA-4). Combretastatin (CA-4) (47) acts as a microtubule 
formation inhibitor by binding to the β-tubulin sub units of microtubules and 
causes destabilization of tubulin cytoskeleton. Structure-activity relationship 
(SAR) studies of combretastatin have led to the identification of the 
configuration and functional group which is fundamental in increasing its 
bioactivity as antimicrotubule agent. The SAR studies of this benzophenone 
derivatives have significant findings which concluded that the introduction of 
an amino group at the ortho position of the benzophenone ring has increased the 
cytotoxicity activity (Hsieh et al., 2003).  
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(46) R= OH, Combretastatin (CA-1) 
            (47) R= H, Combretastatin (CA-4) 
 
     
 
Clusianone (29) could be a good lead compound to create a better 
anticancer entity since its in vitro anticancer activity has been proven on some 
cancer cells such as cervix carcinoma, pancreatic carcinoma, breast carcinoma 
and hepatocarcinoma (Simpkins et al., 2012; Reis et al., 2014). As such in this 
research, the simple chemical modification method was employed to further 
develop clusianone (29) derivatives which could have higher inhibitory activity 
towards cancer cell proliferation. Simultaneously, the approach allows structure 
activity-relationship of clusianone to be studied since clusianone (29) is a 
potential anticancer agent. The chemical modification on naturally occurring 
clusianone (29) allows the study the structure-activity relationship of clusianone 
(29) against anticancer activity since reasonable amount of clusianone (29) has 
been obtained.  
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2.7 Biological and Pharmacological role of microtubule 
Microtubules are essential in cell mitosis for all eukaryotic cells and also 
are required for the maintenance of cell structure, motility and cytoplasmic 
motion within the cell. Microtubules are structurally hollow cylindrical tubes of 
about 30 nm in diameter which are made up of 13 subunits that are called 
protofilaments or tubulin. Tubulin exists as a dimer of two alternating protein 
monomers: α-tubulin and β-tubulin and has a molecular weight of 55 kDa 
(Luduena, 1998).  
During mitosis, the microtubule rapidly reassembles and disassembles 
to form mitotic spindle allowing cell division to occur. There are currently eight 
types of α-tubulin and eight types of β-tubulin isoforms (Verdier-Pinard et al., 
2009; Leandro-García et al., 2010). Besides that, guanosine-5'-triphosphate 
(GTP) is also essential energy carrier substrate which binds at the minus end of 
microtubule cap and function to stabilize the microtubule dynamics. The 
tubulin-GTP subunits were slowly hydrolysed using its derivative guanylyl-
(a,b)-methylene-diphosphonate (GMPCPP) and later discovered that this 
reaction caused major catastrophe to microtubule dynamics by triggering rapid 
disassembly to the structure (Caplow & Shanks, 1996).  
During the prometaphase of mitosis, microtubule assembly occurs 
actively elongating from centrosome and are essential components in the correct 
alignment and positioning of chromosomes at their kinetochores to the spindle 
after nuclear-envelope breakdown. In the subsequent metaphase stage, 
congression happens whereby microtubule has elongated timely for the 
complex movements and at this point all chromosomes are aligned along the 
equator of the cell. Next, the microtubule plays a role in the synchronous 
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separation of the sister chromatids towards opposite sides of the cell in 
anaphase. Finally, telophase occurs, microtubules disassembles and shortens 
towards the centrosome at the opposite pole of the cells (O’Connor, 2008).  
In summary, microtubules emanating from each of the centrosomes 
positioned at the opposite poles make vast growing and shortening with 
excursions growth for long distances (typically 5–10 µm), then shorten almost 
completely, and then regrow again for the next cell cycle phase to take place. 
The absence of microtubule will cause catastrophe during anaphase stage as 
chromosomes are unable to achieve a bipolar attachment to the spindle. 
Consequently causing cell cycle arrest at prometaphase/metaphase stage leading 
to apoptosis since parent cell is unable to divide/duplicate into two genetically 
identical daughter cells (Caplow & Shanks, 1996).  
 
2.7.1 Tubulin function  
Tubulin having a molecular weight of 100 kDa is found to be present as 
10% protein in brain and 3-4% as total protein in cells. Tubulin isotypes 
formation becomes even complex when it undergoes postranslational 
modification such as phosphorylation, detyrosination, acetylation, 
polyglutamylation and polyglycylation. The variation in either the tubulin or the 
subunit tubulin isoforms are crucial in acknowledging the type of interaction 
with microtubule associated proteins (MAP), dynein motors and kinesin (Janke 
& Bulinski, 2011). In other words, these combination of MAPs and β-tubulin 
isoforms results in a complex “tubulin code” which directs the mechanism 
governing the microtubule dynamics and hence altering the microtubule 
architecture (Verdier-Pinard et al., 2009).  
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2.7.2 β-tubulin isotypes and roles in cancer cells 
The different types of β-tubulin isotypes can be distinguished by the 
variation that occurs at the end part specifically the last 15 sequences of the β-
tubulin C-terminal (Luduena, 1998). The differences in β-tubulin isotypes in 
mammalian cells are associated with tissue specific function and some β-tubulin 
isotypes are expressed more in certain types of both normal and cancer cells 
(Burkhart et al., 2001). The various expression of β-tubulin isoforms patterns 
present in the cell will control the mechanism of inhibition of the microtubule 
dynamics which eventually implicate cell division (Leandro-García et al., 
2010). Specific isotope such as the β1-tubulin, β3-tubulin and β2c-tubulin are 
often linked to tumours (Figure 2.10 B). In some chemotherapeutic trials, the 
studies prevailed that the β3-tubulin and β1-tubulin isotypes are resistance to 
the drugs such as paclitaxel (Magnani et al., 2006; Kavallaris, 2010).   
Figure 2.4 β-tubulin isotypes mRNA expressed in numerous human tissues 
calculated by percentage and displayed in bar graphs. (A) The eight β-tubulin 
isotypes mRNA fractions in nontumoral tissues and (B) The eight β-tubulin 
isotypes mRNA fractions in tumoral tissues.The diagram is modified from 
(Leandro-García et al., 2010). 
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These β-tubulin isotypes generally group with its identical isoforms in 
order to attract cluster of MAP’s which then combines together to initiate or 
complete a specialised task (Caplow & Shanks, 1995). This characteristic of the 
β-tubulin isotypes leads to an ideal drug mechanism hypothesis and a target for 
scientist to discover new drug for chemotherapeutic treatment of cancer cells 
(Ohishi et al., 2007; Jirásek et al., 2009; Narvi et al., 2013).  
 
2.8 Antimicrotubule agents from natural product and mechanism of action  
Over the past decades, scientists around the world have studied drugs 
derived from plants as antimicrotubule agents such as vinca alkaloids and 
colchicines (52). One of the types of interaction these drugs works is by acting 
as a microtubule-stabilizing agent which enhance microtubule polymerization 
at high concentrations preventing disassembly progression after anaphase stage. 
Examples of antimicrotubule agents includes the paclitaxel (17), docetaxel (18), 
vinblastine (48), vincristine (49), epothilones (50), laulimalide (51) and 
polyisoprenyl benzophenones (Dumontet & Jordan, 2010). 
 To date, researchers have significantly showed the tubulin binding site 
of taxol (17). The binding occurs at the β-tubulin protein at the N-terminal 31 
amino acids sequence (Dumontet & Jordan, 2010). This mechanism of action 
was distinctive from the binding sites of other mitotic drugs such as vinca 
alkaloids and colchicine (52). Even though the mechanism of action of these 
antimicrotubule agents might differ but eventually all these compounds disrupts 
the normal dynamic reorganization of the microtubule network required for 
mitosis and cell proliferation and ultimately leading to G2/M cell cycle arrest 
(Figure 2.5 & Figure 2.6).  
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Therefore, the next approach of this research was to study the 
mechanism of action of clusianone (29) and derivatives against microtubule 
dynamics of cancer cells. The β-tubulin protein was selected for protein analysis 
using immunostaining technique since β-tubulin isotypes expression contributes 
to some characteristics of tumour and most importantly being the major 
component of microtubule entity. The Western blot methodology allowed β-
tubulin expression in carcinoma cells to be studied at different time point after 
treatment with clusianone (29) and derivatives. 
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Figure 2.5 Polymerization of microtubule extracted from (Jordan & Wilson, 
2004). 
 
Figure 2.6 The different anticancer drug binding sites on microtubule causing 
disassembly and destabilisation of microtubule polymerization modified from 
(Jordan & Wilson, 2004). 
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2.8.1 The binding site of anti-microtubular drugs on β-tubulin  
Taxol and derivatives binding site to beta tubulin protein has been 
discovered using photoaffinity labelling and electron crystallography methods 
(Rao et al., 1994; Rao et al., 1999). Similar experiments using electron 
crystallography was carried out to determine the binding site of epothilone to 
the receptor site of β-tubulin protein. The findings from the experiment revealed 
that the interaction of both taxol and epothilone are both independent to the 
promiscuous binding pocket of the specific N-terminal of β-tubulin protein 
(Nettles et al., 2004). This has prompted some researchers to aim the specific 
binding site of the drugs to the N-terminal 31 amino acids of β-tubulin via 
molecular modelling studies to establish new sets of derivatives that could  
possibly be a more potent anticancer drug.  
The molecular modelling studies approach was combined with 
quantitative structure-activity relationship studies to create drug entity that was 
presumed to have pharmacaphoric element which enhances the binding 
properties to the protein of interest. The studies also include the binding domain 
properties such as lipophilic and hydrophobic characteristic of the specifics sites 
of protein receptor domain sites. Numerous taxol and epothilones derivatives 
were studied and new methods to synthesize the compound were established. 
(Snyder et al., 2001; Maccari et al., 2003; Renzulli et al., 2006). Other 
microtubule stabilizing agents such as colchicines, laulimalide and peloruside 
were also studied using molecular docking studies to determine the β-tubulin-
binding interaction in an independent manner (Pineda et al., 2004).  
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In one of the molecular modelling approach to study taxol binding site 
to microtubule, it was discovered several different moieties results in the 
interaction (Figure 2.7).  These interactions involve lipophilic domain filled by 
C3’ phenyl, C12 methyl, and C4 acetyl group. In addition to this, there is an 
interaction between C7 hydroxyl and oxetane group of taxol with polar cluster 
region defined by (Thr276, Ser277 and Arg278). The domain existing between 
C3’ benzamido and C2 benzoyl is occupied by His229. The studies also revealed 
that hydrogen bonds contacts were present at C2 benzoyl, C2’ hydroxyl, C3’ 
amido and C7 hydroxy group (Renzulli et al., 2006). 
 
 
Figure 2.7 Taxol binding site to N-terminal 31 amino acids of β-tubulin using 
the PrGen software to develop the minireceptor model modified from (Renzulli 
et al., 2006).  
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2.9 Phases of cell cycle and cell cycle regulators  
The cell cycle refers to a cascade of cellular events leading to the division 
and duplication of cells (Figure 2.8). In eukaryotes, the cell cycle can be divided 
into two periods: the interphase and the mitotic (M) phase. The interphase 
consists of three phases: gap phase I (G1), responsible for the synthesis of 
organelles in most cells; synthesis phase (S), during which DNA is replicated; 
and gap phase II (G2), which is a period in preparation for cell division 
(O’Connor, 2008).  
During the initiation and progression of each phase, cell cycle regulators 
are involved and these cell regulators are heterodimeric enzymes made up of 
cyclin dependent kinases (Cdk’s) subunits and cyclin subunits. Cdk4 and Cdk6 
together with cyclin D regulate the early stage of G1 phase. During the transition 
from G1 phase to S phase cyclin E-Cdk2 complex is required while cyclin A-
Cdk2/ essential for the progression of S phase. The M phase leads to segregation 
of chromosomes and results in two daughter cells, which is the end point of cell 
division. Cyclin B1-Cdk1 regulates the entry and exit of M phase (Williams & 
Stoeber, 2012).  
Sometimes, cells become quiescent or senescent after mitosis; this phase 
of is known as G0. The progression and completion of each phase are activated 
by the previous phase. Theoretically, cells will undergo G1 phase for continuous 
growth after the completion of mitosis. However, in multi-cellular eukaryotes 
cells very often enter G0 from G1 if they are nonproliferative. The time span of 
G0 can be very long, even indefinite in the case of neuron cells and cell types 
which are fully differentiated. It is also a phase for cellular responses to DNA 
damage with affected cells becoming senescent, rendering them at a metabolic 
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active state but unable to divide. It is an alternative to programmed cell death, 
apoptosis (Williams & Stoeber, 2012). 
 
 
 
Figure 2.8 The cell cycle phases (G0, G1, S, G2 and M) and the different stages 
of M phase during the cell replication. In M-phase, the cell goes through 5 
phases: prophase, prometaphase, metaphase, anaphase and telophase for 
separation of chromosomes and finally, the cytoplasm is divided through 
cytokinesis to form two daughter cells. The regulatory factors (cyclin and cyclin-
dependent kinases - Cdks) which control the cell cycle are also indicated from 
(O’Connor, 2008). 
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2.9.1 Cdk’s and cell cycle regulation checkpoints  
Cyclin dependent kinases (Cdks) enzyme proteins are classified as a 
family of serine/threonine kinases having the molecular weight within the range 
of 34 to 40 kDa. Specifically, Cdk’s are fundamental components in the 
modification of numerous protein substrate required for cell cycle initiation and 
progression. Most importantly, Cdk’s are actively involved in substrate 
phosphorylation by transporting phosphate groups from ATP to specific amino 
acid sequence. The number and types of Cdk’s in a living organism depend on 
the nature of eukaryotic cells. In fact in yeast, there was only one Cdk present 
compared to four types of Cdk’s found in vertebrates. Cdk’s are inactive until it 
is being associated with cyclin also known as regulatory partners triggering the 
activation of a heterodimer cyclin-Cdk complex. The cyclin-Cdk complex 
phosphorylates large numbers of substrate in the cell resulting in the onset of the 
various specific cell cycle (Morgan, 1997).  
Several checkpoints are present in the eukaryotic cell cycle to confirm 
the occurrence of cell phase’s proceeds or progresses after adequate growth and 
conscientious DNA replication. Cdk’s is a key component in cell regulation and 
also play a major role in the regulation of transcription and mRNA processing 
including biochemical process in cells which includes neuronal signalling, golgi 
membrane trafficking, cell death, cell differentiation and retinal 
phosphodiesterase regulation. The Cdk’s function solely relies on its cyclin 
counter partner. At each checkpoint of the cell cycle, various proteins are 
involved in a series of carefully coordinated biochemical reactions and these 
proteins includes the different Cdk  and cyclin complex formation for the onset 
of each phase in the cell cycle (Satyanarayana & Kaldis, 2009).  
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Throughout the progression of cell cycle and cell division, both synthesis 
and degradation of cyclin occur actively (Figure 2.9). The synthesis of cyclin 
stimulates the formation of cyclin-Cdk complex which then send a signal to  the 
cell to either move to the next phase of cell cycle or regulates the progression 
within the particular cell cycle phase. Eventually, cell signalling to exit certain 
cell cycle phases happens with the deactivation of Cdk when cyclins start to 
degrade. In other words, cyclin levels very much influence the formation of 
cyclin-Cdk complex formation. The relationship between cyclin and Cdk is 
inseparable since the degradation of cyclin causes Cdk’s to lose their 
phosphorylating capability. Similar to Cdk’s there are numerous cyclins with 
various functions in eukaryotic cells (Furuno et al., 1999; Khodjakov & Rieder, 
2009; Hochegger et al., 2008).  
 
Figure 2.9 The correlation between the cell cycle regulators cyclin-Cdk 
complex in  different cell cycle phases from (Hochegger et al., 2008). 
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2.9.2 Cyclin B1-Cdk complex and the G2/M checkpoint 
Antimicrotubule agents interfere with the mitosis phase of the cell cycle 
specifically on the Spindle Assembly Checkpoint (SAC), inducing a mitotic 
arrest and normally leads to cell death. During mitosis phase, the involvement 
of numerous protein kinases has been discovered in this molecular mechanism 
of mitotic progressions such as CDK family (Cdk), Polo Like Kinases family 
(PLKs), Aurora kinases and NIMA (Never In Mitosis A) family. Additionally, 
there are also kinases molecules involved in mitotic exit network, Spindle 
Assembly Checkpoint (SAC) and finally in the cytokinesis completion (Nigg, 
2001). The cyclin B1/Cdk1 complex is the key component to specifically 
regulate and initiate the mitosis phase of the cell and plays the role of 
phosphorylating proteins that are essential for nuclear envelope breakdown, 
chromatin condensation, spindle assembly and centrosome separation (Nurse, 
1990; Lindqvist et al., 2007).  
These cyclin B1-Cdk1 complex exist in both cytoplasm and nuclear 
envelope synchronizing the events in mitosis such as nuclear envelope 
breakdown and centrosome separation. Apart from this, cyclin B1/Cdk1 
complex stimulates mitochondrial ﬁssion activity with the onset of G2/M 
transition (Taguchi et al., 2007). There are also studies reporting substantial 
amount of cyclin B1/Cdk1 complex remaining in the cytoplasm during mitosis 
including active cyclinB1/Cdk1 complex found in cytoplasm and nucleus during 
prophase (Gavet & Pines, 2010).  
The cyclin B1/Cdk1 complex are also present and essential in other 
components of cells such as cytoskeleton microtubule (Vasquez et al., 1999; 
Liakopoulos et al., 2003; Moore & Miller, 2007), actin (Yamashiro et al., 1991; 
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Yamashiro et al., 2001) and intermediate filament networks (Chou et al., 1991; 
Yamaguchi et al., 2005) , caspases (Allan & Clarke, 2007), the Golgi apparatus 
(Lowe et al., 1998; Draviam et al., 2001; Wang et al., 2003; Preisinger et al., 
2005) and nucleolus (Klein & Grummt, 1999; Sirri et al., 2002). In addition to 
this, G1/S and G2/M checkpoints are energy-sensitive and require pronounced 
bioenergy supply for de novo synthesis of biomasses needed for cell-cycle phase 
transitions (Sweet & Singh, 1999). 
The molecular mechanisms determining the balance between these 
responses are not well understood. However, exquisite control of cyclin 
B1/Cdk1 complex activity during the cell cycle to peak at metaphase is 
necessary for a successful G2/M transition (Allan & Clarke, 2007; Clute & 
Pines, 1999). To date, Wang et al. (2014) conducted experiments using isolated 
mitochondrial from mouse liver tissues and the research revealed that cyclin 
B1/Cdk1 complex proteins were found to relocate in the matrix of mitochondria, 
and an increased influx of mitochondrial cyclin B1/Cdk complex was associated 
with elevated mitochondrial bioenergetics in G2/M transition. As a result, 
mitochondria-targeted cyclin B1/Cdk1 increases mitochondrial respiration with 
enhanced oxygen consumption and ATP generation, which provides cells with 
efficient bioenergy for G2/M transition and shortens overall cell-cycle time 
(Wang et al., 2014). 
In summary, cyclin B1/Cdk1 complex has been a target for scientist to 
discover antimitotic anticancer drugs. The strategy is to investigate mitotic cell 
death (MCD) pathway which involves cell cycle regulators dysregulation. 
Undoubtedly, further investigation of the effect of clusianone (29) and 
derivatives on Cdk1 and cyclin B1 expression using immunostaining studies was 
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carried out in this research. The potential anticancer pathway selected is novel 
since there were no studies so far which showed the effects of clusianone (29) 
in mitotic phase specifically targeting mitotic spindle protein β-tubulin and 
G2/M phase cell cycle regulators cyclin B1/Cdk1 complex.  
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CHAPTER 3 : MATERIALS AND METHODS 
3.1 General Procedures for extraction and chemical synthesis experiments 
 Plant extracts and synthesized compound solvents are evaporated in 
vacuo at 40 °C with Buchi Rotary Unit (USA). Melting points of compounds 
were determined using Stuart’s (SMP100) melting point apparatus. Isolation and 
reactions were monitored on thin layer chromatography (TLC) 0.25 mm Merck 
silica gel plates (60 F254), and compounds were visualized with UV light. 
Column chromatography was carried out using Merck silica gel (70-230 mesh). 
Purity quantification studies on selected compounds were performed using high 
performance liquid chromatography (HPLC) with series 600 Link Interface 
Perkin Elmer (USA) on Series 200 UV/Vis detector, autosampler and pump.  
The mass spectrometer used for the Open Access analyses was a Bruker 
MicrOTOF, which was a time of flight mass spectrometer (University of 
Nottingham, UK) on Electro Spray Ionisation (ESI) mode.  1H NMR and 13C 
NMR spectra (500 and 125 MHz respectively) were recorded on a Bruker 500 
UltraShield (Nottingham University UK Campus). Raw data were processed 
using MestReNova LITE NMR processor. IR spectra were recorded on a Perkin-
Elmer series 1600 spectrometers as KBr pellet for solid samples. X-ray 
crystallography analysis on single crystal was carried out using Oxford 
Diffraction Xcaliber Eos Gemini with copper kα radiation at the Department of 
Chemistry of Universiti Putra Malaysia.  
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3.1.1 Plant Sample 
The leaves of G. parvifolia (Miq.) Miq (UNMC 45) were collected from 
trees in a reserved forest Sungai Congkak, Selangor (GPS coordinate: N 03o 
12ꞌ49.8ꞌꞌ,E101o50ꞌ71.1ꞌꞌ, elevation: 234 m) (Figure 3.1). The plant authenticity 
was verified  and deposited with voucher number PID 271210-13 at School of  
Pharmacy, The University of Nottingham Malaysia Campus herbarium and 
Forest Research Institute Malaysia (FRIM) by a co-worker (Ching, 2013).  
 
3.1.2 Maceration of G.parvifolia (Miq.) Miq. 
Dried and powdered leaves of G. parvifolia (Miq.) Miq leaves (1000 g) 
were extracted by maceration. In the first step, 400 g of the powdered leaves 
were placed in a 5 L Erlenmeyer flask. The flask was filled with 3 L of hexane 
solvent and swirled from time to time. After three days the solvent was filtered, 
evaporated and then dried using a rotary evaporator under reduced pressure at 
40 °C in water bath. The maceration procedure was repeated three times and 
with the same duration of three days. From 1000 g of powdered leaves 
macerated, a total of 80 g of hexane extract was obtained (Sarker et al., 2006). 
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     Figure 3.1 (A) Images of G. parvifolia (Miq.) Miq. Leaves (10-15 cm).  
     (B) Images of leaves dried in trays. 
 
 
3.1.3 Extraction and isolation of clusianone (29) from leaves of G. parvifolia 
(Miq.) Miq. 
The hexane extract (5 g) from leaves was chromatographed on silica gel 
(70-230 mesh) in a column (8 × 100 cm) and eluted with diethyl ether of about 
1L. The solvent was removed under reduced pressure using rotatory evaporator 
at 40 °C in water bath. This part of the extract contains major portion of 
chlorophyll since it was obtained from leaves. Therefore, in the next step, the 
chlorophyll was removed. The dry weight of the diethyl ether extract was 
approximately 5 g. First, the diethyl ether extract  was mixed with silica gel: 
activated charcoal in a proportion of 1:3:1, respectively and placed in a column 
with a porous frit. The material was eluted with hexane (300 mL) followed by 
dichloromethane in vacuo (Sargenti & Vichnewski, 2000).  
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The hexane and dichloromethane fractions after chlorophyll removal 
were further chromatographed on silica gel (70-230 mesh). The two extracts 
weighed approximately 2 g of dry weight each. Both the  extracts were 
chromatographed on a column (4 × 100 cm) and eluted with solvent gradient 
mixtures (200 mL of each mixture) as shown in the table below. To isolate the 
compound, the dichloromethane dried fraction (4.8 g) was further 
chromatographed on silica gel (70-230 mesh) and eluted with mixtures of 
cyclohexane/chloroform and chloroform/methanol of increasing polarity (Table 
3.1). A total of 122 fractions were collected in 20 mL vials. Thin layer 
chromatography (TLC) profiling was performed on all the fractions collected 
and compared with the standard clusianone (29) isolated previously by a co-
worker (Figure 3.2). Clusianone (29) spot appears at Rf = 0.45 
(Cyclohexane/chloroform = 1/1).  Thereafter, the targeted fractions F51—F60 
which showed the presence of clusianone (29) via TLC profiling were 
crystallized via slow methanol evaporation. 
 
Table 3.1 Gradient solvent system for dichloromethane extract 
 
Solvent Ratio 
Cyclohexane: chloroform 7:3 
 6.5:3.5 
 6:4 
 1:1 
 4:6 
 3:7 
 2:8 
 1:9 
Chloroform 100% 
Chloroform: Methanol 8:2 
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Figure 3.2 Isolation of clusianone (29) (A) Column chromatography to separate 
clusianone (29) from dichloromethane fraction. (B) Dichloromethane fractions 
collected in scintillation vial after subjected to gradient solvent system column 
chromatography. (C) Fractions collected in scintillation vials are spotted on TLC 
plate to detect the presence of clusianone (29) with standard clusianone (29) as 
reference.   
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3.1.4 Recrystallization of clusianone (29)  
The targeted fractions F51—F60 which showed presence of clusianone 
(29) were recrystallized several times with methanol to give yellow crystalline 
solid (100 mg, 0.05%) over a period of 10 days. Further to this method, the 
seeding technique was used to promote the growth of diffraction-quality crystals 
whereby the supersaturated solution was induced with a small crystal of the 
compound obtained from the previous isolation (Sunagawa, 2005). The solution 
was then left to evaporate through slow evaporation including vapour diffusion 
under controlled temperature below room temperature. These crystals were 
stored at 2 -8 °C (Nagalingam et al., 2013). Clusianone C33H42O4  : Yellow 
crystals;  m.p. 90-92 °C; ESI-MS m/z, [M+H]+: 503.3147 calcd. for 503.3167 
(rel. int. %) = 503 (100), 435 (23), 379 (4.5), 343 (1.9), 311 (4.6), 235 (1.7).  
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3.2 Preparation of clusianone (29) derivatives 
3.2.1 Preparation of CMet (53)  
[(1S, 5S, 7R)-3-benzoyl-4-methoxy-8,8-dimethyl-1,5,7-tris(3-methylbut-2-
en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione]  
            Clusianone (29) (100 mg, 0.20 mmol) was dissolved in acetone (2.0 mL) 
and then K2CO3 (100 mg, 0.10 mmol), and Me2SO4 (0.10 mmol) were 
sequentially added (Scheme 3.1). The mixture was stirred under reflux in water 
bath at 60  °C for 2 hours under the argon atmosphere (Ahmad et al., 2007). The 
reaction was monitored using TLC with dyeing agent vanillin-sulphuric acid and 
along with the aid of heat exposure from hot gun on to the surface of the TLC 
(Rosen et al., 1952). The mixture was cooled to room temperature and  the 
residue was removed by filtration. The solvent was removed in vacuo. The 
residue was purified by column chromatography on Si gel (light 
petroleum/EtOAc  = 9/1) to give CMet (53) as white solids (91 mg, 90%); mp 
108-110 °C; ESI-MS m/z: [M+H]+ calcd. for C34H44O4 517.3318 found 517.3316 
(rel. int. %) = 517 (100), 449 (40.6), 393 (5.3), 357 (4.2), 325 (4.0).   
                         
  Scheme 3.1 Methylation of clusianone (29) 
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3.2.2 Preparation of CHyd (54)  
[(1S, 5S, 7R)-3-benzoyl-1, 5, 7-triisopentyl-4-methoxy-8, 8-dimethylbicyclo 
[3.3.1] non-3-ene-2, 9-dione]  
CMet (53) (20 mg, 0.03 mmol) was dissolved in EtOAc (0.5 mL) and 
palladium on carbon (8 mg, 0.0075 mmol) was added simultaneously. The 
mixture was stirred and hydrogenated at room temperature for 2 hours using 
hydrogenation apparatus affixed to the condenser (Scheme 3.2). The reaction 
was monitored using TLC with dyeing agent potassium permanganate-sulphuric 
acid (Wusteman et al., 1964). The catalyst was then removed by filtration using 
celite (Roux et al., 2000). The filtrate was then purified by column 
chromatography on Si gel (light petroleum/ EtOAc = 9/1) to provide CHyd (54) 
(16.3 mg, 80%) as brown wax; ESI-MS m/z: [M+Na]+ calcd. for C34H50O4Na 
545.3607 found 545.3607 (rel. int. %) = 545 (100), 523 (13.4), 429 (2.8), 413 
(5.5), 385 (3.4), 341 (3.3), 310 (6.0), 226 (4.0). 
 
 
Scheme 3.2 Hydrogenation of CMet (53) 
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3.2.3 Preparation of CMxA (55)  
[(1S, 5R, 7R)-3-benzoyl-4-hydroxy-9-(methoxyimino)-8,8-dimethyl-1,5,7-
tris(3-methylbut-2-en-1-yl)bicycle[3.3.1]non-3-en-2-one] 
Clusianone (29) (15 mg, 0.03 mmol) was dissolved in dichloromethane 
(1.0 mL). Methoxyamine HCl (4.5 mg, 0.05 mmol) and pyridine (0.01 mL) were 
then sequentially added dropwise (Scheme 3.3). The mixture was stirred under 
room temperature for 24 hours. The reaction was monitored using TLC sprayed 
with Dragendoff reagent (Munier, 1953). Once the reaction completed, the 
mixture was washed with  5% HCl (3 × 10 mL) to remove the pyridine (Blatt, 
1939). The combined organic layer was dried over MgSO4 and concentrated in 
vacuo. The filtrate was purified by column chromatography on Si gel 
(cyclohexane/chloroform = 1/1) and afforded CMxA (55) (11.5 mg, 76%) as 
colorless wax; ESI-MS m/z: [M+H]+ calcd. for C34H46NO3 532.3423 found 
532.3423 (rel. int. %) = 532 (100), 500 (4.3), 429 (2.3), 385 (2.6).  
 
 
Scheme 3.3 Methoxyamine addition of clusianone (29) 
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3.2.4 Preparation of CMeA (56)  
[(1S, 5R, 7R)-3-benzoyl-4-hydroxy-8,8-dimethyl-1,5,7-tris (3-methylbut-2-
en-1-yl)-9-(methylimino)bicyclo[3.3.1]non-3-en-2-one] 
 Clusianone (29) (15 mg, 0.03 mmol) was dissolved in dichloromethane 
(1.0 mL). Methylamine HCl (3.5 mg, 0.05 mmol) and pyridine (0.01 mL) were 
then sequentially added dropwise (Scheme 3.4). The mixture was stirred under 
room temperature for 72 hours. The reaction was monitored using TLC sprayed 
with Dragendoff reagents (Munier, 1953). After the reaction completed, the 
mixture was washed with 5% HCl (3 × 10 mL) to remove the pyridine (Blatt, 
1939). The combined organic layer was dried over MgSO4 and concentrated in 
vacuo. The filtrate was purified by column chromatography on Si gel 
(cyclohexane/chloroform = 1/1). The purification provided CMeA (56) (11.25 
mg, 75%) as colorless wax; ESI-MS m/z: [M+H]+ calcd. for C34H46NO3 
516.3478 found 516.3423  (rel. int. %) = 517 (100), 498 (1.7), 490 (2.0), 448 
(1.1). 
 
Scheme 3.4 Methylamine addition of clusianone (29) 
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3.2.5 Preparation  of CEtA (57)  
[(1S, 5R, 7R)-3-benzoyl-9-(ethylimino)-4-hydroxy-8,8-dimethyl-1,5,7-tris(3-
methylbut-2-en-1-yl)bicyclo[3.3.1]non-3-en-2-one]  
Clusianone (29) (15 mg, 0.03 mmol) was first dissolved in 
dichloromethane (1.0 mL). Ethylamine HCl (4.0 mg, 0.05 mmol) and pyridine 
(0.01 mL) were then sequentially added dropwise (Scheme 3.5). The mixture 
was stirred under room temperature for 72 hours. The reaction was monitored 
using TLC sprayed with Dragendoff reagents (Munier, 1953). After the reaction 
completed, the mixture was washed with (3 × 10 mL) of 5% HCl to remove the 
pyridine (Blatt, 1939). The combined organic layer was dried over MgSO4 and 
concentrated in vacuo. The filtrate was purified by column chromatography on 
Si gel (cyclohexane/chloroform = 1/1) to obtain CEtA (57) (11.3 mg, 75.3%) as 
colorless wax; ESI-MS m/z: [M+H]+ calcd. for C34H46NO3 530.3634 found 
530.3621 (rel. int. %) = 530 (100), 526 (0.5), 505 (0.6), 504 (1.9). 
 
Scheme 3.5 Ethylamine addition of clusianone (29) 
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3.2.6 Preparation of CPryl (58)  
[(1S,5S,7R)-3-benzoyl-8,8-dimethyl-1,5,7-tris(3-methylbut-2-en-1-yl)-4-((3-
methylbut-2-en-1-yl)oxy)bicyclo[3.3.1]non-3-ene-2,9-dione]  
            Clusianone (29) (10 mg, 0.02 mmol), 3, 3-dimethylallyl bromide (0.02 
mmol) and anhydrous K2CO3 (10 mg) was stirred in acetone (2.0 mL) and 
refluxed  in water bath at 75 °C (Rullah et al., 2014) (Scheme 3.6). The refluxed 
reaction was monitored using TLC and after 10 hours, the mixture in the round 
bottom flask was cooled to room temperature. Thereafter, the reaction mixture 
was filtrated and evaporated in vacuo. The residue was purified by column 
chromatography on Si gel (light petroleum/EtOAc = 9/1) to give CPryl (58) as 
colorless wax (4.3 mg, 43%); ESI-MS m/z: [M+H]+ calcd. for C38H50O4  
571.3787 found 571.3829 (rel. int. %) = 571 (52.0), 503 (100), 435 (58.9), 379 
(15.0), 343 (5.9), 275 (2.6), 311 (8.4).   
 
Scheme 3.6 Prenylation of hydroxyl group of clusianone (29) 
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3.2.7 Preparation of CGeryl (59) 
[(1S, 5S, 7R)-3-benzoyl-4-(((Z)-3,7-dimethylocta-2,6-dien-1-yl)oxy)-8,8-
dimethyl-1,5,7-tris(3-methylbut-2-en-1-yl)bicycle [3.3.1] non-3-ene-2,9-
dione]  
             Clusianone (29) (10 mg, 0.02 mmol), geranyl bromide (0.02 mmol) and 
anhydrous K2CO3 (10 mg) was stirred in acetone (2.0 mL) and refluxed in water 
bath at 75 °C (Rullah et al., 2014) (Scheme 3.7). The refluxed reaction was 
monitored using TLC and after 10 hours, the mixture was cooled to room 
temperature. Thereafter, the reaction mixture in a round bottom flask was 
filtrated and evaporated in vacuo. The residue was purified by column 
chromatography on Si gel (light petroleum/EtOAc = 9/1) to afford CGeryl (59) 
as yellow wax (2.8 mg, 28%); ESI-MS m/z: [M+H]+ calcd. for C43H59O4  
639.4413 found 639.4458 (rel. int. %) = 639 (11), 571 (3.3), 541 (4.0), 503 (100), 
435 (63.9), 379 (9.4), 343 (6.4), 311 (8.1), 167 (6.7), 149 (19.5). 
 
 
Scheme 3.7 Geranylation of hydroxyl group of clusianone (29) 
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3.2.8 Preparation of CDMet (60)  
[(1S, 5S, 7R)-3-benzoyl-4-hydroxy-1,5,7-triisopentyl-8,8-dimethyl 
bicyclo[3.3.1]non-3-ene-2,9-dione] 
             To a solution of CHyd (54) (9 mg, 0.0045 mmol) in DMSO (0.50 mL) 
was added with LiCl (1.5 mg, 0.035 mmol) and the resulting solution was stirred 
for 2 hours at 120 °C as shown in Scheme 3.8 (Rodeschini et al., 2006). The 
mixture was cooled to room temperature and then diluted with H2O (2 mL). The 
mixture was then extracted with Et2O and the combined organic layer was dried 
over anhydrous MgSO4. The product was spotted on TLC (light petroleum/ 
EtOAc, 90/10) which showed presence of 4 spots. The residue upon purification 
by column chromatography on Si gel (light petroleum/EtOAc = 9/1) afforded 
(60) in 5.0 % yield as brown wax; Rf = 0.35 (light petroleum/ EtOAc = 9/1);  
ESI-MS m/z: [M+H]+calcd. for C33H49O4 509.3630 found 509.3618 (rel. int. %) 
= 509 (100), 413 (1.7), 271 (2.3). 
 
 
 
Scheme 3.8 Demethylation on CHyd (54) 
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3.3 Summary of synthesis results 
 
Several clusianone (29) derivatives were prepared by using synthetic 
routes in small scale conditions. The derivatives were prepared utilising 
synthetic steps of less than four. The products obtained were methylated CMet 
(53), hydrogenated CHyd (54), oxime added CMxA (55), two primary amines 
added CMeA (56), CEtA (57) including prenylation and geranylation of 
clusianone (29) hydroxyl group which gave compound CPryl (58) and CGeryl 
(59) respectively. The deprotected CHyd (54) to produce compound CDMet (60) 
was also reported. The percentage yield of products are listed in Table 3.2. 
 
Table 3.2 Summary of synthesis results steps taken and percentage product 
yield. 
Product Reaction steps from 
clusianone (29) 
Overall yield (%) 
CMet (53) 1 90.0% 
CHyd (54) 2 80.0% 
CMxA (55) 1 76.0% 
CMeA (56) 1 75.0% 
CEtA (57) 1 75.0% 
          CPryl (58) 
  CGeryl (59) 
CDMet (60) 
                        1 
1 
3 
           43% 
28% 
5.0% 
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3.4 X-ray crystallography analysis using crystal data software 
 The X-ray diffraction data also known as the crystallographic 
information file (CIF) obtained for clusianone (29) and CMet (53) were further 
refined using several crystal software such as enCIFer 1.4, CRYSTALS 14.23, 
CAMERON and Mercury 3.3. This software encompasses computing details 
such as cell refinement (Table 3.3), crystal structure in packing unit and various 
characteristics of intermolecular and intramolecular bonds present in the crystal 
structure. 
Table 3.3 Data collection and structure refinement details  
Data collection 
Type of diffractometer Oxford diffraction Gemini 
Radiation source Cu Kα radiation 
Data collection temperature 100K 
θ range for 19011 reflections used in 
lattice determination 
3-71° 
Structure solution and refinement 
Structure solution program CrysAlis PRO (Agilent 2011) 
Primary solution method Direct methods 
Secondary solution method Direct fourier map 
Hydrogen placement Geometric position 
Structure refinement program CRYSTALS 
Refinement method Full matrix least squares on F2 
Treatment of hydrogen method Riding  
Goodness-of-fit o F2  0.034 
Final R indices [I>2σ(I),5269 reflections] 0.084 
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3.5 Modified HPLC method analysis for purity content test 
 
HPLC analysis of selected clusianone (29) derivatives was performed on 
a series 600 Link Interface Perkin Elmer (USA) HPLC instrument with Polaris 
C18 (5 μm C18 column (4.6 х 150 mm)). Elution of the compounds was 
monitored at an absorbance of 254 nm using an isocratic gradient of 85:15 (ACN 
: H2O) over 10 minutes followed by an increasing linear gradient from 85:15 
(ACN : H2O) to 100% acetonitrile over 15 minutes, followed by an isocratic 
gradient of 85:15 (ACN : H2O) for an additional 15 minutes (flow rate of 1 
mL/min). The injection volume was kept at minimum which was 5 µL from each 
sample with concentration of 1 mg/mL. Methods were modified from previous 
co-worker (Ching, 2013).  
 
3.6 General Procedures for biological experiments  
Samples were spectrophotometrically measured at 540 nm using 
Varioskan Flash and SkanIt Software (Thermo Scientific, USA). Phase contrast 
inverted microscope to study the cell morphology (FEI, Quanta) with Nikon 
ECLIPSE TS100. BioRad Mini-PROTEAN® cell for handcast gels and (Sodium 
Dodecyl Sulfate Polyacrylamide gel electrophoresis) SDS-PAGE to run vertical 
mini gel electrophoresis. XCell SureLock® Mini-Cell Invitrogen wet transfer 
system used for transferring the protein on gel membrane to nitrocellulose 
membrane. GS800 Densometer to scan the nitrocellulose membrane after 
staining with TMB solution in order to detect the targeted protein presence and 
intensity. 
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3.6.1 Respiratory cell lines for cytotoxicity testing  
       Cytotoxicity testing’s were conducted on selected panel of respiratory cells 
of both normal and carcinoma cells. The clusianone (29) and  clusianone 
derivatives (53-57) were evaluated for anticancer activity against human 
respiratory mammalian cells as stated in the Table 3.4. 
 
Table 3.4 List of normal and cancer cells tested. 
Cell line code Description and type of cell 
MRC5 Lung fibroblast (normal cells) established from normal 
lung tissue of a 14-week-old male foetus (Jacobs et al., 
1970). 
A549 Lung adenocarcinoma (carcinoma cells) established from 
cell culturing of cancerous lung tissue in 
the explanted tumour  of 58-year-old Caucasian male 
(Giard et al., 1973). 
NP69 Immortalized nasopharyngeal epithelial cell (normal cells) 
established from biopsies from the nasopharynx of patients 
(Tsao et al., 2002). 
HK1 Squamous carcinoma of the nasopharynx (carcinoma cells) 
established from a recurrent squamous carcinoma of a 58 
year old Chinese male after going through 17 and a half 
years of radiation therapy (Huang et al., 1980).  
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3.6.2  Sub culturing mammalian cell  
The human lung cells were obtained from ATCC (Rockville, MD) and 
the nasopharyngeal cells were from collaborator Prof. Tsao George Sai-Wah 
from the University of Hong Kong with proper agreement on material transfer. 
MRC5 (passage 10-20), A549 (passage 10-20) and HK1 (passage 20-30) were 
grown in T-25 flask in growth medium consist of RPMI with L-glutamine (with 
phenol red), 10% (v/v) FBS, 1% (v/v) 100 units/mL of penicillin/streptomycin 
and incubated at 37 °C in 5% CO2 atmosphere.  
The cells were split when it reaches 80-90% confluence and provided the 
morphology indicates healthy cells according to the recommended ATCC 
protocol (No. CCL-171 and CCL-185). The confluent cells in the flask were 
rinsed with 3 mL of PBS prior to incubation with 1 mL of trypsin-EDTA (0.05% 
(v/v) Trypsin, 0.53 mM EDTA.4Na) for 5 minutes at 37 °C. The cells were 
detached and dispersed from the flask surface by tapping gently and shaking the 
flask. The cell detachment was confirmed with inverted microscope. Thereafter, 
3 mL of RPMI with 10% (v/v) FBS medium was added to prevent further 
proteolysis and the cell suspension was spun down in a centrifuge for 5 minutes 
at 1800 rpm (Eppendorf centrifuge 5810R). The supernatant was removed and 
the cell pellet was resuspended in 1 mL RPMI . Finally, 0.25 mL of this 
suspension was then added to 5 mL medium in a clean T-25 flask.  
As for the NP69 cells (passage 60-90), the growth medium used was 
Keratinocyte-SFM and the methods were modified using protocol from 
Keratinocyte-SFM Cat.No.17005 , 0.25% (v/v) Bovine Pituitary Extract, 
0.0014% (v/v) recombinant epidermal growth factor, 0.5% (v/v) of 
penicillin/streptomycin and incubated at 37 °C in 5% CO2 atmosphere. The 
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trypsinization method was similar to the other cells except that the deactivation 
of trypsin after the cell detachment was using 3 mL solutions consisting of 98% 
(v/v) PBS and 2% (v/v) FBS. The cell suspension was spun down in a centrifuge 
for 5 minutes at 1800 rpm. The supernatant was removed and the cell pellet was 
resuspended in 1 mL of the keratinocyte medium with supplements as mentioned 
earlier. Finally, 0.25 mL of this suspension was then added to 5 mL keratinocyte 
medium with supplements in a clean T-25 flask. 
3.6.3 Cryopreservation of mammalian cells and cell thawing 
Cells were harvested and pelleted by centrifugation as described in 
section 3.6.1. After the removal of the supernatant, the cell pellets were 
resuspended with freezing media which consist of 90% (v/v) FBS and 10% (v/v) 
DMSO except for NP69 cell pellet which was resuspended with freezing 
medium consisting 75% (v/v) FBS, 10% (v/v) DMSO and 15% (v/v) Bovine 
Pituitary Extract. Cells were pipetted into cryovials and placed in a Nalgene™ 
Cryo Freezing Container which was kept at -80 oC overnight before being 
transferred to a -150 oC cold liquid nitrogen tank for long-term storage. 
Normally cells with low passage number are stored in liquid nitrogen tank 
(Statebourne biorack 750). 
To re-establish cell cultures, cells were thawed briefly at 37 oC in a water 
bath. Once the contents are thawed partially, the vial was removed from the 
water bath and wiped with 70% (v/v) ethanol to avoid contaminations. The cells 
were then resuspended in 1ml of the cells growth medium before being 
transferred to T-25 cell culture flasks. As for the subsequent passages, some cells 
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were transferred to T-75 flasks and some were cryopreserved to replenish stores 
of stock cells.  
3.6.4 Cell counting  
The number of cells seeded in 96 well plates or 6 well plates has to 
be consistent and accurately calculated using haemocytometer. Therefore, 
cell counting was performed in the resuspended cell suspension prior to cell 
seeding into its respective plates. Firstly, the cells were harvested and 
centrifuged as described in section 3.6.1. After the cells were resuspended in 
1mL of the growth medium, 50 µL of the cell suspension was mixed and 
resuspended with 50 µL of 0.4% (v/v) trypan blue solution. Next, 10 μL of 
this suspension was pipetted and gently delivered between the coverslip and 
well region of the haemocytometer. Viable cells exclude trypan blue while 
dead cells stained blue. The numbers of unstained cells were counted in the 
middle square of the haemocytometer. The calculation of the cell per mL was 
calculated using the formula below. From the total number of the viable cells 
calculated in 1 mL media, the seeding of the cells was done using dilution 
ratio factor to provide 10000 cells in each 100 µL media pipetted into the 96 
well plates.  
Total number of cell  
ൌ Average	number	of	cells	in	one	large	square		 ൈ ∗ dilution	factor		 ൈ 10ସ 
*dilution factor is usually 2 (1:1/ 50 µL:50 µL dilution with trypan blue), but 
may need to further dilute (or concentrate) cell suspensions. 
104 = conversion factor to convert 10-4 mL to 1 mL which was related to volume 
of one square of the well of the haemocytometer.  
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3.6.5 MTT (3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium 
bromide cell viability assay 
 
All stock cultures except the NP69 cultures were grown in T25 flask with 
RPMI with 10% v/v FBS medium. As for the NP69 cell, the cultures are grown 
in keratinocyte-SFM together with the supplement of bovine pituitary extract 
(BFE) and human recombinant (EGF). Freshly trypsinized cell suspension after 
spun down at 1800 rpm for 5 min were seeded into 96-well plates at densities of 
10000 cells in 100 µL medium per well. After one day of culture, the medium 
was removed from each well and were subjected to different concentration of 
compounds starting from 0 µg/mL – 200 µg/mL.  
The compounds were dissolved in DMSO and diluted further with RPMI 
medium for all the cultures, except the NP69 which was diluted with 
keratinocyte-SFM which serves as a stock solution. The DMSO concentration 
used was not more than 0.1% (v/v). The different concentration of compound 
was prepared by serial dilution of the stock solution. The plates were then 
incubated for 48 hours to test its cytotoxicity level. Docetaxol (18) was used as 
a positive control. The docetaxol was dissolved in sodium chloride buffer. The 
well containing the untreated cells serves as negative control. 
After the respective incubation period, all the media in each individual 
well were aspirated prior to treatment of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay (Mosmann 1983). Next, MTT tetrazolium 
salt was prepared in accordance to formulation of 5 mg/mL in PBS, stored in the 
dark at 4 °C and filtered sterile; before it was diluted 1:10 into respective 
RPMI/Kerotinocyte-SFM. Subsequent step involves the addition MTT 
containing medium to each well in a volume of 100 µL and the plates were then 
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covered with aluminium foil and incubated at 37 °C for an additional 4 hours. 
After labelling the cells with MTT for 4 hours, 75 µL medium was carefully 
aspirated out from each well. Finally, 50 µL of DMSO was added to each well. 
The plate was then incubated at 37 °C for 10 minutes. Absorbance reading was 
set at 540 nm using microplate reader and the absorbance was further analysed 
(Gerlier & Thomasset, 1986). 
Table 3.5 Four day routine of MTT assay in the cytotoxicity study  
Day  Cell activities  
Day 1 Cell counting and seeding/plating cells 
Day 2 Treatment with different concentration of compound  
Day 3 - 
Day 4 MTT assay – adding MTT, MTT formazan solubilisation and 
absorbance measurement  
 
 
3.6.5.1 Data analysis for MTT assay 
Absorbance readings from the MTT assay were converted into 
percentage cell death using the following equation:  
 
ቈሺControl-BlankሻAbs  - ሺTreated cell-BlankሻAbsሺControl - BlankሻAbs ቉= The % of cell death  
Abs = Absorbance at 540 nm  
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The results of three independent experiments were obtained and the 
values were presented as mean ± standard deviation. One-way analysis of 
variance (ANOVA) test was applied to analyse P value. P-values less than 0.05 
were considered as statistically significant. The mean ± standard deviation of the 
MTT assays was plotted as a dose-response graph in Graphpad Prism 6. The 
IC50 values were interpolated from the graph. The standard error of the mean 
was calculated to show the reproducibility of the three MTT assays.  
 
3.6.6 Phase contrast inverted microscope study of cell morphology  
The 96 well plates were seeded with the carcinoma cells (A549 and HK1) 
at a density of 105 cells in 100 μL of RPMI with 10% (v/v) FBS. The plate was 
incubated at 37 °C and 5% CO2 for 24 hours. The medium was aspirated from 
all wells and then the cells were treated with 100 μL compounds solution at 
different concentrations 1-10 μg/mL, and  RPMI as a control. The plate was 
incubated for 48 hours. Images of both cell lines captured at the varying 
strengths of clusianone (29) using an optical microscope connected to a 
computer at 10× magnifications. The media were aspirated out of the well to 
improve the image quality and cell images treated at different concentrations of 
the compounds were captured using Nikon ECLIPSE TS100. 
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3.6.7 Western Blotting for protein analysis for clusianone (29) and 
derivatives anticancer pathway studies 
3.6.7.1 Protein extraction from carcinoma cell 
The protein extraction was done using the PRO-PREPTM protein 
extraction solution (iNtRON Biotechnology, Seongnam Korea) and method was 
modified using suppliers protocol. Cells were grown in 6 well plate at a density 
of 106 cells in 2 mL per well. After the time point treatment which covers 8, 16, 
24 and 48 hours with clusianone (29), cells were harvested by trypsinisation and 
washed in phosphate buffered saline (PBS) and centrifuge at 2000 rpm 
(Eppendorf centrifuge 5810R) for 5 min. After washing cells with PBS, cells 
were counted and approximately 5×106 transferred to 2 mL tube. The cell pellet 
was harvested by centrifuging the tube at 13,000 rpm for 5 minutes (Eppendorf 
centrifuge 5452).  
The remnants were removed using a pipette and thereafter the cells were 
resuspended in 400 µL of PRO-PREPTM solution. The cell lysis was then 
induced by incubation for 20 minutes in freezer at -20 °C. The sample containing 
lysed cells in PRO-PREPTM solution were then centrifuged at 13,000 rpm for 5 
minutes (Eppendorf centrifuge 5452) and subsequently the supernatant was 
transferred to a fresh 2 mL tube. The Bradford method was conducted to measure 
the Bovine Serum Albumin (BSA) protein concentration in each of the sample 
treated at different time points and the method was modified from the Quick 
Start Bradford protein assay protocol (Bradford, 1976). The simple method 
involves adding 4 µL of the samples into the same 96 well plate followed by 200 
µL of Bradford Reagent.  
79 
 
After incubating 5 minutes in the dark, the readings were taken at 595 
nm using microplate readers. The protein solutions were assayed in triplicate. 
As for the Bovine Serum Albumin (BSA) standard protocol, the method was 
prepared equally similar with the sample preparation whereby the linear range 
BSA concentration (125-1500 µg/mL) was assayed in a microplate assay. To 
determine the protein concentration of unknown sample (8, 16, 24 and 48 hours) 
treatment, BSA standard curve was created by plotting the 595 nm values (y-
axis) versus their concentration in µg/mL (x-axis). Protein concentrations in cell 
lysate from each sample were then determined using the formulation generated 
by BSA standard curve as shown in (Figure 3.3). 
 
 
Figure 3.3 Standard curve using the microassay procedure with BSA standards. 
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3.6.7.2 SDS PAGE and immunoblotting 
The samples were diluted in loading buffer 94% (v/v) SDS, 10% (v/v) 
2-mercaptophenol, 20% (v/v)  glycerol, 0.004% (v/v)  bromophenol blue, 0.125 
M Tris HCl) and heated at 90 oC for 10 minutes. All the samples were loaded on 
the well including the Rainbow marker Protein ladder (Fisher Scientific). 
Proteins were separated by SDS-PAGE as shown in Table 3.6 with 4-12% (v/v) 
gradient gel (BioRad Mini-PROTEAN®) at 120V. The proteins were then 
transferred to nitrocellulose membrane (0.45 µm) using wet transfer method by 
running the electro blot at 25V for 80 minutes (XCell SureLock® Mini-Cell 
Invitrogen) (Figure 3.4).  
 
 Table 3.6 Formulation of stacking gel and resolving gel 
Chemical/Material Stacking gel 
(4%) 
Resolving gel 
(12%) 
30%  (v/v) Acrylamide 0.66 mL 4.00 mL 
0.5M Tris HCl 1.26 mL - 
1.5M Tris HCl - 2.5 mL 
10% (v/v) SDS 50 µL 100 µL 
Purified water 3 mL 3.35 mL 
Tetramethylethylenediamine (TEMED) 7.5 µL 7.5 µL 
10% (v/v) APS 25 µL 50 µL 
Total Volume 5 mL 10 mL 
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Figure 3.4 Electro blot transfer of protein from polyacrylamide gel to 
nitrocellulose membrane using wet transfer method edited and modified from 
(MacPhee, 2010)  
 
Thereafter, proper concentration of protein was prepared for SDS-PAGE 
analysis. Selection of gradient gel of SDS-PAGE was essential in the separation 
and migration of protein bands. In this research, better protein band separation 
was observed when gel gradient of 4-12% was used instead of single gradient 
gel (Table 3.6 & Appendix A).  As for the molecular weight marker, rainbow 
marker with molecular range from 11.0 kDa to 170.0 kDa was selected since all 
targeted proteins for the research (β-tubulin, Cdk-1, Cyclin B1 and GAPDH) are 
between 30.0 kDa to 60.0 kDa molecular weight as shown in (Table 3.7 & 
Appendix B). 
Next, the membrane was soaked in 20 mL of blocking buffer (PBS-
Tween containing 10% v/v non-fat milk) for 3 hours with gentle agitation at 50 
rpm at room temperature using shaker. Subsequent step involves overnight 
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incubation with gentle agitation using orbital shaker with the membrane 
immersed in primary antibody. The primary antibody solution was freshly 
prepared according to the manufacturer’s recommended dilution as shown in 
Table 3.7. The primary antibody was diluted with blocking buffer (PBS-Tween 
containing 5% (v/v) non-fat milk). The next step involves washing the 
membrane in 10 mL PBS-Tween for three times within 5 minutes interval. The 
membrane was then incubated for 3 hours with secondary antibody of HRP 
conjugate solution at 1:2000 dilutions with gentle agitation using horizontal 
shaker. The secondary antibody was diluted in blocking buffer (PBS-Tween 
containing 5% (v/v) non-fat milk). After 3 hours, the membrane was washed 
three times with PBS-Tween with 5 minutes interval and rinsed thoroughly with 
distilled water prior to staining.  
Finally, the membrane was stained with TMB substrate for detection of 
the targeted protein. The monoclonal antibodies mAb against the following 
proteins were used for immunoblotting: Cdk-1, Cyclin B1, β-tubulin and 
GADPH. GAPDH was used as a loading control (Aldridge et al., 2009). 
Secondary antibodies were chosen according to the primary antibodies used 
(goat anti-rabbit or anti-mouse IgG antibody linked to HRP) (Narvi et al., 2013; 
Cang et al., 2014). 
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Table 3.7 Details of monoclonal antibodies used in immunoblotting 
Antibodies Host species  Molecular 
weight 
Dilution 
factor 
Supplier 
β-tubulin  Rabbit     55 kDa 1:1000 Cell Signalling 
Cdk-1 Rabbit 34 kDa 1:10000 abcam 
Cyclin B1  Rabbit 58 kDa 1:3000 abcam 
GAPDH  Mouse    40.2 kDa 1:10000 abcam 
  
 
The selections of antibodies are decisive in detection of specific band 
relevant to targeted protein and generally, antibodies are categorized as 
monoclonal and polyclonal antibodies. Polyclonal antibodies are derived from 
animal B cells such as mice, rabbits, sheep, goats and donkeys. These antibodies 
consist of immunoglobin molecule that binds to different epitopes on an antigen. 
This action differs in monoclonal antibodies by which it binds to a single epitope 
within an antigen. Monoclonal antibodies contain homogenous cloned 
immunoglobins made by fusing antibody producing B cells from the spleen of 
the immunized animal (rabbit, mouse or rat) with an immortalized cell.  
             As a result, polyclonal antibodies tends to develop higher cross 
reactivity which results in higher background bands since it interacts with 
multiple epitopes. During the course of immunoblot evaluation, it was noticed 
that the use of β-tubulin polyclonal antibody resulted in higher background 
bands as shown in Appendix C. Therefore, monoclonal antibodies are always a 
better choice of primary antibodies in western blot analysis since it detects one 
target epitope and result in less background bands (Kalyuzhny, 2011).  
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3.6.7.3 Densitometry for protein concentration analysis 
The densitometry was an important device in capturing images of 
agarose gel and nitrocellulose membrane. After staining the nitrocellulose with 
TMB substrate, images of the membrane were captured using Quantity One Bio-
Rad software. The imaging software was also used to analyse the protein 
concentration based on the intensity of the band appearing on the nitrocellulose 
membrane.  
The user guide version 4.2.1 (PIN 4000 126-10 Rev A) were used to 
analyse the signals detected in each band. Small boxes are placed around the 
protein band appearing on single lanes. The placement of this rectangle strips 
allows multiple single proteins signals to be quantified. Relative quantification 
was given by the optical density value (defined as Σ(each pixel value - 
background)) which was determined for equal sized boxes drawn around bands, 
with background values taken below each band of interest to account for non-
specific antibody staining in the lane (Appendix D). Any values which were too 
high were taken as a warning and rectangle strips were placed until correlation 
between the rest of the bands on the same lane was observed. At the same time, 
it was noticed that background values were almost negligible and did not 
significantly deviate values of the data. Since each experiment to target Cdk-1, 
Cyclin B1, β-tubulin and GADPH were done in duplicate, the mean optical 
density from both experiments were calculated.   
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CHAPTER 4 RESULTS AND DISCUSSION 
ISOLATION OF CLUSIANONE AND CHEMICAL SYNTHESIS OF 
CLUSIANONE DERIVATIVES 
4.1 Isolation of clusianone (29) from leaves of G. parvifolia (Miq.)Miq 
The hexane extract has been identified to contain  the non-polar phenolic 
compound clusianone (29). Initial step of maceration of leaves was performed 
over 3 days then repeated 3 times subsequently to optimize the concentration of 
the compound of interest. However, the same maceration process also increased 
the concentration of waxes, oily substances and chlorophyll in the hexane 
extract. For removing chlorophyll from hexane extract, a mixture with Si gel 
together with activated charcoal was then subjected to a gravity column 
chromatography and the diethyl ether eluent was collected. Thereafter, 
fractionations were followed by subjecting two different solvents first with 
hexane followed by dichloromethane to the mixture in a column 
chromatography (Sargenti & Vichnewski, 2000). 
This technique was used to decolorize the extract because coloured 
pigments in plants such as chlorophyll which was abundant in leaf extract were 
adsorbed on the surface of the carbon particle. The coloured compounds adsorb 
more strongly to the surface of activated charcoal binding sites. A potential 
disadvantage of this method was that the desired compound clusianone (29) 
might be adsorbed by the activated carbon and  low recovery occurred when 
excessive carbon was added. Therefore, the coloured pigments and compound 
still exist in hexane and dichloromethane fraction and it was separated and 
fractionated through gradient elution column chromatography. The fractions 
collected in vials were then spotted on thin layer chromatography (TLC) after 
evaporation. The fundamental of TLC profiling was based on the standard 
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clusianone (29) spotted and with Rf value of 0.45 in (Cyclohexane/chloroform 
= 1/1). This was to target the particular scintillation vials containing compound 
of interest for recrystallization and at the same time to detect the fractions 
required for further recrystallization work through impurity removal (Sarker et 
al., 2006).  
To date, the isolation of clusianone (29) from dried roots of Hypericum 
hypericoides and stem barks of Garcinia assigu has produced 0.02% and 
0.0021% respectively from its dried plant materials (Christian et al., 2008; Ito et 
al., 2003). The optimization of clusianone (29) from the leave extract of G. 
parvifolia afforded 0.05% yield from the dried plant material and further purity 
test carried out using HPLC showed  > 98% purity. This method proves to be 
sustainable as a source of producing clusianone (29) compared to usage of non-
renewable plant sources such as roots and stem barks since the yield was higher. 
However, the yields were not as promising as reported in the floral resins of 
Clusia fluminensis. Clusianone (29) was quantified using HPLC method and it 
was estimated that 37% of the male flowers composition were reported to 
comprise of clusianone (29) (Bittrich et al., 2000).  
Further to this report, subsequent attempt using high speed counter 
current chromatography (HSCCC) to optimize clusianone (29) form Clusia 
fluminensis was carried out and fractions obtained were subjected to both TLC 
and GC-MS for purity content analysis. The yield was indeed satisfactory with 
6.93% (49.3 mg) of clusianone (29) presence in fraction obtained from the dried 
floral resins (711.3 mg) meanwhile the purity analysis showed that clusianone 
obtained via HSCCC were only 90.32% pure (Silva et al., 2012).  
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4.1.1 Recrystallization of clusianone (29) by crystal seeding and slow 
evaporation method  
  Clusianone (29) was crystallized through two major events which were 
nucleation and crystal growth via slow solvent evaporation (Figure 4.1). Two 
main factors affecting the crystal morphology were temperature and 
supersaturation level of the solution. Recrystallization method was employed to 
separate out the foreign molecules that were present in the fraction that was 
collected previously (Sunagawa, 2005).  
  Further to this, recrystallization technique can be used to refine crystal 
from traces of impurities specifically using crystal seeding technique. 
Clusianone (29) crystal seeds nucleated from previous crystallization were 
introduced into supersaturated solution and acts as a heterogeneous point for the 
occurrence of further crystallization of similar compound (Figure 4.2). Hence, 
allowing only clusianone (29) related target molecule to crystallize 
isomorphously on the clusianone (29) crystal seed. As such the growth of such 
crystal features is called epitaxial since it is known to be single domain 
crystallography lattice which enhances the purity of the crystal compound 
(Bergfors, 2003). 
      Recrystallization method has afforded high purity clusianone (29) 
crystals (>98%) formed in P212121 space group. One of the publications arising 
from this thesis which reports the clusianone (29) in crystalline P212121 space 
group was essential particularly for furthering its potential therapeutic effects as 
anticancer drug (Nagalingam et al., 2013) (Appendix F). The rationale behind 
this was the purity requirements set by ICH (International Conference on 
Harmonization of Technical Requirements for Pharmaceutical on Human Use) 
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for potential drug development (Guideline, 2009). The previous reports on 
clusianone (29) have never mentioned this polymorph state in crystalline 
P212121 space group as discussed in the next subheading. 
       Polymorphism occurrences may cause a difference in pharmacological 
effect in terms of the stability and solubility of clusianone (29) (Bauer, 2008). 
Consequently, the efforts to produce high purity clusianone (29) in crystalline 
form (500 mg) consumed months of effort in order to guarantee the quality and 
purity of the novel derivatives which were produced via structural modification 
of clusianone (29). 
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 Figure 4.1 Clusianone (29) crystal morphology through solvent evaporation 
 
 
Figure 4.2 Crystal growths through seed crystal (A) 100× magnification  
 (B) 40× magnification.  
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4.1.2 Characterisation of clusianone (29) 
 
 Clusianone (29) structure was characterized using FT-IR (Figure 4.3), 
single crystal diffractometer  (Table 4.1 & Figure 4.4), ESIMS (Figure 4.5 & 
Figure 4.6), 13C NMR (Figure 4.8 & Table 4.2), 1H NMR (Figure 4.7 & Table 
4.3), melting point device and polarimeter. The IR spectra of clusianone (29) 
showed absorptions at 3488 cm-1 for hydroxyl groups and 1726 cm-1 for carbonyl 
groups. 
 
     Figure 4.3 FT-IR Spectrum of clusianone (29) isolated from G.parvifolia 
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             Clusianone (29) crystallizes in orthorhombic with space group P212121 
form having melting point of 365-366K (Table 4.1 & Figure 4.4). X-ray 
crystallography data was compared with the first report made for clusianone (29) 
isolated from Clusia congestiflora by McCandlish et al. (1976).  
 
Table 4.1 Ortep structure including crystals parameters of clusianone 
 
 
Clusianone C33H42O4 
 
 
Mr            : 502.69 
Melting point   : 365K 
Cell parameter  : a= 9.2035, b= 13.4629, c= 22.9607 
Cell angle      : α= β= γ= 90 o       
Volume        : 2844.96 
Crystal shape   : orthorhombic 
Space group    : P21 21 21 
Crystal colour   :yellow 
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              A few concerns related to the melting point and crystal space group of 
clusianone (29) were discovered as the data obtained were not consistent and 
contradicts when cross-checked with several literature reviews on clusianone 
(29). The melting point and space group of clusianone (29) by McCandlish et al. 
(1976) was reported as 150-152 °C and Pna21 respectively meanwhile our 
laboratory result showed clusianone (29) melting point in the range of  90-92 °C 
and crystal space group was P212121 (Figure 4.4). 
 
 
Figure 4.4 Clusianone (29) in crystal packing unit P212121 form 
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The X-ray crystallography data comparison was also cross checked with 
literature related to clusianone’s epimer known as 7-epiclusianone (30) in two 
separate reports (Santos et al., 1998; Christian et al., 2012). Unexpectedly, both 
the melting point and crystal space group of clusianone (29) were similar to its 
epimer and this made the data published by McCandlish et al. (1976) 
questionable. A few hypotheses were made based on the findings and additional 
test conducted to analyse and support the hypothesis. The different solvent used 
for the recrystallization method might have caused the polymorphism to occur 
whereby the crystals obtained by McCandlish et al. (1976) were crystallized in 
95% ethanol solution.  
The lack of detail on the specific rotation of clusianone (29) isolated by 
McCandlish et al. (1976) led us to test clusianone (29) crystal using polarimetry 
since naturally occurring clusianone (29) could also exist in both  S-(+)-
clusianone and R-(-)-clusianone enantiomer forms. The specific rotation [α]20 
value was +51.94° indicating clusianone (29) isolated form G. parvifolia was in 
S-(+)-clusianone absolute configuration form. All these findings together with 
intramolecular and intermolecular bonding of clusianone in orthorhombic space 
group P212121 were reported and published in Section E of Acta Crystallography 
(Nagalingam et al., 2013) (Appendix F). 
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Clusianone (29) was confirmed with ESIMS (Figure 4.5) with adduct 
H+ having base peak of (m/z 503.3147, 100%) for the [M+H]+. From the ESIMS 
of clusianone (29), it was  proposed that fragmentation of clusianone (29) 
yielded ions resulting from successive elimination of prenyl side chain at C5 and 
C7. As such, ESIMS fragment ions m/z 435 (23.3%) was a result of loss of prenyl 
chain at C5 [M+H-68]+. Consequently, the fragments at m/z 435 resulted in two 
ions, one from a loss of isobutene chain at m/z 379 (4.5%) and the other at m/z 
311(4.6%) occurring through the opening of bicyclo-[3.3.1]-nonane. The 
fragments proposed were as per shown in (Figure 4.6).  
 
 
Figure 4.5 ESIMS of clusianone (29) from G. parvifolia 
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Figure 4.6  Fragmentation of clusianone (29) predicted from the fragments ion 
based on ESIMS 
 
As for the 1H NMR and 13C NMR interpretation, the 1H NMR (Figure 
4.7 & Table 4.3) and  13C NMR (Figure 4.8 & Table 4.2) details were 
corroborated with previously published report for  clusianone (29) compound 
structure confirmation (Piccinelli et al., 2005). 
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Figure 4.7  1H NMR spectrum of clusianone (29) 
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                                                 Figure 4.8  13C NMR spectrum of clusianone (29) 
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Table 4.2 1H NMR of clusianone (29)   Table 4.3 13C NMR of clusianone (29) 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Structures of clusianone a and clusianone b on page 99  
Proton 
assignment  
 
δ 1H NMR (JH-H in Hz) 
(ppm) 
 clusianone 
a 
clusianone 
b 
1 - - 
2 - - 
3 - - 
4 - - 
5 - - 
6 - - 
   
7 1.57 1.54 
8ax 1.56,  
(t,8Hz) 
1.44,  
(t,8Hz) 
8eq 2.15, m 2.00, dd  
(t, 12Hz) 
9 - - 
10 2.69, m 2.75, m 
11 4.85, m 4.93, m 
12 - - 
13 1.72, s 1.69, s 
14 1.64, s 1.61, s 
15 - - 
16 - - 
17,21 7.38,  
(d, 7.6Hz) 
7.40,  
(d, 7.6Hz) 
18,20 7.55,  
(t, 7.6Hz) 
7.55,  
(t, 7.6Hz) 
19 7.53,  
(t, 7.6Hz) 
7.53,  
(t, 7.6Hz) 
22 2.66, m 2.66, m 
23 5.17, m 5.19, m 
24 - - 
25 1.66, s 1.66, s 
26 1.79, s 1.79, s 
27 1.93, m 2.19, m 
28 5.00, m 5.07, m 
29 - - 
30 1.56, s - 
31 1.61, s - 
32 0.76, s 0.87, s 
33 1.08, s 1.26, s 
Carbon 
assignment 
 δ 13C NMR  
(ppm) 
clusianone 
a 
clusianone 
b 
1 71.0 67.2 
2 192.6 194.7 
3 116.8 116.1 
4 195.4 193.9 
5 59.6 64.6 
6 47.6 48.5 
7 42.3 42.3 
8 41.5 42.9 
9 207.3 207.5 
10 25.5 24.9 
11 119.1 119.1 
12 134.5 134.5 
13 18.0 18.0 
14 25.7 25.7 
15 197.8 197.5 
16 137.2 137.2 
17,21 128.9 128.9 
18,20 127.8 127.8 
19 132.5 132.5 
22 29.8 30.6 
23 120.3 119.9 
24 134.5 134.5 
25 18.1 18.1 
26 26.0 26.0 
27 28.1 28.5 
28 122.2 122.3 
29 133.3 133.3 
30 18.1 17.9 
31 26.0 26.0 
32 16.2 16.3 
33 22.6 23.7 
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4.2 Synthesis of clusianone (29) derivatives  
 
The synthesis of clusianone (29) derivatives was to study the structure-
activity relationship of clusianone (29) and its derivatised compounds against 
selected respiratory cancer and normal cell lines. Eight clusianone (29) 
derivatives were prepared on a scale of 10-100 mg and purified using Si gel 
column chromatography. These successful reactions were also repeated three 
times to assess reproducibility and feasible synthetic plan with good yield 
(˃75%) afforded methylated CMet (53), hydrogenated CHyd (53), oxime added 
CMxA (55) including  two primary amines added CMeA (56) and CEtA (57) 
derivatives. Other reactions produced compound CPryl (58) and CGeryl (59) 
both with yield below 50%. Apart from this, reaction to deprotect by removing 
the methyl group on compound CHyd (54) gave very low overall yield 5.0% of 
compound CDMet (60). The overall synthesis reactions together with the 
expected products are illustrated in Scheme 4.1 and IUPAC names, the 
abbreviated name including molecular weight are shown in Table 4.4.  
 The main objective was to study the importance of existing functional 
group that was present in clusianone (29) and also to integrate other functional 
groups which could lead to a better anticancer entity. Synthesis reactions yielded 
two tautomer’s product since clusianone (a/b) used as starting material exists in 
its tautomer forms (Scheme 4.1). Clusianone (29) derivatives were mainly 
characterized using ESIMS, H1 NMR and C13 NMR spectroscopy results being 
compared to clusianone (29) spectroscopy results shown as ESIMS (Figure 4.5 
& Figure 4.6), 1H NMR (Figure 4.7 & Table 4.3) and 13C NMR (Figure 4.8 & 
Table 4.2). 
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Scheme 4.1 a) Synthesis reaction of clusianone (29) in tautomer forms and 
derivatised product in tautomeric forms. 
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Scheme 4.1 b) Synthesis reaction of clusianone (29) in tautomer forms and  
derivatised product in tautomeric forms. 
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Scheme 4.1 c) Synthesis reaction of clusianone (29) in tautomer forms and 
derivatised product in tautomeric forms. 
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Table 4.4 IUPAC names for clusianone (a/b) and derivatives (a/b) 
Compound  Molecula 
Formula 
IUPAC name 
Clusianone a C33H42O4  (1S, 5S, 7R)-3-benzoyl-4-hydroxy-8,8-dimethyl-1,5,7-tris(3-methylbut-2-en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione 
Clusianone b C33H42O4  (1R, 5R, 7R)-3-benzoyl-4-hydroxy-6,6-dimethyl-1,5,7-tris(3-methylbut-2-en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione 
CMet a C34H44O4  (1S, 5S, 7R)-3-benzoyl-4-methoxy-8,8-dimethyl-1,5,7-tris(3-methylbut-2-en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione 
CMet b C34H44O4  (1R, 5R, 7R)-3-benzoyl-4-methoxy-6,6-dimethyl-1,5,7-tris(3-methylbut-2-en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-
dione 
CHyd a C34H50O4  (1S, 5S, 7R)-3-benzoyl-1,5,7-triisopentyl-4-methoxy-8,8-dimethylbicyclo[3.3.1]non-3-ene-2,9-dione 
CHyd b C34H50O4  (1R, 5R, 7R)-3-benzoyl-1,5,7-triisopentyl-4-methoxy-6,6-dimethylbicyclo[3.3.1]non-3-ene-2,9-dione 
CMxA a C34H45NO4  (1S, 5R, 7R)-3-benzoyl-4-hydroxy-9-(methoxyimino)-8,8-dimethyl-1,5,7-tris(3-methylbut-2-en-1-
yl)bicyclo[3.3.1]non-3-en-2-one 
CMxA b C34H45NO4  (1R, 5S, 7R)-3-benzoyl-4-hydroxy-9-(methoxyimino)-6,6-dimethyl-1,5,7-tris(3-methylbut-2-en-1-
yl)bicyclo[3.3.1]non-3-en-2-one 
CMeA a C34H45NO3  (1S, 5R, 7R)-3-benzoyl-4-hydroxy-8,8-dimethyl-1,5,7-tris(3-methylbut-2-en-1-yl)-9-(methylimino)bicyclo[3.3.1]non-3-
en-2-one 
CMeA b C34H45NO3  (1R, 5S, 7R)-3-benzoyl-4-hydroxy-6,6-dimethyl-1,5,7-tris(3-methylbut-2-en-1-yl)-9-(methylimino)bicyclo[3.3.1]non-3-
en-2-one 
CEtA a C35H47NO3  (1S, 5R, 7R)-3-benzoyl-9-(ethylimino)-4-hydroxy-8,8-dimethyl-1,5,7-tris(3-methylbut-2-en-1-
yl)bicyclo[3.3.1]non-3-en-2-one 
CEtA b C35H47NO3  (1R, 5S, 7R)-3-benzoyl-9-(ethylimino)-4-hydroxy-6,6-dimethyl-1,5,7-tris(3-methylbut-2-en-1-
yl)bicyclo[3.3.1]non-3-en-2-one 
CPryl a C38H50O4  (1S, 5S, 7R)-3-benzoyl-8,8-dimethyl-1,5,7-tris(3-methylbut-2-en-1-yl)-4-((3-methylbut-2-en-1-yl)oxy) 
bicyclo[3.3.1]non-3-ene-2,9-dione 
CPyrl b C38H50O4  (1R, 5R, 7R)-3-benzoyl-6,6-dimethyl-1,5,7-tris(3-methylbut-2-en-1-yl)-4-((3-methylbut-2-en-1-yl)oxy) 
bicyclo[3.3.1]non-3-ene-2,9-dione 
CGeryl a C43H59O4  (1S, 5S, 7R)-3-benzoyl-4-(((Z)-3,7-dimethylocta-2,6-dien-1-yl)oxy)-8,8-dimethyl-1,5,7-tris(3-methylbut-2-en-1-
yl)bicyclo[3.3.1]non-3-ene-2,9-dione 
CGeryl b 
 
 
CDMet       
C43H59O4 
 
 
C33H48O4 
(1R, 5R, 7R)-3-benzoyl-4-(((E)-3,7-dimethylocta-2,6-dien-1-
yl)oxy)-6,6-dimethyl-1,5,7-tris(3-methylbut-2-en-1-
yl)bicyclo[3.3.1]non-3-ene-2,9-dione 
(1S, 5S, 7R)-3-benzoyl-4-hydroxy-1,5,7-triisopentyl-8,8-
dimethyl bicyclo[3.3.1]non-3-ene-2,9-dione 
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4.2.1 Synthesis of CMet (53) 
[(1S, 5S, 7R)-3-benzoyl-4-hydroxy-8,8-dimethyl-1,5,7-tris(3-methylbut-2-
en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione]  
Synthesis method approach on clusianone (29) was first initiated by 
methylation reaction to facilitate subsequent hydrogenation of clusianone (29) 
since too many side reactions occurred during direct hydrogenation of 
clusianone (29) including trials of synthesis in basic conditions. The approach 
was similar to the methylation reaction carried out by Simpkins group using 
K2CO3 and Me2SO4 in acetone under refluxed condition (Ahmad et al., 2007).  
This single step method was completed in two hours and the reaction 
was feasible at a larger scale using 100 mg of clusianone (29) as starting material 
with 90% yield of CMet (53) recovery from Si gel column chromatography 
purification. This made the next step of obtaining CHyd (54) feasible with 
sufficient amount of CMet (53) as a precursor compound for hydrogenation 
reaction. The ESIMS (Figure 4.9) showed a base peak at m/z 517.3316 (100%) 
for the [M+H]+.  
 
 
Figure 4.9 ESIMS of compound CMet (53) 
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The reaction mechanism of methylation on clusianone (29) is illustrated 
in Scheme 4.2. The methyl group presence was confirmed with NMR 
spectroscopic data. The 1H NMR (Figure 4.10 & Table 4.5) and 13C NMR 
(Figure 4.11 & Table 4.6) showed the methyl group was observed at δH 3.65 (s, 
3H) and δC 60.49 respectively. The chemical shifts for both 1H NMR and 13C 
NMR corresponding to methyl group for CMet (53) were corroborated to the 
previously reported methylated clusianone (29) via diazomethane treatment 
(Oliveira et al., 1996).  
 
 
 
      Scheme 4.2  Reaction mechanism for methylation of clusianone (29)
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Figure 4.10  1H NMR spectrum of compound CMet (53) 
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                                                 Figure 4.11  13C NMR spectrum of compound CMet (53)
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Table 4.5 1H NMR of  CMet (53)       Table 4.6 13C NMR of  CMet (53) 
 
 
 
 
 
*Structures of CMet a and CMet b on page 99  
 
Proton 
assignment 
δ 1H NMR (JH-H in Hz) 
(ppm) 
 
CMet a   CMet b 
1 - - 
2 - - 
3 - - 
4 - - 
5 - -
6 - - 
7 1.62 1.62 
8ax 1.71, 
(t, 8Hz) 
1.71, 
(t, 8Hz) 
8eq 2.15, m 2.11, dd  
(t, 12Hz) 
9 - - 
10 2.59, m 2.59, m 
11 4.82, m 4.82, m 
12 - - 
13 1.62, s  
14 1.66, s  
15 - - 
16 - - 
17,21 7.85, 
(d, 7.6Hz) 
7.85,  
(d, 7.6Hz) 
18,20 7.43, 
(t,7.6 Hz) 
7.43,  
(t, 7.6 Hz) 
19 7.55,  
(t, 7.6Hz) 
7.55,(t, 
7.6Hz) 
22 2.57, m  
23 5.09, m 5.09, m 
24 - - 
25 1.65, s 1.69, s 
26 1.78, s 1.78 
27 1.93, m 2.19, m 
28 4.94, m 4.94, m 
29 - - 
30 1.41, s 1.45, s 
31 1.56, s 1.59, s 
32 0.77, s 0.82, s 
33 1.08, s 1.19, s 
34 3.63, s 3.65, s 
Carbon 
assignment
δ 13C NMR 
(ppm) 
 
CMet a    CMet b 
1 71.0 65.6 
2 173.3 172.9 
3 119.8 119.8 
4 196.3 196.3 
5 64.3 64.3 
6 47.0 47.0 
7 41.8 41.7 
8 40.2 40.2 
9 207.7 207.6 
10 25.0 24.5 
11 120.1 120.1 
12 134.1 134.0 
13 17.9 17.9 
14 25.8 25.8 
15 195.6 195.5 
16 137.9 137.9 
17,21 129.2 129.1 
18,20 128.6 128.6 
19 133.3 133.2 
22 29.7 29.5 
23 120.5 120.5 
24 134.1 134.0 
25 17.9 17.9 
26 26.1 26.0 
27 27.9 28.6 
28 122.5 122.6 
29 133.6 133.4 
30 17.9 17.9 
31 25.9 25.9 
32 16.2 15.9 
33 22.4 24.1 
34 60.7 60.4 
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CMet (53) formed single crystal through slow evaporation method in 
methanol solvent. Further to this, the excellent yield also afforded large white 
crystals upon recrystallization using slow methanol evaporation in scintillation 
vials. CMet (53) single crystal was further characterized using single X-ray 
crystallographic analysis (Table 4.7, Figure 4.12 & Figure 4.13). 
 
Table 4.7 ORTEP diagram including crystals parameters of compound CMet 
(53) 
Compound CMet (53) C34H44O4 
 
 
  
 
Mr           : 516.72 
Melting point  : 383K 
Cell parameter : a=10.1811, b= 11.0948, c= 13.1334 
Cell angle     : α= 87.57 o, β= 82.46 o, γ= 89.81 o 
Volume       : 1469.38 
Crystal shape  : triclinic 
Space group   : P1 
Crystal colour  : white  
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Figure 4.12 (A) CMet (53) crystal morphology through solvent evaporation. (B) 
Growth banding observed in single crystal of CMet (53).  
 
Figure 4.13 Compound CMet (53) in crystal packing unit P1 form 
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To date, CMet (53) crystals were obtained by diazomethane treatment of 
clusianone (29) isolated from Clusia spiritu-santensis (male) and the x-ray 
diffraction analysis reported the ORTEP stereoview of  crystal compound. CMet 
(53) compound characterization using MS and NMR was reported previously. 
The report did not cover the crystal properties and characteristic such as space 
group, shape, cell parameters, bond lengths and intramolecular interactions 
including intermolecular interactions (Oliveira et al., 1996). The melting point 
of CMet (53) obtained was 110 °C which contradicts the melting point (123-125 
°C) reported by Oliveira et al. (1996).  
As for the synthesis community, CMet (53) has been an important 
intermediate in total synthesis of clusianone (29) which involves 20 to 40 
reaction steps. CMet (53) was the precursor compound involved in the final step 
of producing clusianone (29) (Ahmad et al., 2007; Qi & Porco, 2007; Garnsey 
et al., 2011). In this research, X-ray diffraction analysis showed CMet (53) 
crystallizes in triclinic system with P1 space group. The presence of strong 
intermolecular hydrogen bond between the O105 atom and H2133 could be also 
the reason for the higher melting point value compared to clusianone (29) 
possessing supramolecular layers in the ab plane were stabilised by weak C—
H···O interactions (Figure 4.13). Currently, there is no information regarding 
the crystal structure of CMet (53) in literature. Since CMet (53) was a 
fundamental component in total synthesis of clusianone (29), the X-ray 
diffraction analysis data for CMet (53) obtained from this research is considered 
valuable information reported in this thesis. 
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4.2.2 Synthesis of CHyd (54) 
[(1S, 5S, 7R)-3-benzoyl-1,5,7-triisopentyl-4-methoxy-8,8- 
dimethylbicyclo[3.3.1]non-3-ene-2,9-dione]  
    Successively, hydrogenation of CMet (53) afforded 80% yield of CHyd 
(54) in a single step. Although there are several options of opening alkene double 
bonds, catalytic hydrogenation using palladium on activated charcoal has been 
an effective and fast way of obtaining the desired product CHyd (54). This 
method has been previously employed by other synthetic researchers studying 
structure-activity relationship of PPAP compounds such as xanthochymol and 
hyperforin (Roux et al., 2000; Gartner et al., 2005). Another method employed 
to hydrogenate CMet (53) using Wilkinson catalyst, ClRh(PPh3)3 was not 
successful (Trost et al., 2006).  Compound CHyd (54) was confirmed with 
ESIMS (m/z 545.3607, 100%) for the [M+Na]+ (Figure 4.14).  
 
 
  Figure 4.14 ESIMS of compound CHyd (54) 
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 The 1H NMR signals corresponding to H-11, H-23 and H-28 of compound 
CMet (53) observed at δ 5.07, δ 5.11 and δ5.08 respectively was not observed 
in compound CHyd (54) (Figure 4.15 & Table 4.8). The deshielding was due 
to the presence of electronegative alkene in tetraprenyl group which increases 
the 1H chemical shifts at about 5.0 ppm. As for the 13C NMR signals, (Figure 
4.16 & Table 4.9) for compound CHyd (54) of the carbon of C-11, C-12, C-23, 
C-24, C-28 and C-29 were found at highfield range between δ 30.0 to δ 35.0. In 
contrast to those in compound CMet (53), 13C NMR signals were found in the 
range between δ 120.0 to δ 134.0. To date, there were no reports of compounds 
having a structure similar to CHyd (54) and hence, CHyd (54) is a newly 
reported clusianone (29) derivative and this was the first time hydrogenation has 
been carried out for clusianone (29) via CMet (53) as a precursor. 
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Figure 4.15  1H NMR spectrum of compound CHyd (54) 
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Figure 4.16 13C NMR spectrum of compound CHyd (54) 
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 Table 4.8 1H NMR of  CHyd (54)      Table 4.9 13C NMR of CHyd (54)  
 
 
 
 
 
*Structures of CHyd a and CHyd b on page 99  
  
Proton 
assignment  
 
δ 1H NMR (JH-H in Hz) 
(ppm)  
 
CHyd a    CHyd b 
1 - - 
2 - - 
3 - - 
4 - - 
5 - - 
6 - - 
7 1.56, m 1.56, m 
8ax 1.59,  
(t, 8Hz) 
1.59,  
(t, 8Hz) 
8eq 2.05, m 2.15, dd 
(t, 12Hz) 
9 - - 
10 1.29, m 1.29, m 
11 1.22, m 
 
1.25, m 
12 1.37, m 1.40, m 
13 0.96, s 0.98, s 
14 0.91, s 0.93, s 
15 - - 
16 - - 
17,21 7.90,  
(d, 7.6Hz) 
7.90,  
(d, 7.6Hz) 
18,20 7.49,  
(t, 7.6Hz) 
7.49,  
(t, 7.6Hz) 
19 7.60, 
(t, 7.6Hz) 
7.60,  
(t, 7.6Hz) 
22 1.13, m 1.13, m 
23 2.02, s 2.05, m 
24 1.31, m 1.31, m 
25 0.82, s 0.83, s 
26  0.79, s 0.81, s 
27 1.94, m 2.02, m 
28 1.54, s 1.54, s 
29 1.44, m 1.48, m 
30 0.83, s 0.85, s 
31 0.86, s 0.88, s 
32 0.71, s 0.74, s 
33 1.00, s 1.13, s 
34 3.72, s 3.74, s 
Carbon 
assignment 
δ 13C NMR 
(ppm) 
 
CHyd a CHyd b 
1 71.5 65.6 
2 172.9 173.4 
3 123.1 123.7 
4 196.1 196.9 
5 57.5 57.5
6 47.1 47.9 
7 41.6 41.8 
8 43.5 43.5 
9 207.9 208.0 
10 27.0 27.0 
11 29.7 29.7 
12 34.1 34.2 
13 22.4 22.4 
14 27.9 27.9 
15 195.6 195.8 
16 138.0 138.1 
17,21 129.1 129.2 
18,20 128.7 128.7 
19 133.5 133.5 
22 29.5 29.1 
23 33.5 33.6 
24 34.1 34.2 
25 22.7 22.9 
26 28.2 28.3 
27 28.8 28.9 
28 33.5 33.6 
29 37.8 37.7 
30 22.7 22.5 
31 23.0 23.6 
32 22.3 22.4 
33 16.2 16.4 
34 60.5 60.8 
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4.2.3 Synthesis of CMxA (55) 
[(1S, 5R, 7R)-3-benzoyl-4-hydroxy-9-(methoxyimino)-8,8-dimethyl-1,5,7-
tris(3-methylbut-2-en-1-yl)bicyclo[3.3.1]non-3-en-2-one]  
            Reduction of ketone was envisioned since clusianone (29) has ketone 
groups on bicyclo [3.3.1] nonane-2, 4, 9-trione skeleton. However, benzoyl 
group was electron withdrawing and ketone reduction at C-15 will not occur and 
acts as hindrance to the ketone reduction of either at C-2 or C-4. Hence, ketone 
reduction at C-9 was successfully carried out using acidic condition using 
dichloromethane solvent together with methoxyamine HCl as starting material. 
To date, ketone reduction at C-9 has never been reported in PPAP compounds 
and all PPAP compounds possess ketone group at C-9 position of the [3.3.1] 
nonane-2,4,9-trione skeleton. Oximination of clusianone (29) reaction afforded 
CMxA (55) which involves the modification of C-9 ketone of clusianone (29) 
to an oxime substituent. The ketone reduction was successful via nucleophilic 
addition under mild acidic condition. The synthesis of CMxA (55) was easily 
achieved in one step with 75% yield.  
 
Scheme 4.3 Addition elimination reaction mechanism of C=O in the formation 
of oxime compound CMxA (55)  
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            The mechanism of this reaction was preceded by addition-elimination 
reaction of the carbonyl group at C-9. The nucleophilicity of nitrogen on the 
methoxyamine was increased by the presence of oxygen. Successive proton 
transfer allows for elimination of water (Scheme 4.3). Pyridine was added to 
stabilize the HCl in the reaction. After 48 hours, the mixture was extracted with 
5% HCl to remove the pyridine. The organic layer was dried over MgSO4 to 
remove the presence of H2O produced as by product in the reaction and further 
purified using Si gel column chromatography.  
 
 
 
 Figure 4.17 ESIMS of compound CMxA (55) 
 
      Compound CMxA (55) was confirmed with ESIMS (Figure 4.17) with 
adduct H+ and Na+ having base peak of (m/z 532.3423, 100%) for the [M+H]+ 
and (m/z 554.3231, 85.9%) for the [M+Na]+ respectively. The methyl group of 
C-34 was confirmed from its 1H NMR (Figure 4.18 & Table 4.10) 
corresponding to the methoxy group were observed at δH 4.10 (s, 3H) meanwhile 
13C NMR (Figure 4.19 & Table 4.11) at δC 62.55.  
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               The 13C NMR signal of C-9 (C=N) attached to oxime group was 
represented at δC 153.0 since the C=N-O-CH3 was less electronegative than 
C=O. Other signals related to C-1 and C-5 observed at δ 64.1 and δ 39.5 were 
shielded due to the effect of oximination which was noticed in the chemical 
shifts of 13C NMR of compound CMxA (55) (Table 4.11). This was because 
generally in six membered heterocycles, decrease in electronegativity of a 
particular group in the ring skeleton shields the α-carbon (Parthiban et al., 2008).  
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Figure 4.18 1H NMR spectra of compound CMxA (55) 
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Figure 4.19  13CNMR spectra of compound CMxA (55)
122 
 
Table 4.10 1H NMR of  CMxA (55)     Table 4.11 13C NMR of CMxA (55) 
 
             
 
 
       *Structures of CMxA a and CMxA b on page 100 
                        
 
Proton 
assignment  
δ 1H NMR (JH-H in Hz) 
(ppm)  
 CMxA a CMxA b 
1 - - 
2 - - 
3 - - 
4 - - 
5 - - 
6 - - 
7 1.56 1.56 
8ax 1.57,  
(t, 8Hz) 
1.46,  
(t, 8Hz) 
8eq 2.16, m 1.96, dd 
(t, 12Hz) 
9 - - 
10 2.74, m 2.76, m 
11 4.75, m 4.75, m 
12 - - 
13 1.70, s 1.70, s 
14 1.68, s 1.68, s 
15 - - 
16 - - 
17,21 7.46,  
(d, 7.6Hz) 
7.46,  
(d,7.6Hz) 
18,20 7.36,  
(t, 7.6Hz) 
7.36,  
(t, 7.6Hz) 
19 7.24,  
(t, 7.6Hz) 
7.24,  
(t, 7.6Hz) 
22 2.66, m 2.66, m 
23 5.19, m 5.19, m 
24 - - 
25 1.66, s 1.66, s 
26 1.75, s 1.75, s 
27 2.54, m 2.56, m 
28 4.99, m 4.99, m 
29 - - 
30 1.56, s 1.56, s 
31 1.62, s 1.62, s 
32 0.76, s 0.84,s 
33 1.05, s 1.19,s 
34 4.10, s 4.11,s 
Carbon 
assignment 
δ 13C NMR 
(ppm) 
 CMxA a   CMxA b 
1 64.1 64.8 
2 179.1 207.5 
3 116.6 116.6 
4 192.6 193.4 
5 39.5 39.5 
6 40.3 40.3 
7 42.2 42.2 
8 46.6 46.7 
9 153.0 - 
10 24.4 24.1 
11 119.3 119.9 
12 132.1 133.0 
13 15.8 16.2 
14 25.8 25.8 
15 207.5 - 
16 133.7 134.3 
17,21 128.5 128.8 
18,20 128.2 128.3 
19 129.5 129.7 
22 29.6 30.1 
23 119.9 120.1 
24 132.1 133.0 
25 17.8 17.9 
26 25.9 25.9 
27 27.7 28.5 
28 122.6 122.9 
29 133.1 133.6 
30 18.1 18.2 
31 23.9 24.1 
32 15.8 16.1 
33 22.5 - 
34 62.55 62.6 
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4.2.4 Synthesis of CMeA (56)  
[(1S, 5R, 7R)-3-benzoyl-4-hydroxy-8,8-dimethyl-1,5,7-tris(3-methylbut-2-
en-1-yl)-9-(methylimino)bicyclo[3.3.1]non-3-en-2-one]  
Next, synthesis of clusianone (29) derivative by installing amine groups 
to carbonyl C-9 of clusianone (29) was envisaged since most antimicrotubule 
agents such as taxol, epothilone and vinca alkaloids contains amine groups in 
the structure (Lucas & Moody, 2010). Reduction of clusianone (29) with 
methylamine HCl gave imine compound CMeA (56) in 75% yield. The 1H 
NMR (Figure 4.21 & Table 4.12) corresponding to the N-CH3 group were 
observed at δH 2.82 (s, 3H). The imine C9 (C=N) bond was shown in 13C NMR 
(Figure 4.22 & Table 4.12) chemical shifts at δC 83.17 ppm. The ESIMS 
(Figure 4.20) showed a base peak at m/z 516.3423 (100%) for the [M+H]+ . 
 
            
Figure 4.20 ESIMS of compound CMeA (56) 
 
 
 
 
124 
 
Thereafter, the addition of bulkier amine compound such as 
aminopiperidine to the carbonyl group of C-9 was envisioned. However, the 
reaction was unsuccessful and subsequent reaction with the addition of simple 
primary amines such as ethylamine was conducted. The reaction was successful 
and afforded formation of imine compound CEtA (57). The reaction mechanism 
of imine compound was similar to oxime compound whereby two major step 
occurs with carbonyl addition of an amine being the first step and dehydration 
elimination of water molecule as the second step to yield the C=N double bond. 
HCl acts as a catalyst in the formation of the imine compound formation 
otherwise; the reaction occurres very slowly (Scheme 4.4).  
Based on the previously published report, it was postulated that 
hydroxyl group in clusianone was responsible for cytotoxic effect in liver 
carcinoma (Reis et al., 2014).  Thus the next strategy was to create clusianone 
(29) derivative with additional hydroxyl group. The ketone reduction to 
carbonyl group of C-9 to be substituted with hydroxyl group was carried out 
using weak reducing agent NaBH4. The reaction indicated no signs of desired 
product formation upon mass spectrum analysis. A second method was also 
introduced, this time using a much stronger reduction agent in the form of 
DIBAL. Unfortunately, this reaction gave complex mixtures as a result of side 
reactions which lead to difficulty in the isolation process.  
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Scheme 4.4 Reaction mechanism of the methylamine addition to clusianone (29) 
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Figure 4.21 1HNMR spectra of compound CMeA (56)
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Figure 4.22 13C NMR spectra of compound CMeA (56) 
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Table 4.12 13C NMR and 1H NMR of compound CMeA (56) 
 
*Structures of CMeA a and CMeA b on page 100 
 
Carbon 
assignment  
δ 13C NMR 
(ppm) 
CMeA a/b 
Proton 
assignment 
 
δ 1H NMR (JH-H in Hz) 
 (ppm)  
CMeA a         CMeA b 
1 70.3 1 - - 
2 210.0 2 - - 
3 120.7 3 - - 
4 210.0 4 - - 
5 47.3 5 - - 
8 41.9 6 - - 
7 42.3 7 1.58, m 1.54, m 
6 30.0 8ax 1.60,  
(t, 8Hz) 
1.60, 
(t, 8Hz) 
9 83.1 8eq 1.95, m 1.97,dd 
(t, 12Hz) 
10 25.4 9 - - 
11 121.2 10 2.42, m 2.42, m 
12 133.7 11 4.96, m 4.96, m 
13 17.8 12 - - 
14 25.6 13 1.73, s 1.73, s 
15 132.3 14 1.68, s 1.68, s 
16 132.5 15 - - 
17,21 128.5 16 7.43,  
(t, 7.6Hz) 
7.43,  
(t, 7.6Hz) 
18,20 126.4 17,21 7.43,  
(t, 7.6Hz) 
7.43,  
(t, 7.6Hz) 
19 132.5 18,20 7.69,  
(t, 7.6Hz) 
7.69,  
(t, 7.6Hz) 
22 29.6 19 - -  
23 121.2 22 2.44, m 2.44, m 
24 133.7 23 4.96, m 4.96, m 
25 17.9 24 - - 
26 25.9 25 1.65, s 1.65, s 
27 
28 
28.5 
122.9 
26 
 
1.76, s 
 
1.76, s 
29 133.1 27 2.09, m 2.09, m 
30 18.0 28 4.80, m 4.80, m 
31 25.8 29 - - 
32 16.4 30 1.54, s 1.54, s 
33 23.0 31 1.62, s 1.62, s 
34 35.5 32 0.71, s 0.87, s 
  33 1.05, s 1.10, s 
  34 2.82, s 2.81, s 
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4.2.5 Synthesis of CEtA (57) 
[(1S, 5R, 7R)-3-benzoyl-9-(ethylimino)-4-hydroxy-8,8-dimethyl-1,5,7-
tris(3-methylbut-2-en-1-yl)bicyclo[3.3.1]non-3-en-2-one]  
Compound CEtA (57) was confirmed with ESIMS (Figure 4.23) with 
adduct H+ and Na+ having base peak of (m/z 530, 100%) for the [M+H]+ and 
(m/z 552, 24%) for the [M+Na]+ respectively (Figure 4.23). Unfortunately, the 
reaction product was unstable and sensitive to certain organic solvents. 
Therefore, compound 1H NMR and 13C NMR of CEtA (57) could not be 
established. In addition, HPLC analysis was carried out to see the purity 
percentage of CEtA  (57) to determine degradation of products due to the low 
stability of the product under normal environment and atmosphere. The 
mechanism of reaction was similar to imine compound CMeA (56) in Scheme 
4.4 but with ethylamine HCl (CH3CH2NH2.HCl) as the starting material. 
              
Figure 4.23 ESIMS of compound CEtA (57) 
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4.2.6 Synthesis of CPryl (58)  
[(1S, 5S, 7R) -3-benzoyl-8,8-dimethyl-1,5,7-tris(3-methylbut-2-en-1-yl)-4-
((3-methylbut-2-en-1-yl)oxy)bicyclo[3.3.1]non-3-ene-2,9-dione]  
 
             Prenyl groups in PPAP compounds were often reported to be 
responsible for activity against carcinoma cell lines. In addition, PPAP 
compound such has hyperforin (11) and its derivative Aristoforin (19) which 
possesses four prenyl compounds surrounding its bicyclo[3.3.1]nonane-2,4,9-
trione core structure have shown remarkable antitumor activity both in vitro and 
in vivo (Gartner et al., 2005; Richard, 2014). As such, the next envision was to 
employ the O-alkylation method to install prenyl group to the hydroxyl group of 
clusianone (29). The reaction to install additional prenyl group to clusianone 
(29) successfully produced compound CPryl (58). The product CPryl (58) was 
in moderate yield of 43% having molecular ion peak at m/z 571 for the [M+H]+ 
(Figure 4.24).  
 
    Figure 4.24 ESIMS of compound CPryl (58) 
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From the ESIMS of CPryl (58), it was proposed that fragmentation of 
CPryl (58) yielded ions resulting from successive elimination of prenyl side 
chain at C2 and C7. As such, ESIMS fragment ions m/z 503 was a result of the 
loss of a prenyl chain at C2 [M+H-68]+ and consecutive elimination of another 
prenyl chain at C7 has led to the fragmentation of ions with m/z 435 (Figure 
4.24). 
The reaction was predicted to yield two tautomer’s product of CPryl 
(58a) and CPryl (58b) since clusianone (a/b) used as starting material exists in 
its tautomer forms (Scheme 4.1 c). The 1H NMR signals corresponding to H-35 
of compound CPryl (58) was observed at δ 5.16 (Figure 4.25 & Table 4.13). 
This signal arises due to the additional prenyl chain (C5H9) added to clusianone 
(29). In addition 1H NMR signals corresponding to H-34 were observed at δ 4.12 
(s, 2H). As for the 13C NMR signals, detailed interpretations of the data relevant 
to the correlation of the carbons in the additional prenyl chain were shown in 
Figure 4.26 & Table 4.13.  The 13C NMR signal of C-34 was observed at δC 
65.4 attributed to the additional prenyl chain.  
An important point to be note in interpreting the NMR signals of CPryl 
(58), the 1H NMR signals corresponding to H-35 and H-23 have overlapped and 
these signals appear as multiplets resembling sextets. However, these were 
overlapped triplet signals arising from the respective 1H NMR signals of H-35 
and H-23.     
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  Figure 4.25  1H NMR spectrum of compound CPryl (58)  
4
.
1
2
4
.
1
4
4
.
4
8
4
.
5
0
4
.
5
1
4
.
5
3
4
.
7
9
4
.
8
1
4
.
8
2
5
.
0
6
5
.
0
8
5
.
1
0
5
.
1
4
5
.
1
6
133 
 
                                                                           
                                                                    Figure 4.26  13C NMR spectra of compound CPryl (58) 
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Table 4.13 13C NMR and 1H NMR of compound CPryl (58) 
 
*Structures of CPyrl a and CPyrl b on page 101 
 
 
Carbon 
assignment  
δ 13C NMR 
(ppm) 
  CPryl a/b 
Proton 
assignment 
 
δ 1H NMR (JH-H in Hz) 
             (ppm)  
(CPryl a)                    (CPryl b) 
1 57.6 1 - - 
2 172.6 2 - - 
3 120.3 3 - - 
4 195.4 4 - - 
5 71.1 5 - - 
6 40.3 6 - - 
7 47.0 7 1.58, m 1.54, m 
8 30.7 8ax 1.57, (t, 8Hz) 1.57,(t, 8Hz) 
9 207.9 8eq 2.01, m 2.05,dd (t, 12Hz) 
10 25.6 9 - - 
11 120.2 10 2.58, m 2.58, m 
12 133.2 11 4.51, m 4.50, m 
13 16.0 12 - - 
14 25.8 13 1.72, s 1.72, s 
15 195.2 14 1.69, s 1.67, s 
16 138.0 15 - - 
17,21 128.5 16 7.41,(t,7.6Hz) 7.43, (t, 7.6Hz) 
18,20 126.4 17,21 7.82, (t,7.6Hz) 7.83, (t, 7.6Hz) 
19 129.2 18,20 7.51, (t,7.6Hz) 7.52, (t, 7.6Hz) 
22 29.6 19 - -  
23 122.8 22 2.48, m 2.48, m 
24 134.0 23 5.08, m 5.08, m 
25 18.1 24 - - 
26 25.9 25 1.63, s 1.63, s 
27 28.0 26 1.67, s 1.67, s 
28 120.4 27 2.42, m 2.42, m 
29 133.3 28 4.81, m 4.81, s 
30 17.9 29 - - 
31 25.0 30 1.54, s 1.54, s 
32 22.5 31 1.62, s 1.62, s 
33 23.0 32 0.75, s 0.79, s 
34 
35 
36 
37 
38      
 
65.4 
118.1 
140.2 
14.1 
22.5 
 
33 
34 
35 
36 
37 
38 
1.06, s 
4.12, s 
5.16, m 
- 
1.56, s 
1.59, s 
1.16, s 
4.14, s 
5.16, m 
- 
1.56, s 
1.59, s 
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4.2.7 Synthesis of CGeryl (59) 
[(1S, 5S, 7R)-3-benzoyl-4-(((Z)-3,7-dimethylocta-2,6-dien-1-yl)oxy)-8,8-
dimethyl-1,5,7-tris(3-methylbut-2-en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-
dione] 
Interestingly type B of PPAP compound such as oblongifolin (22) has 
been tested for tubulin activity and results revealed that this compound interacts 
by inhibiting tubulin assembly activity at a cellular level (Hamed et al., 2006). 
Since oblongifolin (22) compound possesses geranyl group, the subsequent 
reaction was to insert a geranyl group to the hydroxyl group of clusianone (29). 
The product CGeryl (59) was in low yield at 28% having molecular ion peak at 
m/z 639 for the [M+H]+ (Figure 4.27). Based on the ESIMS of CGeryl (58), 
there was clear indication of fragmentation patterns of CPryl (58) which yielded 
ions resulting from successive elimination of geranyl and prenyl side chains at 
C2 and C5 respectively. As a result, ESIMS fragment ions m/z 503 was a result 
of loss of geranyl chain at C2 [M+H-136]+ and consecutive elimination of 
another prenyl chain at C5 has led to the fragmentation of ions with m/z 435 
(Figure 4.27). 
            Figure 4.27 ESIMS of compound CGeryl (59) 
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It was noticed that the presence of more signals of 1H NMR arising in 
the downfield region of δ 4.0 to 6.0 ppm (Figure 4.28) for compound CGeryl 
(59). The deshielding effect was due to the presence of electronegative alkene 
chains which were present in geranyl (C10H17) and prenyl (C5H9)  chains  in 
CGeryl (59). The 1H NMR spectrum of compound CGeryl (59) as shown in 
Figure 4.28 showed proton signals of H-35 and H-40 at δ 5.57 and δ 5.54 
respectively attributed to the presence geranyl chain (Figure 4.28 & Table 
4.14). The presence of geranyl chain was confirmed by both 1H NMR and 13C 
NMR signals which were observed at δH 4.03 (s, 2H) and δC 68.2 respectively. 
The  13C NMR signals and detailed interpretations of the data  relevant to the 
correlation of the carbons in compound CGeryl (59) were shown in Figure 4.29 
& Table 4.14.  
In addition, the reaction was predicted to yield two tautomer’s CGeryl 
(59a) and CGeryl (59b) since clusianone (a/b) used as starting material exists in 
its tautomeric forms (Scheme 4.1 c). In this circumstances, the additional 1H 
NMR signals arising in the region of δ 4.0 to 6.0 ppm were evidence of the 
consequences of the enolizable 1,3-diketone system in clusianone (29) 
producing CGeryl (59) also in two tautomeric forms. On the basis of these 
consideration, some of these triplet signals exhibited two sets of 1H NMR signals 
arising from proton attached to prenyl chain (H-28 and H-11) of either 
compound CGeryl (59a) or CGeryl (59b) (Figure 4.28 & Table 4.14). 
Additionally, the 1H NMR triplet signals corresponding to H-35 and H-40 have 
overlapped and these signals appear as multiplets resembling quartet (Figure 
4.29). 
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                                                                             Figure 4.28  1H NMR spectrum of compound CGeryl (59) 
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Figure 4.29  13C NMR spectra of compound CGeryl (59) 
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Table 4.14 13C NMR and 1H NMR of compound CGeryl (59) 
 
*Structures of CGeryl a and CGeryl b on page 101 
Carbon 
assignment  
δ 13C NMR 
(ppm) 
 CGeryl a/b 
Proton 
assignment 
 
δ 1H NMR (JH-H in Hz) 
             (ppm)  
CGeryl a                 CGeryl b 
1 58.4 1 - - 
2 143.7 2 - - 
3 120.5 3 - - 
4 193.0 4 - - 
5 72.1 5 - - 
8 39.1 6 - - 
7 46.8 7 1.57, m 1.57, m 
6 30.4 8ax 1.60, (t, 8Hz) 1.60,(t, 8Hz) 
9 195.0 8eq 1.95, m 2.05(overlapped) 
10 24.1 9 - - 
11 120.4 10 2.44, m 2.44, m 
12 130.9 11 4.23, m 4.30, m 
13 16.0 12 - - 
14 25.7 13 1.69, s 1.69, s 
15 167.8 14 1.76, s 1.76, s 
16 18.1 15 - - 
17,21 128.8 16 7.53,(t,7.6Hz) 7.71, (t, 7.6Hz) 
18,20 128.6 17,21 7.82, (t,7.6Hz) 7.84, (t, 7.6Hz) 
19 129.2 18,20 7.40, (t,7.6Hz) 7.40, (t, 7.6Hz) 
22 29.7 19 - -  
23 123.5 22 2.55, m 2.55, m 
24 132.0 23 5.07, m 5.07, m 
25 18.0 24 - - 
26 26.2 25 1.61, s 1.61, s 
27 28.9 26 1.76, s 1.76, s 
28 121.0 27 2.09, m 2.09, m 
29 130.9 28 4.70, m 4.81, s 
30 17.9 29 - - 
31 23.8 30 1.30, s 1.33, s 
32 22.7 31 1.42, s 1.46, s 
33 23.7 32 0.75, s 0.79, s 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
68.2 
117.6 
143.1 
14.0 
34.3 
26.0 
124.0 
133.0 
22.5 
14.1 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
1.06, s 
4.03, s 
5.57, m 
- 
1.64, s 
2.05, m 
2.05, m 
5.54, m 
- 
1.74, s 
1.76, s 
1.17, s 
4.05, s 
5.57, m 
- 
1.66, s 
2.05, m 
2.05, m 
5.54, m 
- 
1.74, s 
1.76, s 
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4.2.8 Synthesis of CDMet (60) 
[(1S, 5S, 7R)-3-benzoyl-4-hydroxy-1,5,7-triisopentyl-8,8-dimethyl 
bicyclo[3.3.1]non-3-ene-2,9-dione]  
              Demethylation reaction was carried out to deprotect CHyd (54) using 
previously published method (Ahmad et al., 2007). In this report, Krapcho-type 
conditions (LiCl, DMSO, 120 °C) used afforded 50% of the desired yield. 
Unfortunately, the same reaction performed on CHyd (54) gave (60) in 5.0 % 
yield. Based on the ESIMS result,  it indicated that base peak at 509.3618 
corresponds to the mass of [M+H]+. However, further attempts to increase the 
yield of the product by extending the stirring duration was not conducted due to 
the paucity of precursor compound CHyd (54). 
 
 
 
 
Figure 4.30 ESIMS of compound CDMet (60) 
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4.3 TLC analysis for compound  CMxA (55), CMeA (56) and CEtA (57) 
 
Crystallization efforts on compound CMxA (55) and CEtA (57) were not 
fruitful. The main factor was the formation of by-products through  degradation 
along the process when the compounds were subjected to several organic 
solvents such as ethanol, methanol, chloroform and dichloromethane. In 
addition, exposure to atmosphere while waiting for the crystallization to occur 
via slow solvent evaporation method, indicate that these products were air 
sensitive in solution forms. Therefore, the presence of by-products through  
degradation had suppressed the formation of crystallization. Further purity test 
using TLC profiling and HPLC analysis were necessary to determine the 
existence of possible by-product formation due to instability of the compounds.  
TLC profiles of clusianone (29) added with oxime and imines were 
shown in (Figure 4.31). The orange stains on TLC after spraying with 
Dragendoff reagent confirmed the presence of nitrogen element in the products. 
The black circles indicated starting material clusianone (29) or product CMxA 
(55), CMeA (56) and CEtA (57). White circles spots indicate by-products 
through degrdation formed for compounds when viewed under UV light at short 
wavelength (254 nm).  
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Figure 4.31 TLC images of compounds CMxA (55), CMeA (56) and CEtA (57) 
after reaction and purification through column chromatography. (A) CMxA (55) 
formed stained orange with Dragendoff dyeing agent compared to the starting 
material clusianone (29) not stained. (B) CEtA (57) and CMeA (56) formed 
stained orange with Dragendoff dyeing agent compared to the starting material 
clusianone (29) not stained. (C) CMeA formed from second and third trial of 
reaction.  
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4.3 HPLC analysis of selected compound for purity content analysis 
 
The additions of oxime and amine functional groups to C-9 of clusianone 
(29) via ketone reduction were feasible in a single step. However some of these 
samples CMxA (55) and CEtA (57) showed susceptibility to degradation when 
being exposed to atmospheric moisture and also to organic solvents after 
purification via column chromatography. This occurrence of degradation in the 
sample was noticed after a period of time when compounds were dissolved using 
various solvents such as methanol, chloroform and dichloromethane.  
Purity profiling is crucial and requires critical attention from drug 
companies. Earlier the degradation of product was screened using TLC to see 
by-product spots appearance under short wavelength (254 nm). Thereafter, 
HPLC works were carried out to determine and quantify purity percentage of 
compounds while taking into account by-products presence. Only compound 
CMxA (55), CMeA (56) and CEtA (57) were selectively analysed for purity 
studies. Purity content was determined using HPLC analysis (Table 4.13 & 
Figure 4.32).  
 
Table 4.15 HPLC spectra for selected compound (Absorbance at 254 nm)  
             Compound          Purity percentage (%) 
Clusianone (29) 98.7 
CMxA (55) 86.2 
CMeA (56) 95.1 
CEtA (57) 74.3 
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 Figure 4.32 HPLC Purity analysis of compounds  
 
 
 Therefore, after product purification through column chromatography of 
compound CMxA (55), CMeA (56) and CEtA (57), it is advisable that these 
compounds should be kept in a well closed scintillation vials, away from light 
sources and stored under refrigeration at 2-8°C. In addition, it is recommended 
to apply nitrogen gas as inert environment for storage to avoid any further 
degradation when stored in a closed scintillation vials.   
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4.5 Summary of synthesis of clusianone (29) derivatives 
 
Based on the synthesis results, eight derivatives of clusianone (29) 
abbreviated as CMet (53), CHyd (54), CMxA (55), CMeA (56), CEtA (57), 
CPryl (58), CGeryl (59) and CDMet (60) were obtained via chemical 
modification of clusianone (29). Nevertheless, all these derivatives were 
synthesized using high purity (>98%) clusianone (29) crystals produced through 
recrystallization methods. Interestingly, the highlight of the synthetic reaction 
step involves the ketone reduction on C-9 of naturally occurring clusianone (29) 
to afford imine derivative namely CMeA (56). To date, there was no information 
in naturally occurring PPAP compounds literature about the integration of 
nitrogen element into the core structure of bicyclo [3.3.1] nonane-2,4,9-trione.  
 The next approach was to prepare sufficient amount of clusianone (29) 
derivatives for biological testing. The high yield (>75%) of CMet (53), CHyd 
(54), CMxA (55), CMeA (56), CEtA (57) makes these derivatives feasible 
candidates for cytotoxicity screening, structure-activity relationship studies 
(SAR) interpretation and further antimicrotubule activity studies as described in 
Chapter 5. The yield after modification limits the number of biological 
experiments to be performed. Under this circumstances, small scale synthesis 
reactions were conducted with less than 2 reaction steps in order to produce high 
yield derivatives as outlined in the thesis objective and research scopes. This 
research aim was to produce high yield synthesised derivatives combined with 
economically viable methods which would contribute to medical values of these 
compounds.  
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On the other hand, the purity profiling utilizing HPLC analysis for 
compound CMxA (55) and CEtA (57) having purity percentage of 86.2% and 
74.3% respectively indicated these two compounds were not suitable candidates 
for further therapeutic intervention (Guideline, 2009). Therefore, clusianone 
(29) derivatives CMet (53), CHyd (54) and CMeA (56) were the only ones 
selected to be reported and published in Planta Medica Letters (Nagalingam et 
al., 2016) (Appendix G). This is the first time a concise report on chemical 
modification on naturally occurring clusianone (29) has been established 
including in-depth structure-activity relationship studies (SAR) against normal 
and carcinoma respiratory cell lines.  
Selection of the next synthesis reaction step to produce the novel 
derivatives were focused based on envisaging the functional group that will lead 
to the development of ultimate antimicrotubule agent as outlined in the objective 
of the thesis. Concurrently, the synthesis and cytotoxicity screening of some of 
the derivatives such as CMet (53) and CHyd (54) were conducted as a 
preliminary results for structure-activity relationship studies (SAR).  As such, it 
was revealed that alteration of prenyl and hydroxyl group leads to significant 
loss in cytotoxicity activity in these preliminary SAR studies in all four 
respiratory cell lines that will be described explicitly in Chapter 5. Previous 
report on total synthesis of clusianone derivatives involves 15-30 synthesis 
routes to afford clusianone with additional methyl esters (61) (62) (68), 
trifluoroethyl esters (63), phenyl sulfones (64) (65) (66) (67) and bromobenzoate 
group (69) (Appendix E). It was revealed that the modification of either prenyl 
chain or the hydroxyl group despite the various functional group installed has 
led in lower potency or loss in anticancer activity (Zhu et al., 2014).  
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Further to this, compound CPryl (58) and CGeryl (59) were developed 
to study the significant of the additional prenyl and geranyl chains as compared 
to a hydroxyl group of clusianone (29) in the hope of creating the future lead 
compounds with stronger inhibitory interaction in the domains of microtubule 
structure. The presence of additional prenyl and geranyl chain surrounding the 
bicyclo [3.3.1] nonane-2,4,9-trione is also postulated to increase the lipophilicity 
of the compounds. Hence, enhancing stronger affinity of the compound to the 
cell membranes for optimum pharmacological effect (Rullah et al., 2014). Due 
to time restraints in the current synthesis reaction trial, the yield of CPryl (58) 
and CGeryl (59) have not been optimised and cytotoxicity screening for CPryl 
(58) and CGeryl (59) have yet to be investigated. 
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CHAPTER 5 RESULTS AND DISCUSSION 
BIOLOGICAL ACTIVITY OF CLUSIANONE AND DERIVATIVES 
 
5.1 Cytotoxicity testing on respiratory cells lines using MTT assay 
 
The discovery of bioactive phytochemicals often leads to the cytotoxicity 
test to determine bioactivity in cancer cells and most importantly the impact of 
these compounds on normal cells. These assays affect the different parts of the 
treated cells and are used in measuring various aspects of the compound toxicity. 
There are several cytotoxicity tests that have been used by NCI over the past few 
decades such as tetrazolium assay (MTT and XTT) and sulforhodamine B assay 
(SRB). SRB assay has been selected as the most reliable method by NCI since 
cytotoxicity test conducted by NCI was performed in larger scale with a wide 
range of cell line panels (Boyd, 1995; Shoemaker, 2006). However this 
nontetrazolium SRB assay involves many washing steps compared to MTT 
assay (Keepers et al., 1991). Besides, the SRB assay is used to determine the 
cellular protein content unlike MTT assay determined metabolical activity of 
cells, which is related to mitochondrial action.  
Synthetic clusianone (29) has been tested using reazurin test against 
cervix carcinoma (HeLa), breast carcinoma (MCF7) and pancreatic carcinoma 
(MIA-PaCa-2) cell lines (Simpkins et al., 2012). Reazurin and MTT assays 
evaluate the metabolic activity in the mitochondria in the cells and both assays 
were claimed to be high quality and reliable for high throughput screening 
(Hamid et al., 2004).  MTT assay is an enzyme based method which measures 
the cell viability through bioreduction process in the cell. MTT is associated 
with mitochondrial succinate dehydrogenase and involves the reduction of 
149 
 
pyridine nucleotides NADH to NADPH. During the event of bioreduction, 
tetrazolium salt MTT changes into insoluble form known as formazan which is 
purple in color. The faster cells proliferate or perhaps the more cell viability 
detected, the more formazan crystals are formed, this increases the intensity of 
the purple coloration (Mosmann, 1983; Berridge et al., 1996). Therefore, in this 
research MTT assay has been selected since recent studies on clusianone (29) 
on HepG2 cells showed that clusianone (29) exhibited early mitochondrial 
impairment (Reis et al., 2014). Furthermore, MTT assay is less time consuming, 
cheap, easy to perform, non-destructive and relatively reliable. Most importantly 
it measures the metabolic activity of the cells and not necessarily the viability of 
the cells (Berridge et al., 1996). 
During the MTT assay method optimization, two main factors were 
taken into consideration, firstly the concentration of DMSO used for the 
treatment of cell and secondly the cell number in each well. Colon cancer was 
not affected when subjected up to 10 % DMSO (Haumeil & Rnaud, 2002) while 
Burkitt’s lymphoma cells were easily affected at 1.5% DMSO treatment (Lin et 
al., 1995). It was reported that 1.0% DMSO in lung adenocarcinoma (CL1-5) 
induces cell cycle arrest at G1 phase eventually leading to apoptosis (Wang et 
al., 2012). The optimization test to determine the safe concentration of DMSO 
subjected to both lung and nasopharyngeal cells revealed 0.4% DMSO caused 
zero effect on the cell growth. As such, 0.1% DMSO concentration was selected 
in stock solution as suggested by previous studies to avoid any effects of cell 
death due to DMSO (Chippendale et al., 2012). 
 The seeding number for each well was followed as per NCI 
recommendation between 5000 to 20,000 cell per well (Boyd, 1995). However, 
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after optimization, 10,000 cells per well was chosen as the cell density since the 
absorbance reading were more stable and cell growth including cell morphology 
was consistent in each well when observed under the inverted phase microscope. 
The screening of cytotoxicity of clusianone (29) and its derivatives 
performed using quantitative colorimetric MTT assay against MRC5, A549, 
HK1 and NP69 cells. Cytotoxicity screening test was also performed against 
normal cell lines to validate compound inhibitory activity in cancer cells without 
significantly affecting the viability of the normal cell. 
 Absorbance was measured at 540 ± 5 nm and the absorbance used for 
the cell death percentage was subtracted with the blank absorbance to deduct the 
interference from other sources in the cell media or DMSO. The IC50 values 
were concentration of compounds that causes 50% of cell death at 48 hours and 
were averaged from the three sets of experiments. The IC50 values were 
determined using the interpolation method in GraphPad Prism 6 from the 
resulting dose response plot (Boyd, 1995). Separate graphs were displayed to 
view and study the pattern of cytotoxicity effect of clusianone (29) and 
derivatives against these 4 different cell lines.  
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5.1.1 Cytotoxicity of clusianone (29) against MRC5, A549, NP69 and HK1 
cells 
The cytotoxicity values IC50 of clusianone (29) against all the cells were 
between 1.5-5.5 µM (Table 5.1). A clear cell death trend was seen after 5.0 µM 
(Figure 5.1) since no cell viability was detected after 48 hours of treatment with 
clusianone (29). Clusianone (29) cytotoxicity was higher in A549 carcinoma cell 
line (3.06 µM) compared to HK1 carcinoma cell lines (5.35 µM). Apart from 
that, clusianone (29) was less toxic to both MRC (4.16 µM) and NP69 (3.66 µM) 
normal cells compared to A549 (3.06 µM) carcinoma cells. 
 
 
 
 
 
 
 
       
 
Figure 5.1 Graph showing the change in cell death with increasing clusianone 
(29) concentration in MRC5, A549, NP69 and HK1 cells after 48 hours 
treatment. Each point represents the mean ± standard deviation from three 
independent experiment (n=3) P ˂ 0.05.  
Table 5.1 IC50 values of clusianone (29) interpolated from Figure 5.1 then 
converted to μM using molecular weight of 502.69. Docetaxel (18) IC50 values 
were used as the positive control. 
 
Cell type MRC5 A549 NP69 HK1 
IC50 Clusianone (μg/mL)
 
2.09 1.54 1.84 2.69 
 IC50 Clusianone (μM) 4.16 3.06 3.66 5.35 
 IC50 Docetaxol (μM) 0.006 0.006 0.006 0.006 
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5.1.2 Cytotoxicity of CMet (53) against MRC5, A549, NP69 and HK1 cells  
Compound CMet (53) was inactive since there were no signs of cell 
death which occurred below 10 µM (Figure 5.2). Besides, CMet (53) IC50 values 
against all the cell line occurred in a wide range from 60-120 µM (Table 5.2). 
Even though CMet (53) was less toxic to normal cells MRC5 and NP69, the 
CMet (53) was considered ineffective as anticancer potential compound since 
carcinoma cell death occurred at a very high CMet (53) dose. 
 
 
Figure 5.2 Graph showing the change in cell death with increasing compound 
CMet (53) concentration in MRC5, A549, NP69 and HK1 cells after 48 hours 
treatment. Each point represents the mean ± standard deviation from three 
independent experiment (n=3) P ˂ 0.05.  
Table 5.2 IC50 values of CMet (53) interpolated from Figure 5.2 then converted 
to μM using molecular weight of 516.712. Docetaxel (18) IC50 values were used 
as the positive control. 
 
 
Cell type MRC5 A549 NP69 HK1 
IC50 Compound CMet (μg/mL)
 
62.20 44.80 52.20 32.40 
 IC50 Compound CMet  (μM) 120.38 86.70 101.02 62.70 
 IC50 Docetaxol (μM) 0.006 0.006 0.006 0.006 
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5.1.3 Cytotoxicity of CHyd (54) against MRC5, A549, NP69 and HK1 cells 
Similar to CMet (53), the CHyd (54) prevailed its cell death effect 
against all the cell lines above 10 µM treatments (Figure 5.3). The IC50 values 
of CHyd (54) were between the range of 40.0 to 70.0 µM (Table 5.3). In addition 
to this, CHyd (54) exhibit high toxicity against MRC5 normal cells compared to 
A549 carcinoma cells with IC50 values of 47.15 µM and 57.70 µM respectively. 
Meanwhile, IC50 cytotoxicity values of NP69 and HK1 cells were almost the 
same with 68.80 µM and 65.55 µM respectively.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Graph showing the change in cell death with increasing compound 
CHyd (54) concentration in MRC5, A549, NP69 and HK1 cells after 48 hours 
treatment. Each point represents the mean ± standard deviation from three 
independent experiment (n=3) P ˂ 0.05.  
Table 5.3 IC50 values of CHyd (54) interpolated from Figure 5.3 above then 
converted to μM using molecular weight of 521.75. Docetaxel (18) IC50 values 
were used as the positive control. 
 
 Cell type MRC5 A549 NP69 HK1 
IC50 Compound CHyd (μg/mL)
 
24.6 30.1 35.9 34.2 
  IC50 Compound CHyd  (μM) 47.15 57.70 68.80 65.55 
  IC50 Docetaxol (μM) 0.006 0.006 0.006 0.006 
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5.1.4 Cytotoxicity of CMxA (55) against MRC5, A549, NP69 and HK1 cells 
 As for compound CMxA (55), IC50 values indicate cell death below 
10 µM against all the respective cells (Figure 5.4 & Table 5.4). The IC50 values 
of CMxA (55) was considered active against HK1 cells (4.85 µM). However, it 
was observed that toxicity related to normal cells were rather high with 5.12 µM 
in NP69 cells. The toxicity effect was even higher in MRC5 cells (2.82 µM) 
compared to A549 cells (7.67 µM).  
 
Figure 5.4 Graph showing the change in cell death with increasing compound 
CMxA (55) concentration in MRC5, A549, NP69 and HK1 cells after 48 hours 
treatment. Each point represents the mean ± standard deviation from three 
independent experiment (n=3) P ˂ 0.05.  
Table 5.4 IC50 values of CMxA (55) interpolated from Figure 5.4 above then 
converted to μM using molecular weight of 531.73. Docetaxel (18) IC50 values 
were used as the positive control. 
 
 
Cell type MRC5 A549 NP69 HK1 
IC50 Compound CMxA (μg/mL)
 
1.50 4.08 2.72 2.58 
  IC50 Compound CMxA  (μM) 2.82 7.67 5.12 4.85 
  IC50 Docetaxol (μM) 0.006 0.006 0.006 0.006 
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5.1.5 Cytotoxicity of CMeA (56) against MRC5, A549, NP69 and HK1 
cells 
Interestingly, IC50 values of compound CMeA (56) were almost 
comparable with clusianone (29). The IC50 values of CMeA (56) for both 
carcinoma cells were less than 4 µM (Figure 5.5 & Table 5.5). In particular, 
CMeA (56) IC50 value against HK1 cells was 3.43 µM. Most importantly both 
the IC50 values against MRC5 and NP69 normal cells were above 10 µM. Thus 
indicating less toxicity of CMeA (56) compared to the rest of the compounds. 
 
Figure 5.5 Graph showing the change in cell death with increasing compound 
CMeA (56) concentration in MRC5, A549, NP69 and HK1 cells after 48 hours 
treatment. Each point represents the mean ± standard deviation from three 
independent experiment (n=3) P ˂ 0.05.  
Table 5.5 IC50 values of CMeA (56) interpolated from Figure 5.5 then 
converted to μM using molecular weight of 515.73. Docetaxel (18) IC50 values 
were used as the positive control. 
 Cell type MRC5 A549 NP69 HK1 
IC50 Compound CMeA (μg/mL)
 
5.26 2.11 5.17 1.77 
 IC50 Compound CMeA  (μM) 10.20 4.09 10.02 3.43 
 IC50 Docetaxol (μM) 0.006 0.006 0.006 0.006 
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5.1.6 Cytotoxicity of CEtA (57) against MRC5, A549, NP69 and HK1 cells 
 
The IC50 values of CEtA (57) were all observed above 10 µM for all the 
four types of cells (Figure 5.6 & Table 5.6). Based on the result both carcinoma 
cells A549 and HK1 cells IC50 values were below 15 µM while normal cells 
NP69 and MRC cells IC50 values were above 15 µM.  
 
 
Figure 5.6 Graph showing the change in cell death with increasing compound 
CEtA (57) concentration in MRC5, A549, NP69 and HK1 cells after 48 hours 
treatment. Each point represents the mean ± standard deviation from three 
independent experiment (n=3) P ˂ 0.05.  
Table 5.6 IC50 values of CEtA (57) interpolated from Figure 5.6 above then 
converted to μM using molecular weight of 529.75. Docetaxel (18) IC50 values 
were used as the positive control. 
 
 Cell type MRC5 A549 NP69 HK1 
IC50 Compound CEtA (μg/mL)
 
8.19 6.27 8.87 6.63 
 IC50 Compound CEtA (μM) 15.46 11.84 16.74 12.52 
 IC50 Docetaxol (μM) 0.006 0.006 0.006 0.006 
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5.1.7 Summary of cytotoxicity results 
 
The results of the MTT bioassay were summarised in (Table 5.7). 
Clusianone (29) tested on A549 and MRC cells showed IC50 values of 3.06 μM 
and 4.16 μM respectively indicating that the cytotoxicity effect of clusianone 
(29) was higher 26.44% in lung carcinoma compared to normal lung fibroblast 
cell lines. Meanwhile, the IC50 values of clusianone (29) against HK1 and NP69 
were 5.35 μM and 3.66 μM respectively resulting in higher 31.58% toxicity of 
clusianone (29) in normal epithelial nasopharyngeal cells compared to its effect 
on nasopharyngeal carcinoma cells.  
 
Table 5.7 Cytotoxicity IC50 (µM) of clusianone (29) and derivatives against 
MRC5, A549, HK1 and NP69 cells. 
 
 
 
 
 
 
Compound MRC5 A549 NP69 HK1 
Clusianone (29)  4.16  3.06  3.66  5.35  
CMet (53) 120.38  86.70  101.02  62.70 
CHyd (54) 47.15 57.70  68.80  65.55  
CMxA (55) 
CMeA (56) 
CEtA (57) 
2.82            
10.20  
16.49  
7.67  
4.09  
11.84  
5.12  
10.02  
16.74  
4.85  
3.43  
12.52  
Docetaxol (18) a 0.006 0.006 0.006 0.006 
aDocetaxol (18) control  *MRC5 (lung fibroblast) , A549 (lung adenocarcinoma),
NP69 (immortalized nasopharyngeal epithelial cell) and HK1 (squamous carcinoma 
of the nasopharynx) . 
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Synthetic clusianone (29) tested on HeLa, MCF7 and MiAPaca-2 
carcinoma cells using resazurin assay showed IC50 values in the range of 5.0-8.0 
μg/mL (Simpkins et al., 2012). However, the IC50 of the resazurin assay were 
analysed after 72 hours of synthetic clusianone (29) treatment. This indicates 
clusianone (29) exhibited good anticancer activity in A549 cells within 48 hours 
of treatment in the present MTT assay conducted. It was reported that 7-
epiclusianone (30) was tested against non-small lung cancer (NCI- 460) and 
numerous cancer cell lines using SRB assay showed IC50 values of more than 5 
μM after 48 hours treatment (Murata et al., 2010). Further to this, 7-
epiclusianone (30) was tested against non-small lung cancer (A549) using MTS 
assay. The IC50 value was above 15µM.  In comparison to its epimer (30), 
clusianone (29) definitely has exhibited higher cytotoxicity activity at a lower 
dosage in non-small lung cancer cells. 
Clusianone (29) derivatives were tested using MTT assay in order to 
study the structure-activity relationship of these derivatives on both carcinoma 
and normal cell lines. Based on the results (Table 5.7), several findings were 
summarized. First, compound CMet (53) bioactivity against carcinoma cells 
A549 and HK1 cells had decreased with IC50 value of 86.70 μM and 64.45 μM 
respectively. It was noticed that the methylation has decreased the cytotoxicity 
effects of CMet (53) on both cancer and normal cells by 30 fold at least. 
Compound CMet (53) was also less toxic to normal cells in terms of the 
concentration which was lethal to 50% of the cells population. Upon 
hydrogenation of tetraprenylated group of CMet (53) leads to a more lipophilic 
domain of this compound which has indeed decreased the cytotoxicity effect of 
CHyd (54) by 20 folds. The IC50 values for A549 and HK1 cells were 59.70 μM 
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and 65.50 μM. In terms of solubility of the compound CMet (53) and CHyd (54) 
in DMSO, both compounds were vortexed and further sonicated for 15 minutes 
at 30oC since both methylation and hydrogenation of clusianone (29) have made 
the compounds to possess less polarity or perhaps lipophilic characteristics 
which made these compounds less soluble in DMSO. 
 In contrast, to compound CMet (53) and CHyd (54), compound CMxA 
(55), CMeA (56) and CEtA (57) were easily dissolved in DMSO without much 
vortex force since these compounds possess both hydroxyl and amine groups 
which were highly polar compounds. The cytotoxicity results of compounds 
CMxA (55), CMeA (56) and CEtA (57) indicates good activity since IC50 value 
was in the range of 3.0 to 20.0 μM. Compound CMxA (55) demonstrated 
potential anticancer activity on both A549 and HK1 cells with IC50 value of 2.82 
μM and 5.12 μM respectively. However, compound CMxA (55) has cytotoxicity 
which affects the normal cells more significantly than the carcinoma cells. The 
plausible reason to these could be due to the presence of N-O bond in CMxA 
(55) which was linked to its low bond dissociation energy. As such, this weak 
bond with electron rich N-O group was susceptible to nucleophilic attack by 
proteins in biochemical assays resulting in false positives (Rishton, 2003; 
Axerio-Cilies et al., 2009). 
 Remarkably, compound CMeA (56) exhibited good activity on both 
A549 and HK1 cells with IC50 values of 4.09 μM and 3.43 μM. Most 
importantly, compound CMeA (56) suppressed the growth rate of MRC5 and 
NP69 normal cells at a higher concentration above 10.0 μM indicating more than 
50% less cytotoxicity to normal cells compared to carcinoma cells. As for 
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compounds CEtA (57), IC50 values were all beyond 10.0 μM for both normal 
and carcinoma cells indicating moderate effect on the normal cell lines.  
Antimicrotubule drug docetaxol (18) was used as control drug since type 
B PPAP compounds have been demonstrated to exhibit inhibitory activity of 
tubulin assembly of carcinoma cells (Roux et al., 2000). The effect of docetaxol 
(18) was 500 times potent in inhibiting the cells from proliferating when being 
compared to clusianone (29). Among the six compounds, CMeA (56) was 
chosen for further study due to less cytotoxicity effect on normal cells and most 
importantly for the good anticancer activity below 5.0 μM concentration against 
cancer cells (Boik, 2001). Clusianone (29) and compound CMeA (56) were 
further studied for morphology studies since both compounds have shown 
interesting anticancer activity as a result of MTT assay. 
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5.2 Morphology changes in treated A549 and HK1 cells 
 
The effects of clusianone (29) in different concentration were tested on 
both the A549 and HK1 cells by cell morphology observation under inverted 
phase microscope. In addition to this, cell morphology studies were carried out 
for compound CMeA (56) which displayed significant cytotoxicity activity 
against the A549 and HK1 cells while having moderate effect on the normal 
cells. The selections of both the compounds were made based on characteristics 
set by Boik. (2001), whereby IC50 values of pure compounds should be less than 
5.0 µM. The reason for this criterion was that these compounds will have a better 
efficacy in the in vivo test and less chances of toxicity which can cause adverse 
effect (Boik, 2001). Since cytotoxicity test using MTT assay was only able to 
show cell-killing property without demonstrating the specific cell death 
mechanism, further studies such as morphology observation of the treated cells 
under inverted phase microscope were crucial in understanding the mechanism 
of action of both clusianone (29) and compound CMeA (56) against A549 and 
HK1 cells.  
Cell death occurrence happens in two main mechanisms known as 
apoptosis and necrosis. Apoptosis is a programmed cell death which is 
physiological process by which unwanted cells are eliminated during either 
development stage or during the course of any other biological process in the 
cells. On the other hand, necrosis is cell death process triggered by a pathological 
process, which usually occurs when cells are exposed to serious physical or 
chemical affront (Eisel et al., 1998). 
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There were several distinct morphological changes cells go through 
during apoptosis. These features include cell shrinkage, chromatin aggregation, 
cytoplasmic fragmentation and formation of membrane bound vesicles which 
eventually forms apoptotic bodies. In contrast to apoptosis, necrosis begins with 
the loss of membrane integrity which leads to the swelling of cytoplasm and 
mitochondria and ends with total cell lysis (Eisel et al., 1998). 
 Cell morphology of A549 cells cell treated with clusianone (29) 
indicated cell death via apoptosis since cell shrinkage and apoptotic bodies 
predominated at both IC50 and 5 µg/mL (Figure 5.7). Images from the 
clusianone (29) treated HK1 cells morphology experiments shows evident signs 
of apoptosis such as cell shrinkage and pyknotic body both IC50 and 5 µg/mL 
(Figure 5.7). There was also a decline in the number of cells in both A549 and 
HK1 cells clusianone (29) treated at IC50 and 5 µg/mL due to adherent cell 
detachment. This cell detachment phenomena occurs via two major events of 
either apoptosis which causes loss of cellular adhesion or necrosis which causes 
the disruption of the plasma membrane (Rello et al., 2005). 
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Figure 5.7 Morphology changes of carcinoma cell A549 (top to bottom left) and 
HK1 (top to bottom right) cells treated with clusianone (29). Cells were treated 
with clusianone (29) for 48 hours and imaged by inverted phase contrast 
microscope (magnification 200×). The arrow indicates (1) control cell, (2) 
condensed nuclei, (3) cell shrinkage, (4) membrane blebbing, (5) apoptotic 
body, (6) cell lysis/blistering (7) echinoid spikes and (8) pyknotic body. 
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In contrast to the control cells, clusianone (29) treated cells showed 
decline in cell number since apoptotic bodies no longer possess cellular adhesion 
and most of these cells eventually detached from the surface of tissue culture 
plates (Figure 5.7). This apoptotic characteristic inducing early detachment 
occurrence of monolayer cells from their basal cell membrane are also known 
as anoikis (Rahman et al., 2013). 
As for the A549 cells treated with compound CMeA (56), majority cell 
showed cell shrinkage characteristics which indicated apoptosis typical 
appearance at IC50 concentration. On the contrary, domination of cell lysis 
characteristic which was distinctive necrosis appearance occurred at 5 µg/mL 
(Figure 5.8). The effect of compound CMeA (56) against HK1 cells at IC50 
concentration showed that majority cells attributed membrane blebbing 
appearances (Figure 5.8). Decline in the number of cell are observed in both 
cells as the CMeA (56) treatment was increased from 0-5 µg/mL. Generally, 
membrane blistering was common in both A549 and HK1 cells treated with 
CMeA (56) at 5 µg/mL which reveals cell death via necrosis (Rello et al., 2005). 
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Figure 5.8 Morphology changes of carcinoma cell A549 (top to bottom left) and 
HK1 (top to bottom right) cells treated with CMeA (56). Cells were treated with 
CMeA (56) for 48 hours and imaged by inverted phase contrast microscope 
(magnification 200×). The arrow indicates (1) control cell, (2) condensed nuclei, 
(3) cell shrinkage, (4) membrane blebbing, (5) cytoplasmic contents, (6) cell 
lysis/blistering and (7) echinoid spikes. 
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The HK1 cells treated at 5 µg/mL showed necrosis characteristic. Cell 
lysis occurrence was observed with compound CMeA (56) treated on HK1 cells 
which were a prominent attribution of cell death via necrosis. One of the most 
distinctive morphology of cell death via necrosis observed was cellular swelling 
due to the loss of membrane integrity. During this stage, water influx through 
plasma membrane occurs causing the cell to appear vacuolated. Consequently, 
this will cause membrane blebbing which will finally lead to cell lysis whereby 
all cell cytosolic contents including non-functional organelles are spilled out 
(Eisel et al., 1998). 
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5.3 Mode of action pathway studies of clusianone (29) and CMeA (56) 
treated against A549 and HK1 cells through immunostaining 
  
Immunostaining technique became an important tool in order to further 
study the inhibition effect of clusianone (29) and compound CMeA (56) against 
A549 and HK1 cell lines. This technique emphasizes antibody utilization to 
detect specific protein in samples also known as immunohistochemistry. There 
are several immunostaining methods such as flow cytometry, Western blot, 
enzyme linked-immunosorbent assay, microarrays and electron microscopy 
(Hughes et al., 2014). However, Western blot was employed as the best 
methodology for this study since the technique has broad cell heterogeneity as 
compared to flow cytometry (Kornblau et al., 2005). Western blot detects the 
specific proteins in cell sample in tissue homogenate or extract form (Kurien & 
Scofield, 2003). The method has been used for both qualitative and quantitative 
analysis over the past decades and has been an important analytical tool in 
specific protein detection research field (Taylor & Posch, 2014).  
 Cytotoxicity assay using the MTT assay revealed that clusianone (29) 
and compound CMeA (56) prevailed significant antiproliferative activity against 
both A549 and HK1 cells showing IC50 values below 5 µg/mL. This prompted 
further pathway studies of clusianone (29) and CMeA (56) as potential 
antimicrotubule agent or antimitotic agent by observing the expression of β-
tubulin and cell check point cycle regulators cyclin B1/Cdk1 complex at 
different time point (8, 16, 24 and 48 hours) of the treated carcinoma cells by 
immunostaining. The cells were treated with respective IC50 concentration 
determined from MTT test since these concentrations were considered 
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proapoptotic dose which caused at least 50% of cell death population (Berridge 
et al., 1996). 
 Based on the results of Western blot analysis as shown in (Figure 5.9), 
clusianone (29) exhibited profound dysregulation in the β-tubulin protein 
expressed in A549 cells. The downregulation of protein can be observed across 
the different time treatment as compared to the control untreated cells protein 
blots. The expression of β-tubulin protein mainly declined after 16 hours 
(43.18%) of treatment with about 50% downregulation was estimated compared 
to cell treated at 8 hours (102.02%). From this observation, it can be deduced 
that only after 16 hours of treatment the onset of apoptosis rapidly occurred in 
A549 cells. The β-tubulin protein decreased gradually and finally after 48 hours 
of treatment, it was observed only 10.72% β-tubulin proteins were expressed. 
On an account of this, both the cell cycle regulator Cdk-1 and cyclin B1 protein 
expression were also downregulated from 16 hours onwards. 
 Overall, the decrease in the protein band intensity was noticed after 16 
hours of treatment and clusianone (29) has a strong inhibitory effect on both β-
tubulin and Cdk-1 activity. Cdk-1 are important cell cycle regulators which also 
phosphorylates β-tubulin (Fourest-Lieuvin et al., 2006). Hence, clusianone (29) 
showed signs of interference with mitotic phase related proteins and it could be 
postulated that the mechanism of action of clusianone (29) consequently causes 
cell cycle arrest at G2/M phase in A549 cells. The plausible reason could be the 
antimicrotubule effect by clusianone (29) consequently leading to dysregulation 
of cell cycle regulators (Nurse, 1990; Lindqvist et al., 2007).  
 
 
 
169 
 
 
 
Figure 5.9 A549 cells treated at IC50 of clusianone (29) and protein extraction 
harvested after 8, 16, 24 and 48 hours for western blot analysis. A. β-tubulin, 
Cdk-1 and Cyclin B1 were immunoprecipitated with appropriate antibodies and 
GAPDH level was used as an internal loading control for protein amount. 
Western blot densitometry quantification results: B. Percentage of β-tubulin 
protein; C. Percentage of Cdk-1 protein; D. Percentage of Cyclin B1 protein at 
8, 16, 24 and 48 hours of treated A549 cells compared to the control (untreated 
A549 cells harvested after 48 hours). Results are presented as mean ± SD from 
two independent experiments. 
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Meanwhile,  similar pattern of protein expression was not observed for 
HK1 cells treated with clusianone (29) specifically referring to cell cycle 
regulator protein expressions as time progressed from 8 hours to 48 hours of 
treatments (Figure 5.10). Both Cdk-1 and cyclin B1 protein expression in HK1 
cells were not affected by clusianone (29).  It was clear that β-tubulin 
downregulation occurs after 24 hours (79.0%) treatments and interestingly less 
detection of β-tubulin protein after 48 hours (39.37%) treatment. Arising out of 
this was the doubling time for HK1 cells which was probably more than 30 hours 
as compared to A549 cells which have a doubling time less than 24 hours (Huang 
et al. 1980; Chan et al., 2012). Under these circumstances, the cells indicate late 
apoptosis and cells cycle regulators of cell division progression were not 
affected at even at 48 hours treatment. Nonetheless, it remains to be further 
investigated to the increase in Cdk-1 protein expressions after 48 hours treatment 
with 107.63% protein expressed compared to control untreated cells. 
 This result suggests that clusianone (29) has interfered with the 
microtubule system since β-tubulin protein has declined abruptly in HK1 cells 
after 48 hours treatment with clusianone (29) (Ohishi et al., 2007; Jirásek et al., 
2009; Narvi et al., 2013). Conversely, consistent expressions of both Cdk-1 and 
cyclin B1 protein levels indicate that clusianone (29) was not contributing to cell 
cycle arrest at G2/M phase. However, the cell death occurrence could possibly 
happen at a later stage of mitotic phase since the expression of β-tubulin protein 
has been altered after  48 hours treatment with clusianone (29) (Allan & Clarke, 
2007; Clute & Pines, 1999). 
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Figure 5.10 HK1 cells treated at IC50 of clusianone (29) and protein extraction 
harvested after 8, 16, 24 and 48 hours for western blot analysis. A. β-tubulin, 
Cdk-1 and Cyclin B1 were immunoprecipitated with appropriate antibodies and 
GAPDH level was used as an internal loading control for protein amount. 
Western blot densitometry quantification results: B. Percentage of β-tubulin 
protein; C. Percentage of Cdk-1 protein; D. Percentage of Cyclin B1 protein at 
8, 16, 24 and 48 hours of treated HK1 cells compared to the control (untreated 
HK1 cells harvested after 48 hours). Results are presented as mean ± SD from 
two independent experiments. 
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Next, CMeA (56) was tested against A549 cells and results are shown in 
(Figure 5.11). Interestingly, all three proteins blots indicated decline in protein 
expression in a time dependent manner. In particular, after 48 hours treatment, 
the decline in β-tubulin protein (0%) was linked to the decline in Cdk-1 protein 
(54.59%). Meanwhile, decrease in cyclin B1 (0%) protein was more marked 
compared to the Cdk-1 protein. This was a clear indication of cell cycle arrest in 
the progression of cell division since all proteins required for mitosis phase 
progression are downregulated significantly especially after 24 hours treatment 
(Taguchi et al., 2007). Nevertheless, A549 cells doubling time is around 22 
hours which indicates that the downregulations of these proteins occurred during 
the mitosis stage of the cells.  
The decrease in the level of cyclin B1 has affected the level of Cdk-1. 
Consequently, the reduction in Cdk-1 protein has disrupted the level of β-tubulin 
level since Cdk-1 is responsible for the phosphorylation of tubulins (Fourest-
lieuvin et al., 2006). Most importantly all three protein levels were reduced, 
demonstrating high possibility of cell death through cell cycle arrest at G2/M 
phase including mitotic catastrophe probably arising from the microtubule 
spindle formation (Nurse, 1990; Lindqvist et al., 2007).    
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Figure 5.11 A549 cells treated at IC50 of compound CMeA (56) and protein 
extraction harvested after 8, 16, 24 and 48 hours for western blot analysis. A. β-
tubulin, Cdk-1 and Cyclin B1 were immunoprecipitated with appropriate 
antibodies and GAPDH level was used as an internal loading control for protein 
amount. Western blot densitometry quantification results: B. Percentage of β-
tubulin protein; C. Percentage of Cdk-1 protein; D. Percentage of Cyclin B1 
protein at 8, 16, 24 and 48 hours of treated A549 cells compared to the control 
(untreated A549 cells harvested after 48 hours). Results are presented as mean 
± SD from two independent experiments. 
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Subsequent time dependent treatment of CMeA (56) against HK1 cells 
revealed similar downregulation of proteins pattern with CMeA (56) time 
dependent treatment against A549 cells. The decrease in β-tubulin (19.28%), 
Cdk-1 (46.5%) and cyclin B1 (51.16%) were notable especially after 48 hours 
treatment (Figure 5.12). Besides, the decline in the level of Cdk-1 and cyclin 
B1 proteins were most probably following the onset of apoptosis which was 
initiated after 16 hours treatment (Allan & Clarke, 2007; Clute & Pines, 1999). 
Mitosis rapidly occurs in actively proliferating cells, particularly in HK1 cell 
lines have doubling time within 25-30 hours. Therefore, any failure in cell cycle 
check point regulations within this period culminates in unrestricted cell division 
and eventually leading to cell death. 
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Figure 5.12 HK1 cells treated at IC50 of compound CMeA (56) and protein 
extraction harvested after 8, 16, 24 and 48 hours for western blot analysis. A. β-
tubulin, Cdk-1 and Cyclin B1 were immunoprecipitated with appropriate 
antibodies and GAPDH level was used as an internal loading control for protein 
amount. Western blot densitometry quantification results: B. Percentage of β-
tubulin protein; C. Percentage of Cdk-1 protein; D. Percentage of Cyclin B1 
protein at 8, 16, 24 and 48 hours of treated HK1 cells compared to the control 
(untreated HK1 cells harvested after 48 hours). Results are presented as mean ± 
SD from two independent experiments. 
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To date, experiments using isolated mitochondrial from mouse liver 
tissues and the research revealed that cyclin B1/Cdk1 complex proteins were 
found to relocate in the matrix of mitochondria and an increased influx of 
mitochondrial cyclin B1/Cdk1 complex was associated with elevated 
mitochondrial bioenergetics in G2/M transition. Noteworthy, mitochondria-
targeted cyclin B1/Cdk1 complex increases mitochondrial respiration with 
enhanced oxygen consumption and ATP generation which provides cells with 
efficient bioenergy for G2/M transition and shortens overall cell-cycle time 
(Wang et al., 2014).  In the present study, both Cdk1 and Cyclin B1 was 
markedly downregulated in clusianone (29) treated A549 cells possibly 
decreasing mitochondrial bioenergetics in G2/M transition eventually leading to 
the occurrence of cell death. This was also relevant to the discovery that revealed 
clusianone (29) at low micromolar concentration depletes the ATP level of 
mitochondria in HepG2 cells leading to cell death (Reis et al., 2014). 
Previous anticancer pathway study of clusianone (29) was tested against 
HepG2 cells which were estrogen receptor (ER) positive cells. It was also 
postulated that clusianone (29) interaction with estrogen receptor may have 
contributed to apoptosis via intrinsic pathway in HepG2 cells (Reis et al., 2014). 
According to the report by Reis et al. (2014), clusianone (29) possessing 
hydroxyl group may have the binding activity that is similar to estradiol which 
binds to estragon receptor sites leading to signalling cascade of cell death 
pathway. However in this research, male derived lung cells A549 and 
nasopharyngeal cells HK1 were examined and these cells expressed almost 
insignificant estrogen receptors compared to cells derived from female cells. The 
A549 and HK1 cells overexpresses human growth factor receptor (EGFR) 
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(Stabile et al., 2005; Ma et al., 2010). This fact suggests less probability of 
clusianone (29) and CMeA (56) causing cell death by binding to estrogen 
receptors (ER) of A549 and HK1 cells. It is plausible that clusianone (29) and 
CMeA (56) are micromolar inhibitors of human growth factor receptor (EGFR).    
 In silico studies have proven that interaction between C7 hydroxyl 
groups in taxol interferes with polar cluster region (Thr276, Ser277 and Arg278) 
of β- tubulin protein structure (Figure 2.7). Consequently, this leads to the 
stabilization of microtubule structure and preventing disassembly of 
microtubule for the next stage of mitosis phase progression to occur. Similarly, 
clusianone (29) possessing hydroxyl group is postulated to interact with polar 
cluster region (Thr276, Ser277 and Arg278) of β- tubulin protein structure. 
Interestingly, CMeA (56) possessing both hydroxyl and amine compound is 
postulated to have exerted a greater interaction with β-tubulin protein based on 
the cytotoxicity immunostaining results. The presence of lone pair on amine 
group could be the main contributor in the interaction between CMeA (56) and 
microtubule receptor which leads to microtubule disruption. This theory 
postulated was supported by the fact shown in molecular modelling studies using 
taxol interaction with β-tubulin protein. In this study, benzamido group having 
lone pairs on amide group was occupied by Asp26. There were also hydrogen 
bonds reported between this groups which enhance the interaction (Renzulli et 
al., 2006).  
In conclusion, clusianone (29) and compound CMeA (56) have exhibited 
antimicrotubule activity since expression of β-tubulin, Cdk1 and cyclin B1 
complex has declined especially after 48 hours treatment.  
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CHAPTER 6 CONCLUSIONS & RECOMMENDATIONS FOR 
FUTURE STUDIES 
6.1 Conclusions 
The isolation of clusianone (29) from the leaves of G. parvifolia (Miq.) 
Miq., has led to attain 500 mg of clusianone (29) crystals. The optimization of 
clusianone (29) via recrystallization afforded x-ray diffraction quality crystals 
which allowed the single x-ray analysis of clusianone (29) crystal obtained in 
P212121 polymorph form. Synthesis of clusianone (29) derivatives led to 
structural-activity relationship (SAR) of clusianone (29) against lung and 
nasopharyngeal carcinoma including cytotoxicity effect on normal lung and 
nasopharyngeal cell lines.  
Eight derivatives of clusianone (29) were obtained from five types of 
chemical reactions. These clusianone (29) derivatives were routinely prepared 
on a scale of 10-100 mg and purified using column chromatography. Clusianone 
(29) was methylated, hydrogenated, added with oxime and primary amines 
functional groups and alkylated to install additional prenyl chain and geranyl 
chain. Compound CMet (53) afforded crystals through slow evaporation of 
methanol evaporation crystal and seeding technique which were further 
characterized using single crystal X-ray crystallography analysis. 
The overall MTT assay data confirmed that CMeA (56) exhibited better 
inhibitory against the A549 and HK1 respiratory carcinoma cells compared to 
other derivatives. Focusing on the structural requirements based on SAR study 
of this research, CPryl (58) and CGeryl (59) were developed to unravel the 
potency of clusianone (29) derivatives with additional prenyl and geranyl chain 
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as antimicrotubule agent. However, due to low yield and time restraint the 
biological activities of these two compounds have not been tested. 
Morphology studies using inverted phase microscopy were selectively 
analysed on treated A549 cells and HK1 cells. Clusianone (29) and compound 
CMeA (56) were treated at different concentration (0-5 µg/mL) to these cells 
and visualized under the inverted phase microscopy after 48 hours treatment. It 
was observed that clusianone (29) induces cell death of both A549 and HK1 
cells via apoptotic manner with majority cells displaying cell shrinkage and 
apoptotic bodies. Conversely, A549 cells and HK1 cells treated with CMeA (56) 
showed cell morphology predominated by necrosis characteristics. 
Based on the Western Blot results, both clusianone (29) and CMeA (56) 
lead to mitotic cell death (MCD) which is essential during cell division with β-
tubulin being hallmark for the inhibitory effect Cdk1 and cyclin B1 have been 
identified as the checkpoint checkmate in the cell death occurrences in both 
A549 and HK1 cells treated with clusianone (29) and CMeA (56). Thus, 
suggesting validity to further the study of both clusianone (29) and CMeA (56) 
on tumour cells, since tumour cells undergo unrestricted growth as compared to 
normal cells dividing rate. Despite being the shortest phase of the cell cycle, the 
mitotic phase has been a target for both clusianone (29) and CMeA (56). β-
tubulin and Cdk1 are targets for small molecule inhibitors which leads to mitotic 
cell death (MCD) pathway. 
The introduction of nitrogen element into the core of CMeA (56) bicyclo 
[3.3.1] nonane-2,4,9-trione structure provides added values to the overall 
anticancer activity against respiratory carcinoma cell. First hypothesis arising 
based on the increased antimicrotubule activity is that the nitrogen lone pair 
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provides binding ability to the specific microtubule binding sites. This 
hypothesis is also supported by the fact the imine derivatives have high water 
solubilty properties because the nitrogen elements exist as acid salts in water 
(Yamazaki et al., 2012).  
  There was no information about the mechanism of action of clusianone 
(29) as antimicrotubule agent in the literature. Most importantly, the SAR 
studies from this research providently indicate the fundamental of hydroxyl, 
prenyl and imine groups which were postulated to be interacting in the 
microtubule binding domains. This eventually culminates in cell death of the 
A549 and HK1 respiratory carcinoma cells. In this research, the mode of action 
of clusianone (29) and its potent derivative CMeA (56) as the potential 
antimicrotubule agent have been successfully studied and will be reported and 
published in due course.  
Naturally occurring PPAP compounds are found in a number of edible 
and medicinal plants. As such, there are many publications emphasizing the 
various biological activities of PPAP compounds and many PPAP natural 
product researchers  have conducted in vivo animal model test including some 
under clinical trials. More information in these in vivo test warrants the effect of  
PPAP compounds in human (Wu et al., 2014). However, there was lack of 
literature on understanding the function of different moieties present in PPAP 
compounds through concise SAR studies for in-depth understanding of their the 
molecular targets and mechanism of action.  
Therefore, the SAR studies arising from this research were thought to 
provide valuable information about the desirable and undesirable moieties which 
accounts for the  PPAP compound’s cytotoxicity activity and antimicrotubule 
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inhibitor characteristics. Nonetheless, the study provides insight molecular 
mechanism that could potentially further clusianone (29) to be tested for in vivo 
studies specifically aimed to treat lung adenocarcinoma and  squamous 
nasopharynx carcinoma.  
6.2 Recommendation for future studies 
  This research successfully synthesized eight clusianone (29) 
derivatives. Providentially, clusianone (29) and compound CMeA (56) 
demonstrated good cytotoxicity activity against both A549 cells and HK1 cells. 
In addition, extended protein works via Western blot analysis has indicated that 
clusianone and compound CMeA (56) indeed inhibit cancer cell progression 
through mitotic cell death. There are several recommendations that could be 
carried out to further the studies. Since both clusianone (29) and compound 
CMeA (56) has hydroxyl groups and compound CMeA (56) has an amine group, 
more clusianone (29) derivatives possessing hydroxyl and amine group should 
be prepared.  
Following this approach, in silico test utilizing molecular docking 
studies to determine the interaction between clusianone (29) and compound 
CMeA (56) in the β-tubulin protein domain. The studies will determine the 
functional groups responsible for stabilizing the microtubule polymerization or 
perhaps absolute orientation and position in β-tubulin domain. Besides β-tubulin 
protein, since clusianone (29) and compound CMeA (56) downregulate Cdk1 
cell cycle regulators expressions, molecular modelling should also emphasize 
the possibility of interaction between these compounds and Cdk1 protein.   
 Tubulin assembly assay has been a topic of interest for researchers 
working with type B PPAP. In the course of the present work, it was found that 
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both clusianone (29) and compound CMeA (56) downregulate β-tubulin 
expression particularly after 48 hours treatment. Theoretically, the results 
suggest that both compounds exhibit microtubule dynamics disruption by 
interfering with tubulin assembly dynamics. However, the rate of binding of 
clusianone (29) and compound CMeA (56) to enhance polymerization of tubulin 
has not been explored. To date, with the availability of microtubule cytoskeleton 
assay kits containing tubulins isolated from animal cells makes this kinetic 
profiling studies possible. In addition, the assay kit includes positive control 
drugs such as paclitaxel should be used to compare the rate of activity of 
compound’s tested against tubulin assembly activity.  
 Selection of ideal drug involves various physicochemistry test and most 
importantly preclinical trials on animal models have been compulsory from 
regulatory point of view. Therefore, clusianone (29) and compound CMeA (56) 
which have been tested for biological activity on in vitro scale should be tested 
and validated using in vivo experiments. In vivo test is crucial to further 
understand the efficacy of clusianone (29) and compound CMeA (56) through 
absorption, distribution, metabolism and excretion (ADME) studies. 
Nevertheless, in vivo test determines the dosage of the compound which are safe 
for both animal and human through toxicity assessments. With reference to this, 
proper lead compound formulation can be developed together with in depth 
pharmacokinetic and pharmacodynamics analysis.  
 Over the past decades, the paradigm of clinical cancer treatment has 
evolved from just depending on chemotherapy solely to combining both targeted 
therapy and chemo drugs for better prognosis for cancer patients. Chemo drugs 
rapidly kill dividing cells but drawbacks related narrow therapeutic value and 
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toxicity side effects often becomes an issue or perhaps remains uncertain. Hence, 
the use of targeted therapy in conjunction with chemotherapy has been preferred 
by clinicians. On account of this, clusianone (29) and compound CMeA (56) can 
be tested for synergistic effect between other targeted therapy drugs such as 
Gefinitib, Erlotinib and Afabtinib. These drugs specifically targets EGFR for 
inhibitory effects in cancer cell lines and since both A549 and HK1 cells highly 
express EGFR, this synergistic approach has a promising therapeutic effect.  
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APPENDICES  
 
 
 
 
 
 
 
 
 
 
 
Appendix A: 12% SDS-PAGE showing protein bands of A549 cells stained 
with Coomassie Blue. Lanes L1: Molecular weight marker, L2: 8 hours 
treatment with compound CMeA (56), L3: 16 hours treatment with compound 
CMeA (56), L4: 24 hours treatment with compound CMeA (56) and L5: 48 
hours treatment with compound CMeA (56). 
 
 
 
 
 
 
 
 
 
 
Appendix B: Proteins transferred from SDS-PAGE to nitrocellulose membrane 
and incubated with β-tubulin monoclonal antibody. Less background of the 
protein bands are noticed upon staining with TMB substrate. Lanes, U1: Control 
HK1 cells (Untreated), U2: 8 hours treatment with compound clusianone (29), 
U3: 16 hours treatment with compound clusianone (29), U4: 24 hours treatment 
and U5: 48 hours treatment with compound clusianone (29).  
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Appendix C: A549 cells treated with compound CMeA (56) and proteins 
transferred from SDS-PAGE to nitrocellulose membrane and incubated with β-
tubulin polyclonal antibody. High background of the protein bands are noticed 
upon staining with TMB substrate. 
 
 
 
 
 
 
 
 
 
 
   
Appendix D: Protein quantification method using Quantity One Bio-Rad 
software and further statistical analysis to quantify total protein stains based on 
optical density value. Lanes, U1: Control HK1 cells (Untreated), U2: 8 hours 
treatment with clusianone (29) , U3: 16 hours treatment with compound 
clusianone (29), U4: 24 hours treatment and U5: 48 hours treatment with 
compound clusianone (29). 
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Appendix E: Table of total synthetic clusianone (29) derivatives by other 
synthetic research group and the derivatives tested for anticancer activities. 
 
Total synthetic derivatives 
of clusianone (29)  
(Red formula indicates new 
functional group installed) 
 
Anticancer activity 
 
Reference 
 
  
JQ-101 (61) 
 
aMTS assay against 
lung carcinoma cells 
H460 (IC50 = 30	μM) 
A549 (IC50 = 40	μM) 
 
bSIRT1 activity assay 
(IC50 = 30	μM) 
 
(Qi & Porco, 2007) 
(Zhu et al., 2014) 
 
  
JQ-02 (62) 
 
bSIRT1 activity assay 
(IC50 = > 90 μM) 
Loss of activity 
(Qi & Porco, 2007) 
(Zhu et al., 2014) 
 
C
OCH3
O
O
O
O
O
F
F
F
 
JQ-08 (63) 
bSIRT1 activity assay 
(IC50 = > 90 μM) 
Loss of activity 
(Qi & Porco, 2007) 
(Zhu et al., 2014) 
a MTS assay :  3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2Htetrazolium assay to assess cell viability. 
b SIRT1 assay : Nicotinamide adenine dinucleotide (NAD)-dependent histone 
deacetylase inhibitory assay as preliminary anticancer test. 
187 
 
 
 
Total synthetic derivatives 
of clusianone (29) 
(Red formula indicates new 
functional group installed) 
 
Anticancer activity 
 
Reference 
 
 
JQ-11 (64) 
 
bSIRT1 activity assay 
(IC50 = > 90 μM) 
Loss of activity 
(Qi & Porco, 2007) 
(Zhu et al., 2014) 
 
H3CO
OO
O
S
O
O
  
JQ-05 (65) 
 
bSIRT1 activity assay 
(IC50 = > 90 μM) 
Loss of activity 
(Qi & Porco, 2007) 
(Zhu et al., 2014) 
 
HO
OO
O
S
O
O
  
JQ-34 (66) 
 
bSIRT1 activity assay 
(IC50 = > 90 μM) 
Loss of activity 
(Qi & Porco, 2007) 
(Zhu et al., 2014) 
b SIRT1 assay : Nicotinamide adenine dinucleotide (NAD)-dependent histone 
deacetylase inhibitory assay as preliminary anticancer test. 
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Total synthetic derivatives 
of clusianone (29) 
(Red formula indicates new 
functional group installed) 
 
 
Anticancer activity 
 
Reference 
 
  
JQ-32 (67) 
 
bSIRT1 activity assay 
(IC50 = > 90 μM) 
Loss of activity 
 
(Qi & Porco, 2007) 
(Zhu et al., 2014) 
 
CO2CH3
H3CO2C
O
OHO
O
  
JQ-10 (68) 
 
bSIRT1 activity assay 
(IC50 = > 90 μM) 
Loss of activity 
(Qi & Porco, 2007) 
(Zhu et al., 2014) 
 
Br
O
CO2CH3
H3CO2C
O
OO
O
 JQ-04 (69) 
 
bSIRT1 activity assay 
(IC50 = > 90 μM) 
Loss of activity 
(Qi & Porco, 2007) 
(Zhu et al., 2014) 
b SIRT1 assay : Nicotinamide adenine dinucleotide (NAD)-dependent histone 
deacetylase inhibitory assay as preliminary anticancer test. 
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